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@Abstract
Chlamydia trachomatis is the leading infectious cause of preventable 
blindness and the most common sexually transmitted bacterium worldwide. Trachoma 
presents an environment in which to investigate chlamydial pathogenicity, the 
conjunctivae serving as an accessible model with an objectively observable 
phenotype. The Bijagós Archipelago is a unique setting where trachoma is 
hyperendemic. The primary aims of this study were to use novel molecular, 
bioinformatic and geostatistical approaches in conjunction with population-based 
clinical and epidemiological metadata to investigate the micro-epidemiology of ocular 
C. trachomatis and active trachoma in this population.
The prevalence of trachoma and ocular C. trachomatis infection have been 
documented, and socio-environmental risk factors have been identified that may be 
important in the implementation of trachoma elimination activities in these 
communities. 
A strong association was found between C. trachomatis ocular load (estimated 
using droplet digital PCR) and the level of conjunctival inflammation. Geostatistical 
analyses suggest that ocular C. trachomatis load may be important in transmission, as 
spatial clusters of high load infections were identified, whilst spatial clusters of low 
load infections were absent.
This study includes the first population-based pathogen genome-wide 
association scan (GWAS) for C. trachomatis, using high quality next generation 
whole genome sequence data obtained directly from clinical samples. The genome-
wide associations with conjunctival inflammation (incE) and C. trachomatis load 
(mutY and CTA_0271) present genes involved in specific biological characteristics of 
C. trachomatis, the functions of which suggest that early interactions with host cells 
are important in C. trachomatis pathogenesis. Pathogen GWAS, applied in this 
context, is a powerful approach in the identification of multiple targets for further 
study in pathogenesis and directed study of potential vaccine candidates, allowing a 
greater understanding of association and interaction of genes on a genome-wide scale.
Following a single round of mass drug treatment with oral azithromycin 
(MDA) in these communities the prevalence of active trachoma and ocular C. 
trachomatis were significantly reduced. Individual and median loads of C. 
Atrachomatis were reduced and the highest burden of disease and infection were 
concentrated in young children. Spatial clustering of infection identified using 
geostatistical tools was intensified following MDA, but the number of clusters of high 
load infections was reduced. The severity of conjunctival inflammation was reduced 
following MDA.
This study suggests that chlamydial load is important in disease pathogenesis 
and may be important in transmission of infection. Geospatial tools may be useful in 
the context of MDA to identify clusters of infection and thresholds of C. trachomatis
bacterial load that may be important foci of transmission. The association between 
conjunctival inflammation and C. trachomatis load may reflect pathogen virulence. 
This is supported by the presence of genome-wide associations with C. trachomatis
load and conjunctival inflammation identified by pathogen GWAS. Further 
epidemiological, in vitro and in silico studies are required to provide a more complete 
picture of the relationship between disease severity, bacterial load and chlamydial 
diversity in the context of transmission and elimination dynamics.
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Chapter 1 Introduction: Trachoma and ocular Chlamydia trachomatis infection
1.1 Background
Infection with the obligate intracellular human pathogen Chlamydia 
trachomatis is the leading infectious cause of preventable blindness and the most 
common sexually transmitted bacterial infection, thus contributing to significant 
global morbidity and mortality. Trachoma is caused by ocular infection with C.
trachomatis and manifests as distinct clinical syndromes beginning with an acute self-
limiting keratoconjunctivitis then progressing to chronic inflammatory disease with 
subsequent conjunctival scarring and blinding sequelae. In 1997 the World Health 
Organization (WHO) launched a global effort to eliminate blinding trachoma through 
the implementation of the SAFE (Surgery for trichiasis, Antibiotics for active disease, 
Facial cleanliness and Environmental improvement) strategy to reduce transmission 
of infection. 
1.2 Epidemiology and transmission
Trachoma is endemic in some of the poorest countries in the world, 
predominantly in poor rural areas of Africa and Asia, often in marginalised, displaced 
and remote populations. It is endemic in over 50 countries, with the highest 
prevalence of active disease and trichiasis in sub-Saharan Africa, in the savannah 
areas of East and Central Africa and in the Sahel of West Africa [1]. In these regions
the distribution of disease is heterogeneous [2]. 
Ocular C. trachomatis is probably transmitted between individuals through 
direct spread from eye to eye during close contact, direct or indirect spread of infected 
nasal or ocular secretions on dirty fingers or cloths (fomites) and indirect passive
transmission by eye-seeking flies. There is no known animal reservoir of C.
trachomatis in endemic environments.
Many studies have suggested that the prevalence of disease is associated with 
environmental risk factors such as poor sanitation, access to water and latrine use [3, 
4]. Eye seeking flies (Musca sorbens) have also been associated with disease as a 
passive vector [5,6] but significant disease exists in areas where fly populations are 
scarce and are therefore less likely to contribute to disease transmission [7]. M.
sorbens breeds in human faeces and there may be overlap between fly populations 
and lack of latrine access or use [3].
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Social risk factors such as migration events and crowded living conditions 
have also been shown to be important in transmission of C. trachomatis and the 
appearance of active disease [8,9].
Clustering of disease at the community, household and bedroom levels has 
been noted and is likely to reflect the dynamics of transmission between family 
members with prolonged close contact and the infectious nature of C. trachomatis
[3,8-10]. Most transmission events occur at the household level with more gradual 
spread within the community [11]. Clustering of infection with C. trachomatis has 
also been demonstrated at household level [12]. 
The epidemiological dynamics of trachoma transmission are complex and not 
well understood. Trachoma endemicity is likely to be important, such that in 
hypoendemic populations disease may naturally decline [13-16] or disappear after a 
single round of community mass treatment with antibiotics [17,18]. In mesoendemic 
populations, disease prevalence may stabilize following community mass antibiotic 
treatment [19], and in hyperendemic populations disease and infection persist despite 
continued rounds of community mass treatment [20]. Mathematical models have been 
developed to attempt to capture these transmission dynamics and have focused on the 
effects of mass treatment on disease prevalence [21-24]. Others have examined 
household transmission [11,21] and the effect of repeated infection in the 
pathogenesis of trachoma [25]. Thus far it has not been possible to model the 
underlying mechanisms for positive feedback seen in trachoma transmission, where 
the hazard of a susceptible individual becoming infected (per case of infection) 
increases with increasing endemicity [26]. By incorporating individual-level factors 
such as socio-behavioural contact, C. trachomatis bacterial load, C. trachomatis strain 
diversity and superinfection, it may be possible to develop models that are able to 
account for these positive feedback effects, taking infection and disease endemicity 
into account. The use of in silico predictive models will complement the longitudinal 
study of transmission, which is time-consuming, expensive and labour-intensive, and 
allow for modeling of transmission within the context of treatment interventions.  
1.3 Clinical features and natural history of disease
Trachoma is a progressive disease. Acute keratoconjunctivitis occurs most 
commonly in early childhood and is often referred to as ‘active disease’ or ‘active 
trachoma’. This stage of disease is characterised by a follicular conjunctivitis with 
inflammation. Follicles (subepithelial clusters of lymphoid cells) are easily visible on 
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the everted upper tarsal conjunctiva as circular yellow-white elevations of >0.5mm 
diameter. Papillary hypertrophy (engorgement of small vessels with surrounding 
oedema representing conjunctival inflammation) may also occur and obscure 
underlying deep tarsal vasculature if severe. Infected individuals may be 
asymptomatic or have only mild symptoms despite variable signs of disease on 
clinical examination. Repeated infection with C. trachomatis causes recurrent 
inflammatory episodes, the resolution of which may lead to upper tarsal conjunctival 
scarring. Scarring from follicle resolution at the corneal limbus results in the 
formation of shallow depressions known as ‘Herbert’s pits’, which are the only
pathognomonic sign of trachoma.  As the scarring progresses, the conjunctiva 
becomes distorted, resulting in the inward turning of the lid margin (entropion) 
causing contact between the eyelashes and the globe of the eye (trichiasis). Corneal 
opacification is caused by corneal abrasion from inturned lashes, which leads to the 
blinding sequelae of trachoma. The direct abrasive effects of inturned lashes leads to 
an increased likelihood of secondary bacterial and fungal infections, compounding the 
patterns of chronic inflammation and scarring [27].
The majority of cases of active disease and ocular infection with C.
trachomatis occur in childhood with a decline in prevalence as individuals enter 
adulthood [10]. Adult bacterial load with C. trachomatis is lower than in children and 
duration of infection and disease episodes are shorter, which may in part be due to an 
acquired immune response [21,28]. Conversely, the prevalence of scarring sequelae 
increases with age, reflecting cumulative insult from recurrent infection and 
inflammation. The pathogenesis of trachomatous scarring is complex, involving both 
host and pathogen factors. In areas where the prevalence of active disease is very 
high, scarring sequelae may be evident in younger age groups [29]. Recurrent 
infection and persistent inflammatory disease increase the likelihood of developing 
scarring sequelae [3,30].
1.4 Clinical diagnosis and grading systems
Examination of the eye for clinical signs of trachoma involves inspection of 
the lashes, the cornea and limbus and the upper tarsal conjunctiva (after everting the 
eyelid) (Figure 1). A binocular magnifying loupe (x2.5) and adequate lighting are 
required, but this is a simple examination that can be conducted in field conditions.
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Figure 1. Zones of the upper tarsal conjunctiva used in trachoma grading
The entire central zone of the upper tarsal conjunctiva is examined when using the WHO simplified 
grading system (A) [31]. The upper tarsal conjunctiva is further divided into zones (1-3) used for 
scoring with the modified FPC (Follicles, Papillae, Conjunctival scarring) system (B) [33].
Grading systems have been employed to standardize the diagnosis of trachoma 
in field surveys and research studies. There are a number of different systems referred 
to in the literature [2]. The system currently used by trachoma control programmes is 
the WHO simplified grading system (Table 1) [31]. This system has shown to have 
good inter-observer reliability, which is not dependent on level of training of the 
examiner [32] and is easy to use and suitable for field studies, yielding useful
information on the prevalence of active and scarring disease. 
G!H
G5H
?@
Table 1. The WHO Simplified Grading System [31]
Grade Description
Trachomatous inflammation – follicular 
(TF)
Presence of IROOLFOHV!PPGLDPHWHURQWKHXSSHU
tarsal conjunctiva
Trachomatous inflammation – intense 
(TI)
Pronounced inflammatory thickening of the upper tarsal 
conjunctiva, causing 50% of the deep tarsal vessels to be 
obscured
Trachomatous scarring (TS) Presence of scarring on the upper tarsal conjunctiva
Trachomatous trichiasis (TT) At least one eyelash rubbing the globe
Corneal opacity (CO) Easily visible central corneal opacity over the pupil
For research purposes, a more detailed system is often used such as the 
modified FPC (Follicles, Papillary hypertrophy, Conjunctival scarring) system 
developed by Dawson et al. [33] (Figure 1 & Table 2) to ‘describe more precisely the 
intensity of inflammatory trachoma and potentially disabling and disabling lesions’. 
Table 2. The Modified FPC (Follicles, Papillary hypertrophy, Conjunctival scarring) 
Grading System [33]
Grade Description
F Upper tarsal follicles
F0 No follicles
F1 Follicles present but LQWRWDOLQ]RQHVDQGWRJHWKHU
F2 >5 follicles in zones 2 and 3 but less than 5 in zone 3
F3 IROOLFOHVLQHDFKRI]RQHVDQG
P Papillary hypertrophy and diffuse infiltration
P0 Absent; normal appearance
P1 Minimal: individual vascular tufts (papillae) prominent but deep subconjunctival tarsal 
vessels not obscured
P2 Moderate: more prominent papillae, normal vessels appear hazy, visible to naked eye
P3 Severe: conjunctiva thickened and opaque, more than 50% deep tarsal vessels obscured
C Conjunctival scarring
C0 No scarring
C1 Mild: fine scattered scars on upper tarsal conjunctiva OR scars on other parts of 
conjunctiva
C2 Moderate: more severe scarring but without distortion of upper tarsus
C3 Severe: conjunctival scarring with distortion of upper tarsus
T/E Trichiasis and/or Entropion
T/E0 No trichiasis or entropion
T/E1 Lashes deviated towards eye but not touching globe
T/E2 Lashes touching the globe but not rubbing the cornea
T/E3 Lashes constantly rubbing the cornea
CC Corneal scarring
CC0 Absent
CC1 Minimal scarring or opacity but not involving the visual axis; clear central cornea
CC2 Moderate scarring or opacity involving the visual axis; papillary margin visible through 
opacity
CC3 Severe central scarring or opacity with papillary margin not visible through opacity
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Simplified 
(WHO simplified)
Detailed 
(modified FPC)
Implication
TF F2 or F3 Presence of inflammatory trachoma
TI P3 Severe intensity of inflammation
TS C1*, C2 or C3 Presence of scarring trachoma
TT T/E2 or T/E3 Potentially visually disabling lesion
CO CC2 or CC3 Visually disabling lesion
*C1 may include scarring outside the central upper tarsal conjunctiva and is therefore not 
directly compatible
1.5 Trachoma control and elimination
In communities hyperendemic for trachoma a community mass treatment 
approach is advocated. The Global Alliance for the Elimination of Blinding Trachoma 
by the year 2020 (GET2020) was established by the WHO in 1997. The SAFE 
strategy is the focus of these control activities. Although the integration of all 
components of SAFE are thought to be important, most control programmes focus on 
surgery and antibiotic administration. Implementation of SAFE aims to eliminate 
blinding trachoma as a public health problem.
Surgery for trichiasis
Surgical correction of trichiasis may reduce the risk of corneal opacification 
and resultant blindness. Indications for and timing of surgery vary between 
programmes. The outcome of surgery is dependent on technique and operator, pre-
operative disease severity and post-operative infection. Recurrence may occur in up to 
40% of patients depending on duration of follow-up, though most recurrence is 
reported to occur within the first six months of surgery [34].
Antibiotics for infection 
Antibiotics may be administered at the community and individual levels with 
the aim of reducing infection rates within communities or households, assuming that
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transmission will be interrupted and subsequent scarring disease reduced. However, 
all trachoma prevalence estimates are based on clinical signs of trachoma rather than 
evidence of infection with C. trachomatis. The WHO currently recommends mass 
treatment with azithromycin on the basis of community prevalence of follicular 
trachoma (TF) in children aged 1-9 years of age (Table 4). Despite current WHO 
recommendations on frequency and duration of treatment, optimal parameters are 
uncertain. WHO recommended treatments are currently single dose oral azithromycin 
(20mg/kg up to a maximum dose of 1g) or tetracycline eye ointment (TEO) (applied 
twice daily for six weeks). This recommendation follows results from a large multi-
centre study in three endemic countries where community mass treatment with 
azithromycin resulted in a marked reduction in the prevalence of chlamydial 
infection, sustained for 12 months’ follow-up [35]. Other studies have found similar 
results [18]. Currently, 19 trachoma endemic countries have received over 225 million 
doses of azithromycin (Zithromax®) through the International Trachoma Initiative 
(ITI) as a philanthropic donation from Pfizer. 
Table 4. WHO criteria for mass antibiotic treatment distribution [36]
Prevalence of TF in 1-9 year 
olds
Recommendation
District level  Mass treat district annually for 3 years and then re-evaluate 
prevalence in district
District level < 10% Community level assessment
Community level  Mass treat community annually for 3 years and then re-evaluate 
prevalence in community
Community level EXW
10%
Target treatment to affected children and the members of their 
household
Community level < 5% Antibiotic treatment not recommended
Azithromycin is not licensed for use in pregnancy. There is no evidence thus 
far suggesting that it is harmful. This is supported by other studies on the treatment of 
sexually transmitted diseases [37]. Azithromycin is not used in infants under the age 
of six months; an alternative six-week regime of TEO is recommended by the WHO. 
Azithromycin is well tolerated and safe and has additionally been shown to 
have a beneficial effect on morbidity and mortality [38-40]. There does not appear to 
be any evidence of azithromycin resistance with respect to C. trachomatis. Transient 
development of resistance that is not felt to be clinically significant has been noted in 
Streptococcus pneumoniae [41,42]. 
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Promotion of facial hygiene and environmental improvement
Promotion of facial cleanliness and hygiene and environmental improvement 
are thought to be important, but the evidence-base is lacking and the addition of these 
components to a control programme is labour-intensive and not always effective 
[5,43].
1.6 Ocular infection with Chlamydia trachomatis
1.6.1 Detection of infection with C. trachomatis
Trachoma control programmes currently rely on the clinical signs of disease 
for diagnosis and to decide when treatment should be initiated in accordance with 
local and WHO policy. In research studies it is often important to know the 
individual’s infection status. There is no ‘gold standard’ in the diagnosis of infection 
with C. trachomatis. Cell culture of C. trachomatis is expensive, labour-intensive, 
technically challenging and lacks sensitivity [2]. Previously used tests include 
microscopy with Giemsa staining for inclusion bodies on a conjunctival smear and 
direct immunofluorescence with monoclonal antibodies to C. trachomatis antigens. 
Serology using enzyme-linked immunoassays (EIA) has moderate sensitivity, but 
lacks specificity due to cross-reactivity with other bacteria [2]. Nucleic acid 
amplification tests (NAAT) using a polymerase chain reaction (PCR) or transcription-
mediated amplification (TMA) are the current tests of choice in diagnosing infection 
with C. trachomatis. NAAT are highly sensitive and specific, due their ability to 
amplify low levels of specific target DNA or RNA template, and are able to identify 
significantly more individuals with chlamydial infection within a trachoma endemic 
population than had previously been identified. Quantitative PCR (qPCR) has also 
been employed to measure bacterial load in endemic populations [18]. However, 
expense and complexity precludes these tests from use in the programmatic context at 
present, with the ultimate panacea being a simple, field-friendly NAAT-based point of 
care test. 
1.6.2 Infection with C. trachomatis and the presence of clinical signs
C. trachomatis is thought to be the primary stimulant triggering inflammatory 
trachoma. However, C. trachomatis is not detected in all cases of active disease 
[3,44,45] even using highly sensitive NAAT. C. trachomatis may be detected in 
individuals at different stages of disease in hyperendemic communities, including 
individuals with no signs of clinical disease. In communities with low trachoma 
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prevalence, C. trachomatis is only found in a minority of cases of active disease, and 
in some areas infection is not found at all. Individuals with intense trachomatous 
inflammation are more likely to be infected and have higher bacterial loads than those 
with follicular disease [2,3]. 
There may be an incubation period where infection is present but disease has 
not yet manifest. There is a lag time between clearance of infection and resolution of 
clinical signs [28], which may last for several weeks or longer, and may indicate the 
impact of the host immune response in the disease process. Age is also a determinant 
of how long disease and infection episodes persist, durations being longer in children. 
It is also hypothesized that a subclinical persistent infection may exist, where C. 
trachomatis does not replicate and thus may not induce clinical signs [46]. The 
clinical signs of conjunctival folliculitis and inflammation are not specific for 
trachoma and occur in conjunctivitis caused by a number of microorganisms 
including viruses, Moraxella spp. and other chlamydiae [47].  Detection of chlamydial 
infection by NAAT is also dependent on factors such as swab collection, storage and 
preparation and ultimately only tests for the presence of chlamydial DNA or RNA, 
thus a transient inoculation may also give a positive result that may not represent an 
established infection. 
1.6.3 Characterisation of C. trachomatis 
C. trachomatis is an obligate intracellular bacterium. During its development, 
C. trachomatis exists in two principal forms: the metabolically active intracellular 
reticulate bodies (RB) and the metabolically inactive extracellular elementary bodies 
(EB). The RB may also exist in a ‘cryptic’ state where it remains in a metabolically 
inactive arrested phase [48]. It is usually the EB which is the form facilitating transfer 
between host cells and chlamydiae. The C. trachomatis developmental cycle is shown 
in Figure 2.
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Figure 2. Developmental Cycle of Chlamydiae [48]
C. trachomatis was first isolated in 1957 by Tang et al. [49], and was initially 
thought to be of viral origin. Extensive efforts have been made to characterise this 
important human pathogen into different types or strains. The identification of 
chlamydial strains is of vital importance to epidemiological studies of chlamydial 
infection, defining transmission, establishing test of cure parameters and in comparing 
the roles of persistent infection with reinfection. Currently there is lack of clarity in 
how to completely define chlamydial strains in a meaningful way that is comparable 
between studies. This has been due to the limited resolution of typing strategies that 
are not able to encompass the extent of full genomic diversity. The limited resolution 
of current single or multi-gene chlamydial sequence-based typing systems means that 
they are limited in their usefulness in studies focusing on the development of sequelae 
or strain-dependent virulence associations. 
Two C. trachomatis biovars, trachoma and lymphogranuloma,
(distinguishable based on physiological characteristics) have been described. 
Serotyping can further classify these biovars on the basis of possession of sequence-
binding epitopes in their major outer membrane protein (MOMP) that are recognized 
by sera or monoclonal antibodies (mAbs). There are approximately 19 serovars 
(trachoma (A-C), sexually transmitted infection (D-K) and lymphogranuloma (L1-3)) 
[50]. Genetic sequence differences for the gene encoding MOMP (ompA) reflect the 
15 MOMP serovars described originally by Wang and Grayston [51]. These strains 
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were further defined by epitope-mapping of ompA genes with a panel of mAbs [52]. 
This and other studies have resulted in ompA genotyping superceding serotyping due 
to the detail afforded by genotyping in the classification of strains that are unable to 
be serotypically characterised [53]. Subsequently, ompA genotyping data have 
expanded the classification of chlamydial strains to >20 genovars [54]. 
MOMP is a member of a family of genetically related surface-exposed outer 
membrane proteins. MOMP functions as a structural protein [55], porin [56-58] and 
cytoadhesion molecule [59-60]. The most widely studied and accepted function of 
MOMP is as a general diffusion porin [56]. Structural studies have been challenging 
due to the low solubility of MOMP, rendering structural details less clear [61,62]. 
Further knowledge of its structure will be crucial to understanding its role in the 
pathogenesis of chlamydial infection. 
Since variable MOMP domains recognized by mAbs exist on the surface of 
the EB, immune pressure may drive its variability [63-66]. MOMP has also been 
suggested as a virulence factor with pathogenic roles including bacterial adhesion, 
invasion and intracellular survival, evasion of host defenses and stimulation of pro-
inflammatory cytokines [65]. MOMP mosaics and natural recombination generate 
variability which may have pathogenic potential [53]. OmpA has been shown to be 
highly variable, and a hotspot for recombination [67]. In light of these phenomena it 
is not surprising that the analysis of ompA sequence data has failed to reveal 
convincing pathobiologic distinctions between genovars [66,68]. Occasional reports 
have suggested a link between disease severity and particular genovars [69], but these 
studies are limited in their methodology and sample size [54]. Strain typing using 
MOMP and ompA provides only a partial insight into strain variation and the 
pathobiology of C. trachomatis and thus other methods must be used to establish 
whether there are relationships between chlamydial strains, virulence and disease 
severity.
Other PCR-based genotyping methods with higher resolution have been 
developed: Multi-locus sequence typing (MLST) and Multiple loci variable number 
of tandem repeats (VNTR) analysis (MLVA). MLVA utilizes combined PCR and 
sequencing of ompA plus three VNTR loci to obtain higher diversity between strains 
of C. trachomatis [70]. In one study the resultant diversity showed a Simpson’s index 
of diversity (D) of 0.94 (approaching the recommended index value for a 
discriminatory typing method (D=0.95) [71,72]) and the loci were found to be stable. 
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A classical MLST system involving seven housekeeping genes is probably most 
suited to analyse evolutionary changes and was not assessed for discriminatory 
capacity [73]. An alternative MLST uses sequence determination of five genomic 
targets plus ompA [74]. One study comparing current genotyping systems found the 
diversity index to be 0.82, 0.81, 0.95, 0.96 and 0.97 for ompA, classical MLST, 
alternative MLST, VNTR alone and MLVA respectively [75]. Another study found 
similar results with D being 0.78 for ompA and 0.95-0.99 for alternative MLST, 
MLVA and a combination of MLST+MLVA [76]. These systems are advantageous in 
that it is possible to conduct the tests on clinical specimens from routine NAAT 
diagnostics. It is less clear whether MLVA or MLST are sufficiently discriminatory in 
answering questions relating to disease severity and whether this level of 
discrimination would also be true for ocular isolates (as these studies refer to 
urogenital strains of C. trachomatis).
The first whole genome sequence of a serovar D C. trachomatis isolate was 
published by Stephens et al. in 1998, revealing a small (~1-Mb) highly conserved 
genome [77]. Since then much has been learned about chlamydial genetics, including 
the observation that current typing systems may be misleading when the underlying 
whole genome sequence is analysed [78]. This whole genome sequence (WGS)
analysis by Harris et al. demonstrated that there is extensive recombination within the 
ompA gene, which can occur partially or completely both within and between biovars 
(also noted in other studies [67,79]) and that there is also evidence for genetic 
exchange and recombination within the cryptic plasmid. This evidence may explain 
why many studies have failed to find a significant association between disease 
severity and strain type [80,81]. However, strain-specific differences using WGS data
related to in vitro virulence and in vivo clinical disease severity (in non-human 
primates) have been demonstrated [82]. This evidence of recombination in clinical 
strains has challenged our knowledge of chlamydial diversity and highlighted the 
implications of recombination in monitoring and epidemiological studies using other 
methods of strain typing.
WGS and comparative genomics have already been shown to be an effective 
strategy to discover loci associated with disease severity and virulence [78,79,81]. 
This is of particular importance as although genetic transformation of C. trachomatis
has been achieved [83,84], working with chlamydiae in the laboratory remains 
inherently problematic, which severely limits definitive work on in vitro studies of 
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chlamydial virulence factors. Thus coupling WGS analysis with clinical phenotype 
and disease epidemiology may enable further characterization of C. trachomatis. 
Putative virulence factors identified include the polymorphic outer membrane protein 
(pmp), TARP and cytotoxin genes, chlamydial type III secretion systems (TTSS), 
plasticity zone mutants (such as trpB) and the cryptic plasmid [54].
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Chapter 2 A review of Chlamydia trachomatis virulence loci and their association 
with disease severity
2.1 Introduction
There is evidence of strain-dependent virulence associations in both urogenital 
and ocular C. trachomatis infection [1]. Some strain-dependent patterns have been 
demonstrated and studies are required to establish associations, and causality, 
between C. trachomatis strains and disease severity. Characterising C. trachomatis
remains a challenge. Using current typing systems, C. trachomatis strains remain 
poorly defined with respect to their intracellular cell biology, virulence and ecological 
success. Now that it is possible to genetically manipulate chlamydia [2,3], perform 
mutagenesis studies [3,4,5] and obtain whole genome sequence data direct from 
clinical samples [6, Christiansen MT et al., in press], it may be possible through 
laboratory and clinico-epidemiological studies to better define chlamydial strains and 
their association with disease severity.
2.2 The Major Outer Membrane Protein (MOMP)
The historical system of characterizing C. trachomatis by serological 
differences elicited by variable segments of MOMP and subsequent genotypic 
sequence differences for the gene encoding MOMP (ompA) is discussed in Chapter 
1.6.3. Several authors have suggested that immune pressure drives MOMP variation 
[7,8], and that MOMP variability reflects strain-related virulence [9]. Whole genome 
sequence analysis has shown ompA as a hotspot for recombination, and questioned its 
suitability as a marker for virulence [10]. Whilst some studies have described ompA 
variation in relation to ocular C. trachomatis load [11] the apparent inability of some 
hosts to clear infection caused by homotypic ompA genovars [12] and the suggestion 
that ompA is under purifying selection [11,13], it has not been possible to attribute 
pathobiological differences to ompA genovars [14,15]. 
2.3 Polymorphic outer membrane proteins (Pmp)
Chlamydial pmp genes were originally described by Longbottom et al. [16,17] 
and subsequently by Stephens et al. [18] based on whole genome sequence data 
related to large surface proteins in Chlamydia psittaci [19]. The nine-member family 
of pmp genes (pmpA-pmpI) in C. trachomatis all appear to be transcribed and encode 
proteins. The pmp gene family accounts for approximately 14% of the coding 
capacity for C. trachomatis [20,21].
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Pmp proteins appear to fulfill several biological functions, but the full extent 
of their role is not entirely clear. Pmp A and D are highly conserved amongst C. 
trachomatis isolates, but others (Pmp E, F, H, I) are variable. Pmp D and pmpH are 
surface expressed [21,22]. These exported bacterial proteins have been shown to 
function as autotransporters within the Chlamydial outer membrane [21-23].
Pmps are involved in transmembrane transport as part of the chlamydial type 
five (autotransporter) secretion system, delivering effector proteins directly into 
specific host cell membranes [22, 24-26]. The N and C terminal domains of specific 
families share conservation between species, but the passenger domain provides 
unique function for these proteins, and they may be cleaved, uncleaved or surface 
expressed and therefore involved with the bacterial surface [27]. Several chlamydial 
Pmps (Pmp D, E, G, H) have been detected on the chlamydial elementary body (EB) 
surface [21]. Pmps B, D and H are strongly immunogenic and elicit a pro-
inflammatory response [21]. Thus they have a putative role in virulence regarding 
modulation of inflammation and adherence to and invasion of host cells [23]. Pmp 
strain types have been shown to associate C. trachomatis isolates with pathobiotype 
and tissue tropism [28,29]. Currently data are limited to a small number of laboratory 
strains, but they are good candidates for further study of the virulence and 
pathogenesis of Chlamydial infection. 
2.4 Chlamydial plasticity zone: Chlamydial cytotoxin and phospholipase D family 
The chlamydial plasticity zone (PZ) is the site of extensive genomic variation 
between the chlamydial serovars [30,31]. The PZ contains a chlamydial toxin whose 
function is thought to involve GTPase inactivation and guanylate binding protein 
neutralization resulting in interferon gamma (IFN-g) resistance [32-24]. IFN-g 
stimulation of cells in vitro and in vivo induces transcription of genes that co-operate 
to eliminate intracellular bacteria, suggesting that inhibition of this mechanism may 
contribute to the pathogenesis of chlamydial disease [34]. Cytotoxin genomic 
variability has been associated with phenotypic variability relating to localization of 
GTPases to the inclusion membrane [34]. This genomic variability of the cytotoxin 
correlates with disease phenotypes such that genital strains have a single gene with a 
large deletion, LGV strains lack the gene and closely related Chlamydia muridarum
has three copies [35,36]. This may explain the invasive nature of LGV strains versus 
the apparent restriction of urogenital and ocular strains to mucosal surfaces.
Furthermore, cytotoxin gene polymorphisms have distinguished between ocular and 
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genital C. trachomatis isolates, where there may be either complete or partial 
cytotoxin genes present [32,37]. Further studies looking at associations within clinical 
strains have not yet been conducted, nor has the full detail of the structure and 
function of the protein been confirmed. Evidence to date suggests that there is 
unlikely to be differing toxic potential between strains, since there is little selective 
advantage for cytotoxin-bearing strains in humans. 
The membrane attack complex/perforin (MACPF) protein (CT153) and 
members of the phospholipase-D (PLD) family are also encoded within the PZ [31]. 
The PZ PLDs are present in C. trachomatis [38] and other Chlamydiaceae [39-41]. 
There are limited data on the function of these proteins. They are known to modify 
lipids and membranes, may be secreted and localize to the inclusion membrane [42]. 
Reactivation of C. trachomatis from a gamma interferon-induced persistent state is 
blocked by primary alcohols, which are potent inhibitors of PLDs, implicating a role 
for the plasticity zone PLDs in this process [43].
2.5 Translocated Actin Recruiting Phosphoprotein (TARP)
TARP has been noted to have considerable sequence variation, a considerable 
proportion of which is in the form of a variable number of insertions/deletions (indels) 
between isolates [36,37,43]. C. trachomatis entry into a host cell results in 
reconfiguration of the host cell actin skeleton, mediated by TARP. It is suggested that 
TARP is involved in pathogen-directed phagocytosis (during the initial attachment 
phase of uptake of the elementary body) [44]. After phosphorylation TARP is thought 
to promote internalization via an actin recruiting mechanism [43-45]. In addition to 
the characteristic indels, there are several single nucleotide polymorphisms (SNPs) 
between C. trachomatis serovars, suggesting that intra-serovar recombination has a 
role in the diversity of these genes [10,46]. Given the variability between 
pathobiotypes it has been suggested that these genes may be associated with disease 
severity. 
2.6 Inclusion membrane proteins (Incs)
Inclusion membrane proteins were originally identified prior to the advent of 
whole genome sequencing for chlamydia. High-resolution sequencing has provided 
significant information regarding inc genes and their proteins. Genomic analysis has 
shown that many Inc proteins are produced by each chlamydial species and several 
are produced early in development. Inc proteins may be important antigens in cell-
mediated immune responses following chlamydial infection. IncA has been defined as 
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an effector protein, proposed to mediate inclusion fusion in C. trachomatis [47,48]. 
They also exhibit an innate ability to form vesicles, enter the membrane of 
intracellular compartments and are type III effector proteins [49]. The epidemiology 
of natural incA mutants has been studied suggesting that strains with an inability to 
express incA are associated with reduced virulence [50]. Since then further work has 
been conducted which is less conclusive [51]. Many more incs have now been 
identified. Inc proteins appear to be important in chlamydial biology, but their roles 
remain unclear [51,52]. Further investigation into their role in host-pathogen 
interaction is warranted.
2.7 Chlamydia Type III Secretion System (T3SS)
The T3SS provides Gram-negative bacteria with a specialized mechanism for 
arranging proteins for subsequent interaction with the host cell membrane, insertion 
of effector proteins into the cytosol and subsequent manipulation or modification of 
host cell behaviour. Early work on chlamydial T3SS [53] in combination with the 
advent of whole genome sequencing of chlamydia [18] demonstrated the T3SS 
secretion mechanism as a candidate system for a family of chlamydial proteins that 
have been shown to localize to the inclusion membrane during intracellular 
chlamydial growth [54]. This system is important in bacterial pathogenesis and is 
essential for full virulence of a number of clinically significant bacterial species 
including Yersinia spp., Salmonella spp., Shigella flexneri, Pseudomonas aeruginosa, 
Escherichia coli, Bordatella spp., Burkholderia spp. and Vibrio spp. [55]. In most of 
these pathogens the structural and effector genes are located on distinct pathogenicity 
islands [56]. In chlamydia, these genes are scattered across a number of operons and 
use the sigma factor for constitutive gene expression, suggesting that additional 
activators or repressors are required if components of the T3SS are developmentally 
regulated [57]. Putative structural components, effectors and chaperones have been 
identified [58-60]. Inc proteins, Pmps and TARP have been suggested as putative 
effector proteins. Given the intracellular existence of chlamydia, it seems that type 
three secreted products are likely to be important in chlamydial pathogenesis. 
Therefore some of these effectors and apparatus components may be suitable 
candidates for therapeutics or vaccines. 
2.8 Chlamydial stress response proteins
Immunological studies have implicated host responses to a subset of 
chlamydial stress response proteins (chlamydial heat shock proteins (Hsp60 and 
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Hsp10) and GroEL/GroES homologues) with disease severity [61-65]. Heat shock 
proteins are specialized molecules performing different and essential roles in the cell 
including protein degradation, folding and trafficking. The chlamydial Hsp60 antigen 
shares nearly 50% sequence identity with the human homologue, therefore molecular 
mimicry has been suggested as being responsible for the severe inflammatory 
chlamydial disease found in individuals reacting against Hsp60 [61,65]. A study 
looking at women with urogenital C. trachomatis infection showed that in recurrent 
chlamydial infections, higher titres of antibodies to Hsp10 and Hsp60 were found 
[66]. 
Chlamydial GroEL is reported to signal through the toll like receptor (TLR) 
system, suggesting that it is also a potential mediator of inflammation during 
chlamydial disease. The groE operon (groES/groEL) remains highly conserved within 
and between chlamydial species [18] therefore association with disease phenotype 
seems unlikely due to lack of variability. It may be that the groE operon is important 
in pathogenesis and is implicated as a mediator of disease, but may not be differential 
in strain-dependent virulence. Gene expression and functional studies may be 
important to elucidate the function of these genes and whether or not they may be 
suitable potential vaccine candidates.
2.9 Chlamydial lipopolysaccharide and other glycolipids
Lipopolysaccharide (LPS) and lipooligosaccharides (LOS) are the primary 
lipid components of the outer cell membrane and are vital for cell viability in most 
Gram-negative bacteria. Studies blocking chlamydial LOS have shown that 
chlamydia remained viable and developed an inclusion but were not infectious [67]. 
In chlamydia cultured under these conditions, reticulate bodies accumulated, but 
failed to express essential proteins facilitating their transition to elementary bodies. 
This suggests an important interaction between LOS and an outer membrane 
developmental quality control system that facilitates transition from reticulate to 
elementary bodies [67]. Inhibiting LPS has been shown to reduce chlamydial 
infectivity suggesting a role for LPS in infectivity, although underlying mechanisms 
and details of host cell interaction are unknown [68]. Chlamydial LPS may act 
through TLRs and structural features may be associated with disease severity patterns, 
although it is not thought to be a LPS antagonist [69]. The functional role of genus-
specific LPS is complex and not fully elucidated [70]. 
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2.10 Chlamydial cryptic plasmid
The chlamydial plasmid is a small, highly conserved, non-conjugative, non-
integrative DNA molecule that is virtually ubiquitous in C. trachomatis. There has 
been significant recent interest and progress in understanding the function of the 
plasmid in the context of disease pathogenesis. The 7.5-kb C. trachomatis plasmid has 
been shown to function as a virulence factor in animal models [71,72]. Phenotypic 
differences exist between plasmid-cured and wild-type C. trachomatis strains with 
respect to infectivity, glycogen accumulation, induction of inflammation and 
activation of TLR pathways [73,74]. Plasmid deletion mutagenesis studies showed 
that deletion of the plasmid-encoded pgp4 gene results in an in vitro phenotype 
identical to that of a plasmid-free strain [5]. This supports bacterial transcriptome 
analysis showing a decrease in transcript levels of a subset of chromosomal genes in a 
naturally occurring plasmid-free strain of C. trachomatis, demonstrating that the 
plasmid is a transcriptional regulator of virulence-associated genes [75]. Maintenance
of the plasmid at low copy number carries inherent risk during cell partition [76] but
naturally occurring plasmid-free strains are rare [77-79]. A lower risk higher copy 
number system is metabolically expensive but may confer a ‘fitness’ advantage. Thus, 
the maintenance of 5-6 plasmids per genome [80] may maximise infectivity or 
intracellular survival whilst provoking minimal host immune response. The plasmid is 
clearly strongly selected for during successful infection or transmission of the 
pathogen within a host population [74].
Though there is convincing evidence that the chlamydial plasmid is a 
virulence factor [73-75,81-83], recent population-based data from a trachoma-
endemic population suggest that plasmid copy number is not associated with disease 
severity and that additive gene dosage effects do not appear to correlate with pathogen 
virulence in vivo [80]. This supports in vitro work showing no association between 
plasmid copy number and tissue tropism [84]. Previous work in vitro and in animal 
models suggests that subtle genomic differences between chlamydial isolates are 
associated with differences in growth kinetics, immune responses and pathology 
[85,86].
The plasmid has also been investigated as a vaccine candidate. Recent studies 
have shown that plasmid deficient C. trachomatis strains are less virulent in ocular 
infection of macaques and functions as a live attenuated vaccine in that system [87]. 
Further epidemiological and in vitro studies using comparative pathogen genomics to 
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examine these associations are required to fully understand the role of the plasmid in 
human chlamydial disease. 
2.11 Metabolic processes and chlamydial virulence
2.11.1 Tryptophan metabolism
Tryptophan metabolism has been shown to differentiate between ocular and 
urogenital strains of chlamydia, suggesting tissue-specific virulence association. 
Urogenital strains of C. trachomatis have evolved to survive under tryptophan-limited 
conditions through activation of tryptophan-synthase genes and acquisition of indole 
as a substrate from commensal bacterial flora [88]. This is thought to be achieved 
through functional partial tryptophan operons in urogenital strains [89]. Ocular strains 
present an enigma since they should be exquisitely sensitive to IFN-g-mediated 
tryptophan depletion as they do not appear to possess a functional tryptophan operon.
2.11.2 Iron and micronutrients
Hypoferraemia and transferrin receptor modulation is a known consequence of 
the inflammatory response [90]. Chlamydia respond to iron limitation in a regulated 
way, typical of many bacteria [91,92]. Iron in a form usable to the pathogen is often a 
limiting factor in any environment, thus to be able to effectively sequester iron may 
be important to chlamydial virulence. There is evidence that defining metabolic 
activity can give insight into biological processes relating to chlamydial infectivity 
[93]. 
Further studies on nutritional stress and other metabolic processes will emerge 
from a combination of transcriptomal and expression-based analyses in appropriate 
host-pathogen interaction models. These findings suggest that there may be rationale 
in suggesting that other metabolic pathways may be important in defining disease 
severity phenotypes amongst chlamydial strains. In combination with in vitro
experiments, pathogen whole genome sequence analysis and corresponding clinical 
and epidemiological metadata, a more complete picture of metabolic pathways and 
their role may be elucidated.
2.12 Conclusion 
Studying pathogen virulence factors at population level should enable the 
assignment of the relative importance of putative virulence associated genes and loci. 
This requires knowledge of host genetics, the microbial environment at the time of 
infection, host demographic data and longitudinal study as these factors will all 
impact on disease severity and the course of disease. To fully understand these 
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interactions, detailed host-pathogen data are required. Comparative bioinformatics 
analyses are powerful tools that can assist in investigating such complex data sets. 
Identification of pathogen virulence factors is crucial to understanding pathogenesis 
and transmission of infection, and will impact on future public health interventions 
such as surveillance following treatment with antibiotics and the development of a 
chlamydial vaccine. 
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Chapter 3 Study Rationale, Hypotheses, Aims and Objectives
3.1 Study Rationale
The Bijagós Archipelago of Guinea Bissau has a significant burden of both 
active and scarring trachoma, with some of the highest disease rates in the world. The 
reasons why disease is so prevalent and severe on these islands are unclear. Socio-
behavioural, environmental and host-pathogen factors are likely to be important. 
Using the eye as an accessible clearly defined phenotype and whole genome sequence 
analysis in conjunction with next generation PCR technology, a unique opportunity 
existed to investigate the pathogenicity of ocular strains of C. trachomatis in this 
geographically remote treatment-naïve population. Population-based survey 
methodology was employed to investigate trachoma and ocular C. trachomatis
infection in the context of spatial trends in disease, socio-environmental risk factor 
associations, clinical (including disease phenotype and bacterial load) and chlamydial 
whole genome sequence data. 
3.2 Hypotheses
1. The Bijagós Archipelago is trachoma-hyperendemic. 
2. There are socioeconomic and environmental risk factors associated with active 
trachoma on the study islands of the Bijagós Archipelago.
3. There are spatial processes underlying the distribution of active trachoma and 
ocular C. trachomatis infection.
4. There is spatial clustering of ocular C. trachomatis infection.
5. Higher bacterial loads of C. trachomatis are associated with more severe 
clinical disease in active trachoma.
6. There is an association between (virulence) plasmid copy number (per C. 
trachomatis genome) and clinical disease severity.
7. There are genes and loci present on the C. trachomatis plasmid and 
chromosome that are associated with ocular C. trachomatis load and disease 
severity in active trachoma.
8. A single round of community mass drug treatment with oral azithromycin will 
reduce the prevalence and severity of active disease and ocular C. trachomatis
infection on the study islands. 
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3.3 Aims
1. To establish the prevalence and spatial distribution of trachoma and ocular C. 
trachomatis infection on the study islands.
2. To examine the relationship between active trachoma and ocular C. 
trachomatis infection and their socio-environmental risk factor associations.
3. To examine the spatial epidemiology of active trachoma and ocular C. 
trachomatis infection.
4. To examine spatial clustering of ocular C. trachomatis infection in relation to 
C. trachomatis bacterial load.
5. To examine the relationship between clinical disease severity in active 
trachoma and C. trachomatis bacterial load.
6. To examine the relationship between clinical disease severity, C. trachomatis
ocular load and C. trachomatis genomic diversity.
7. To assess the impact of a single round of mass treatment with azithromycin in 
an endemic island setting in the context of the spatial and molecular 
epidemiology of trachoma and ocular C. trachomatis infection.
3.4 Specific objectives  
1. To examine a population-based sample of individuals for clinical signs of 
trachoma and capture the clinical phenotype accurately using a detailed 
trachoma grading system and digital conjunctival photography.
2. To investigate the relationship between clinical phenotype and infection with 
C. trachomatis load using accurate estimates of bacterial load obtained using a 
quantitative next generation droplet digital PCR (ddPCR) using both plasmid 
and genomic targets. 
3. To conduct a household survey to examine socio-environmental risk factors 
for disease at household and individual levels using mixed effects regression 
models.
4. To create prevalence maps for active trachoma and ocular infection with C.
trachomatis using geographic information systems (GIS).
5. To examine the spatial structure of active trachoma and ocular C. trachomatis
infection using measures of spatial autocorrelation and spatial regression 
models.
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6. To examine spatial clustering of ocular C. trachomatis infection in relation to 
C. trachomatis bacterial load using local indicators of spatial association.
7. To obtain C. trachomatis whole genome sequence data directly from C. 
trachomatis ddPCR-positive conjunctival samples to investigate associations 
between clinical phenotype and infecting genotype of C. trachomatis using 
comparative genomics and pathogen genome-wide association scan analysis to 
identify genes and loci associated with disease severity on the C. trachomatis
plasmid and chromosome.
8. To conduct a single round of community mass drug treatment with 
azithromycin on the study islands.
9. To evaluate the effect of a single round of mass drug treatment at one year on 
active trachoma and ocular C. trachomatis infection using geostatistical and 
molecular methods.
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Chapter 4 Study Setting and Study Design
4.1 Study Setting 
The study was conducted on the Bijagós Archipelago of Guinea Bissau, West 
Africa. The study was conducted on four islands (Bubaque, Canhabaque, Soga and 
Rubane) on the archipelago (Figure 1). These four islands comprise a total rural 
population of 5,613 (National Population Census, 2010, Instituto Nacional de 
Estatística, Guiné-Bissau). The Bijagós Archipelago has a total area of more than 
10,000 km2 and is situated approximately 60km off the coast of Guinea Bissau. It is 
possible to travel by boat between Bubaque and each of the other three study islands 
within one hour. The surface area covers approximately 900 km2, of which 350 km2 is 
covered with mangrove forest [1]. Altitude does not exceed 50m. The climate is 
humid and tropical, with a prolonged rainy season, during which average monthly 
rainfall is 400mm3 [2]. The mean monthly temperature is 27.30C (25.1-29.20C), with 
peak temperatures occurring prior to the rainy season. Water sources are available 
within walking distance from all settlements throughout the year. Such climatic and 
environmental factors make these unique trachoma-endemic communities, differing 
greatly to communities inhabiting arid, dusty environments typical of trachoma-
endemic regions. 
There are 88 islands and islets of which only about 20 are permanently 
inhabited. The remainder are inhabited periodically for seasonal agriculture and 
traditional initiation ceremonies. Inhabitants of the island are predominantly 
fishermen and hunter-gatherers, leading a traditional lifestyle in villages within the 
forest (Figure 2). 
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Figure 1. The Bijagós Archipelago of Guinea Bissau
Figure 2. Communities on the Bijagós Archipelago
4.2 Study Design
A cross-sectional population-based household survey with geospatial 
representation on the four study islands was conducted to obtain prevalence estimates 
of infection with C. trachomatis, active and scarring trachoma reflecting the 
geographical setting, risk factor exposure, chlamydial genomic diversity and bacterial 
load. Mass drug administration of azithromycin was conducted in communities in 
accordance with WHO guidelines and evaluated with longitudinal follow-up of the 
treated cohort one year after treatment.
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4.3 Sample size calculation and sampling strategy
The 2010 population census indicated a rural population of 5,613 and pilot 
work suggested a prevalence of TF (1-9 year-olds) of 25% on the four islands. Pilot 
data (Appendix I) were used to make the following calculations. A 1:5 random sample 
of households (with over-sampling in small communities to ensure geospatial 
representation) was expected to lead to an adequate sample of 1,500 people in all 38
villages (Bubaque (14 villages), Canhabaque (17 villages), Soga (5 villages) and 
Rubane (2 villages)). This is representative of a one stage (2nd stage of cluster random 
sampling) probability sample design and satisfied desired criteria for population-
based prevalence surveys [3,4]. 
We expected to find approximately 300 people with active trachoma and at 
least 225 with scarring sequelae. Pilot data (Appendix I) indicated the presence of 
infection in 60% of those with signs of active disease and 10% of those with sequelae. 
Thus we expected to find approximately 200 infections within our sample. 
Oversampling in small settlements aimed to increase the chance of finding an 
infection to represent that space-point for the spatial analysis. A minimum 
requirement of six households or 50 people per settlement was expected to yield five 
infections (or a 1/32 chance of failing to find a case of infection). 
4.4 Statistical power calculation to detect risk factor associations
A sample of 1,500 individuals gave adequate power to detect associations of 
common risk factors with modest effect sizes and rare risk factors with large effect 
sizes using conservative correction (design effect of 4) for anticipated disease 
clustering. Power to detect a risk factor (ocular/nasal discharge) found in 20% of 
normal subjects and 33% of cases (OR (Odds Ratio) = 2, 95% confidence) is 0.92. 
Similarly, with 95% confidence, for a risk factor present in 5% of normal subjects 
with an OR of 3 in cases, power is 0.94 and a risk factor present in 3% of normal 
subjects with an OR of 5 in cases is 0.99.  
Studies investigating the molecular diversity of C. trachomatis have focused 
on a limited number of genetic targets making it difficult to anticipate and quantify 
diversity in terms of allele frequency and strain distribution. Therefore, there was 
limited basis for calculating a sample size for this aspect of the work, particularly with 
the inherent challenges related to obtaining whole genome sequence data directly 
from clinical samples. To compensate for this, stringent p-value thresholds were 
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employed in the analysis of sequence data with relation to detecting associations with 
clinical phenotype (see Chapter 6 and Chapter 10).
4.5 Precision for mapping
Pilot data (Appendix I) suggested that the prevalence of TF in 1-9 year olds ass 
>25% on all four study islands. The sample size calculation allowed the prevalence of 
TF in 1-9 year olds to be estimated at 25% on Rubane (±10%), Soga (±6%) and 
Bubaque and Canhabaque (±4%). This was deemed adequate to determine whether 
the islands would require community mass treatment with azithromycin as per WHO 
and national policy. 
4.6 Participant inclusion and exclusion criteria
Inclusion Criteria
All individuals in the target population who consented or for whom consent was 
obtained were included in the study.
Exclusion Criteria
Individuals who declined to participate, were unable to give consent, or unable to 
participate in the  examination or sample collection due to
x illness
x incapacity 
x inability to communicate 
were not included in the study.
4.7 Protocol for community mass treatment with oral azithromycin
Single dose directly observed mass treatment with oral azithromycin (20mg/kg 
(maximum 1g) for children over the age of 6 months) was administered to rural and 
semi-urban populations on the study islands according to WHO guidelines [5]. 
Individuals with known or suspected hypersensitivity to azithromycin, self-reported 
pregnant women and infants <6 months in age were offered tetracycline eye ointment 
to be applied for six weeks in accordance with national policy. A follow-up survey 
one year following treatment was conducted to evaluate the impact of treatment on 
pathogen diversity, clinical disease, risk factors and spatial distribution using the 
methodology described.
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Chapter 5 Survey, Clinical and Laboratory Methods 
5.1 Field team recruitment and training
A dedicated field team were recruited and trained at the start of the research 
study. They were recruited using a transparent and competitive interview process. 
They were trained in issues surrounding consent and confidentiality, sensitization and 
survey methodology. Specific training was given to field research assistants 
responsible for digital conjunctival photography and procurement and handling of 
conjunctival samples for laboratory analysis. Refresher training sessions were 
conducted throughout the study to ensure high quality field data collection. 
5.2 Community sensitization
Discussions were held in each village with leaders and communities. 
Knowledge and opinions on trachoma and blindness (active disease, trichiasis, 
blindness) and to what extent they felt these were problems in the community were 
discussed. Information about trachoma, its transmission and treatment was given, 
using visual aids. Participation in the study was discussed and agreed at community 
level. Opportunity for questions to be answered was given at each stage of the 
process. The study was further explained to household heads and each adult 
participant using locally accepted infrastructure. 
A ‘Study Advocate’ (leader, health personnel, responsible adult) was identified 
in each village to aid community mobilisation. Broadcasts from the local radio station 
were used to inform about trachoma and publicise the study. 
5.3 Household selection and census
Field assistants identified a responsible adult in the household to consent to 
census data collection. The adult was informed that their household may be included 
in the survey and that household members would be examined for clinical signs of 
trachoma and that conjunctival swabs would be taken. The concept of random 
selection was illustrated using local analogy. Household head lists were generated for 
each village (Appendices II & III) from which 1:5 households were randomly selected 
using a computerized random number generator (RANDBETWEEN, MS Office, 
Microsoft®Office). A responsible adult from each selected household was asked to 
provide the name, gender, and age for all individuals resident in the household using 
the nationally accepted definition of a household; those who are part of the same 
‘fugon’ – i.e. they eat from the same cooking pot. Prior to examination days the field 
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assistants updated the census in the study villages to ensure correct details of the de 
facto population (i.e. those who slept in the household the night before). 
5.4 Ethical approval
This study was conducted in accordance with the declaration of Helsinki. 
Ethical approval was obtained from the Comitê Nacional de Ética e Saúde (Guinea 
Bissau), the LSHTM Ethics Committee (UK) and The Gambia Government/MRC 
Joint Ethics Committee (The Gambia). Ethical approval documentation is presented in 
Appendix IV.
5.5 Informed consent
Consent was obtained at the community level from the village leader. 
Household heads from selected households were asked for verbal consent for the 
household to participate in the risk factor survey after the study information leaflet’s 
contents were explained in the appropriate local language. If the household head was 
absent, the most senior person identified by household members was requested to 
provide consent. For ocular examination, each adult participant was asked for written 
consent before participating in the study. For all children examined, written (or 
thumbprint) consent was obtained from the parent/guardian or household head and 
witnessed, with the witness also signing the consent form. If consent was not 
obtained, such households or individuals were excluded. See Appendix V for consent 
information and forms (English and Portuguese).
5.6 Risk Factor Survey
Geographical, demographic, socio-economic and environmental information 
was collected at the household and individual levels (Appendix VI). Household-level 
risk factor data were obtained using questionnaires administered to the household 
head and included the level of household head education, presence and use of latrines, 
water and sanitation and whether there had been a face washing health education 
programme in the community in the last year. Individual-level data on facial 
cleanliness (the presence of ocular and/or nasal discharge and whether or not there 
were flies on the face during examination) were collected at the time of examination 
(Appendix VII). 
Demographic, socio-economic and environmental information was collected 
at household and individual levels. Household-level risk factor data were obtained 
using questionnaires administered to the household head or an appropriate responsible 
adult and included items on the level of education of the household head, their socio-
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economic status, whether the household had been exposed to any health education or 
promotion within the community, household access to and use of latrines, access and 
use of water and measures of sanitation, waste and presence of flies in the 
environment. The questionnaire was supported through observational data collected 
on water use, latrine use and environmental sanitation. Household size (measured as 
number of members of all ages) and number of children under the age of 10 years 
within the household was recorded. The researcher (AL) was blinded to the household 
members’ trachoma status at the time of collection of household level risk factor and 
geospatial data.
5.7 Geo-coding Data 
To satisfy adequate geospatial representation at village-level, all 38 villages on 
the four study islands were included in the survey. Small villages may be over-
represented by the minimum sampling criteria imposed: 1:5 households were sampled 
with a minimum number of households required per village (six) to ensure spatial 
representation of that settlement. In very small settlements with less than six 
households in total, all households were sampled. Data were geo-coded at household 
and village level using the Garmin eTrex H handheld Global Positioning Systems 
(GPS) unit (Garmin Ltd., UK).
Each Garmin eTrex H was coded for use during the surveys. Waypoints were 
marked with accuracy P:D\SRLQWVZHUHUHFRUGHGRQGDWDIRUPVXVLQJWKH
device code, waypoint number and GPS coordinates (Appendix VII). Data were saved 
on the device and downloaded each day using Garmin MapSource® v6.16.3 (Garmin 
Ltd., UK). GPS coordinates were projected into UTM Zone 28N in MapSource® and 
subsequently merged with the main database using household codes.
5.8 Ocular Assessment
Following the household risk factor survey all individuals from study 
households were invited to attend for clinical examination and conjunctival sampling 
at a central examination point in the village. Individuals’ age, sex and ethnic group 
and data on facial cleanliness (the presence of ocular and/or nasal discharge and 
whether or not there were flies on the face) were collected at the time of examination. 
The examination team performed up to two further visits to that village to maximise 
uptake of the examination. Reserve households were used if households were unable 
or unwilling to attend for examination. 
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A trained examiner (AL) assessed each participant using two grading systems 
(detailed in Tables 1&2 in Chapter 1.4). The WHO simplified [1] and modified FPC 
[2] grading systems were employed to assign a trachoma grade to the right and left 
upper tarsal conjunctivae of each consenting participant using adequate light and a 
2.5x binocular magnifying loupe. Both methods were used in order that the data from 
this study should be comparable to data from other studies and with control 
programme parameters, and so that detailed information relating to disease severity 
was recorded to test the hypotheses for this study. In the modified FPC system, 
follicles (F), papillae (P), conjunctival scarring (C), trichiasis and entropion (T/E) and 
corneal opacification (CC) are each assigned a separate grade from 0-3. FPC grades 
of F2/3 or P3 equate to a diagnosis of active disease (TF or TI by the WHO simplified 
system).  
The examiner (AL) was standardized annually (achieving Kappa scores of 
0.85 using the WHO simplified grading system in the field and with conjunctival 
photographs) against an international expert in trachoma grading (RB), and conducted 
all conjunctival examinations and obtained all conjunctival swabs. 
              
Ocular assessment for clinical signs of trachoma in the field
5.9 Conjunctival digital photography
Two digital photographs were taken of each left everted upper tarsal 
conjunctiva to record the clinical phenotype (Appendix VIII). These serve as a record 
of evidence for clinical phenotype at baseline that may be useful in future longitudinal 
studies. The WHO simplified grading and conjunctival digital photography methods 
are robust, reproducible and objective [3]. Both WHO and modified FPC grading 
systems have been used previously in similar settings [4,5].
5.10 Conjunctival sampling  
Two specimens from the upper tarsal conjunctiva of the left eye of each 
participant were obtained with Dacron swabs (Fisher Scientific) using a validated, 
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well-tolerated standardised procedure involving sweeping the swab three times 
horizontally across the upper tarsal conjunctiva rotating the head of the swab by 1/3 
with each pass [3] The first swab was stored in Copan Universal Transport Medium 
(UTM) (Copan Diagnostics Inc., USA) for chlamydial culture and whole genome 
sequencing. The second dry swab was collected for molecular diagnostics. 
Obtaining samples and digital photographs of the conjunctiva in the field. 
5.10.1 Maintenance of the cold chain
The swabs were kept on ice in the field and frozen to -800C within 8 hours of 
collection. Specimens were transported in batches in liquid nitrogen dry shippers from 
the field base to the MRC Laboratories in Fajara, The Gambia for continued storage at 
-800C. Following DNA extraction, sample extract was stored at 40C. Swabs collected 
in UTM for chlamydial culture were maintained at -800C throughout.
5.10.2 Specimen collection quality control (QC)
To avoid cross-contamination in the field, the examiner (AL) changed gloves 
before each participant was examined. A new packet containing two swabs was used 
for each participant. The swab was passed to the examiner by a field assistant in its 
newly opened packaging. The field assistant also wore gloves and providing that no 
used swabs were touched and there was no visible dirt on the gloves, they were 
changed after every 15 examinations. Swabs were stored in cryovials. Labels with 
unique swab identifiers were placed on each cryovial and the corresponding data 
forms (Appendices VII, IX, X). 
Control swabs (1 in every 100) were also taken to ensure both field and 
laboratory QC. These were swabs that were pre-marked and drawn at random from 
the swab dispenser in the field. Instead of passing the swab over the conjunctiva, 
when a control swab was taken, the field assistant would alert the examiner, who 
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would pass the swab 10cm in front of the eye ensuring that no contact was made 
between the swab tip and the participant. In all other respects, the control swab would 
be treated in the same way as any other, including labeling. The data form label was 
placed in a designated box on the form (Appendices VII & X). These swabs were 
processed in the same way as all other samples in the laboratory, with the laboratory 
operator masked to the fact that they were control swabs. 
5.11 Laboratory processing of conjunctival specimens
5.11.1 DNA extraction 
DNA was extracted from swabs by a single operator. After suspending the dry 
swab in sterile phosphate buffered saline (PBS), DNA was extracted from the dry 
swab using an adapted whole blood protocol on the QIAxtractor® (Qiagen, Crawley, 
UK) automated instrument (Appendix XI).
5.11.2 Detection of Chlamydia trachomatis 
Qualitative detection of C. trachomatis DNA was performed using the 
validated Roche Amplicor® CT/NG PCR assay (Roche Molecular Systems, NJ USA) 
(Appendix XII). Quantitative detection was performed using a next generation droplet 
digital PCR assay that was evaluated against Amplicor during this study [6] 
(Appendices XII-XIII).
5.11.3 Quantitation of chlamydial load
The Droplet Digital™ PCR (ddPCR™) system (Bio-Rad Laboratories, Hemel
Hempstead, UK) was used to quantitate both the chlamydial plasmid and 
chromosome in each sample. ddPCR is considered the third generation of PCR 
technology, enabling the absolute quantitation of target DNA molecules, rather than a 
relative measure obtained with real-time PCR.  Following generation of an oil/water 
emulsion droplet which partitions each sample into thousands of nanolitre-sized 
droplets, PCR is performed on a thermal cycler (C1000 Touch™). Each droplet 
contains PCR mastermix (11!l), nuclease-free water (3.85!l), forward and reverse 
primers and probes for the human DNA target (HURNASE-P), which acts as an 
endogenous control, and one of either the cryptic plasmid or the chromosomal target 
(omcB) (total 2.2!l of primer/probe supermix depending on chosen target). Each well 
containing droplets is inoculated with DNA extract (4.95!l). Four wells per plate 
serve as no template controls. After PCR, droplets from each sample are streamed 
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single file through the QX100™ droplet reader. Each droplet produces a fluorescent 
positive or negative signal indicating whether target DNA is present or not. Positive 
and negative droplets are counted in each sample and the concentration of target DNA 
is calculated (per !l) automatically by QX100™ software. Table 1 shows the 
primer/probe sequences in the assay and Figure 1 illustrates the process. Detection 
and quantitation methods have been published for use in this study [6-8].
Table 1. Primer and probe sequences for control and C. trachomatis targets using the 
ddPCR system
Molecular Target Nucleotide sequence and modification
Internal Control: Homo sapiens RPP30 (encoding ribonuclease 
P/MRP 30kDa subunit)
Forward (HURNASE-P-F) 5’ AGA TTT GGA CCT GCG AGC G 3’
Reverse (HURNASE-P-R) 5’ GAG CGG CTG TCT CCA CAA GT 3’
Probe (HURNASE_HEX_BHQ1) 5’ FAM-TTC TGA CCT GAA GGC TCT 
GCG CG-BHQ1-3’
Target One: C trachomatis cryptic plasmid pLGV440 (circular; 
genomic DNA; 7500bp)
Forward (Ct-Plasmid-F) 5’ CAG CTT GTA GTC CTG CTT GAG 
AGA 3’
Reverse (Ct-Plasmid-R) 5’ CAA GAG TAC ATC GTT CAA CGA 
AGA 3’
Probe (Ct-plasmid_FAM_BHQ1) 5’ HEX-CCC CAC CAT TTT TCC GGA 
GCG A-BHQ1-3’
Probe (Ct-plasmid_HEX_BHQ1) 5’ HEX-CCC CAC CAT TTT TCC GGA 
GCG A-BHQ1-3’
Target Two: C. trachomatis (Serovar A) omcB gene
Forward (Ct-OMCB-F) 5’ GAC ACC AAA CGC AAA GAC AAC 
AC 3’
Reverse (Ct-OMCB-R) 5’ ACT CAT GAA CCG GAG CAA CCT 
3’
Probe (Ct-OMCB-HEX-BHQ1) 5’FAM-CCA CAG CAA AGA GAC TCC 
CGT AGA CCG-BHQ1-3’
D?
Figure 1. Droplet Digital PCR Workflow
5.12 Whole genome sequencing of Chlamydia trachomatis
5.12.1 Pre-sequencing sample enrichment (SureSelectXT)
Whole genome sequence (WGS) data were obtained direct from clinical 
samples. DNA baits spanning the length of the C. trachomatis genome were compiled 
by SureDesign and synthesized by SureSelectXT (Agilent Technologies, UK). C. 
trachomatis DNA extract from clinical samples was quantified and carrier human 
genomic DNA added to obtain a total of 3 !g input for library preparation. DNA was 
sheared using a Covaris E210 acoustic focusing unit. End-repair, non-templated 
addition of 3’ –A adapter ligation, hybridisation, enrichment PCR and all post-
reaction clean-up steps were performed according to the SureSelectXT Illumina 
Paired-End Sequencing Library protocol (V1.4.1 Sept 2012). All recommended 
quality control measures were performed between steps.
5.12.2 Chlamydial DNA sequencing 
Pathogen whole genome sequencing was undertaken at the Wellcome Trust 
Sanger Institute. 
1.Droplet generation 2.Amplification by PCR
Droplet generation allows partition of PCR reaction mixture. Each reaction 
partitioned into 20,000 droplets with target and background DNA randomly 
distributed among reactions
3.Detection: Each reaction 
produces a +/- fluorescent signal 
indicating presence of absence of 
target DNA per droplet. Fraction of 
+ droplets used to calculate 
concentration DNA/!l for pathogen 
and human targets.
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5.12.2.1 Next generation Illumina sequencing
Illumina (Genome Analyzer IIx or HiSeq2000, Illumina Inc.) sequencing uses 
cluster generation followed by sequencing by synthesis methods using a reversible 
terminator-based method that enables detection of single bases as they are 
incorporated into growing DNA strands. A fluorescently-labelled terminator is 
imaged as each deoxyribonucleoside triphosphate (dNTP) is added and then cleaved 
to allow incorporation of the next base. Since all four reversible terminator-bound 
dNTPs are present during each sequencing cycle, natural competition minimises 
incorporation bias. The end result is true base-by-base sequencing (Figures 2 & 3).
Figure 2. Cluster generation by bridge amplification (Illumina)
Illumina utilizes a unique "bridged" amplification reaction that occurs on the surface of the flow cell. 
The flow cell surface is coated with single stranded oligonucleotides that correspond to the sequences of the 
adapters ligated during sample preparation. Single-stranded, adapter-ligated fragments are bound to the surface of 
the flow cell exposed to reagents for polyermase-based extension. Priming occurs as the free/distal end of a ligated 
fragment "bridges" to a complementary oligo on the surface. (www.illumina.com) 
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Figure 3. Sequencing by Synthesis (Illumina)
A flow cell containing millions of unique clusters is loaded into the sequencer for automated cycles of extension 
and imaging. The first cycle of sequencing consists first of the incorporation of a single fluorescent nucleotide, 
followed by high resolution imaging of the entire flow cell. Any signal above background identifies the physical 
location of a cluster, and the fluorescent emission identifies which of the four bases was incorporated at that 
position. This cycle is repeated, one base at a time, generating a series of images each representing a single base 
extension at a specific cluster. The use of physical location to identify unique reads is a critical concept for all next 
generation sequencing systems. (www.illumina.com) 
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Chapter 6 Analytical Methods
6.1 Data cleaning
Demographic, socio-economic, clinical and laboratory data were double 
entered into a customised database (Microsoft Access 2007) and discrepancies 
resolved through reference to original data forms. Data were cleaned and analysed in
STATA 13 (Stata Corporation, College Station, Texas USA) and the R statistical 
package v3.0.2 (The R Foundation for Statistical Computing (http://www.r-
project.org). 
6.2 Prevalence and socio-environmental risk factor association analysis 
Random effects logistic regression models were used to assess the variability 
between villages and households assuming a three tier hierarchy to the data (at 
village, household and individual levels). Null models were used to examine the 
effect of cluster variables on the outcome using the likelihood ratio test (LRT). The 
log likelihood and the LRT were used to compare models.
Univariable associations with active trachoma (TF/TI) and infection with C. 
trachomatis were examined using two-level hierarchical random effects logistic 
regression, accounting for between-household variation. Covariates associated with 
active trachoma or C. trachomatis infection with p<0.10 (using the Wald test) were 
sequentially added to multivariable models after a priori adjustment for age and 
gender. Covariates were retained in the final model if the Wald p-value 0.05 unless 
otherwise specified. Further exploration of environmental predictor variables was 
conducted using logistic and hierarchical random effects logistic regression models as 
appropriate using the same criteria. C. trachomatis infection is on the causal pathway 
between several risk factors and active trachoma, therefore models with and without 
C. trachomatis infection were fitted. The model including C. trachomatis infection 
provides estimates of independent associations of other risk factors with active 
trachoma which are not mediated through C. trachomatis infection. Statistical 
significance was determined at the 5% level.
6.3 Disease severity and C. trachomatis infection association analysis 
C. trachomatis load data were log(e) transformed due to the presence of 
significant negative skew. The geometric mean of load, respective standard error (SE) 
and 95% confidence intervals (CI) were calculated. An analysis of variance 
(ANOVA) with pair-wise comparisons was used to compare load across detailed 
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clinical phenotypes. Assessment of group differences and multiple comparisons were 
adjusted for using the Scheffé correction [1]. Associations between load and detailed 
clinical phenotype were examined using univariable and multivariable mixed effects 
linear and logistic regression models accounting for household-level clustering as 
described in section 6.2. 
6.4 Geospatial analysis of disease and infection 
Geocoded data were projected into UTM Zone 28N. ArcGIS 10.1 (ESRI Inc., 
USA) and the R statistical package v3.0.2 (The R Foundation for Statistical 
Computing (http://www.r-project.org) using spdep, automap and nlme packages) were 
used for geostatistical analyses [2-4].
6.4.1 Conceptualisation of spatial relationships
Spatial statistics integrate space and spatial relationships into statistical 
models. This requires adequate conceptualisation of spatial relationships within these 
models. There are a number of methods that can be used to conceptualise spatial 
relationships. These include inverse distance, fixed distance, zone of indifference, K 
nearest neighbour, and contiguity models. The choice of model is dependent on the 
nature of the observations in the data set. 
The first three strategies are discussed as they are most relevant to the point 
data collected in this study. Other strategies are more suited to polygon data. The 
inverse distance models represent distance decay or impedance suggesting that the 
impact is reduced with increasing distance (Figure 1(A)). Fixed distance models are 
useful when fixed distances are known, such as travel-related distance. The fixed 
distance model imposes a sliding window across the data, outside which observations 
do not influence the model (Figure 1(B)). Neighbouring observations within this 
window are all weighted equally. The zone of indifference (Figure 1(C)) combines 
both inverse distance and fixed distance concepts, such that observations within a 
threshold distance are included as they would be within a fixed distance model. 
Beyond that critical threshold cut-off, the level of influence decays, as with the 
inversed distance model.
Fixed distance and zone of indifference methods are most appropriate with 
point data. The zone of indifference has the added benefit that it does not impose 
sharp boundaries on neighbouring relationships. The zone of indifference includes all 
observations as neighbours of each other. 
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Figure 1. Representation of the conceptualisation of key spatial relationships for use 
in geostatistical analyses.
(A) Inverse distance (distance decay)
(B) Fixed distance window
(C) The zone of indifference
Where y = Impact/Weight and x = 
Distance
In the spatial analyses conducted, the zone of indifference was used to define 
adjacency. This method assumes that each observation has local influence that 
decreases with distance beyond a critical distance cut-off, resulting in an adapted 
model of impedance, or distance decay, such that all features have an impact on all 
other features, but this impact decreases with distance. This method is appropriate for 
point data and takes into account the extent of spatial autocorrelation in selecting a 
data-driven threshold cut-off of 1700m, derived from semivariogram analysis (see 
Chapter 8).
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6.4.2 Spatial autocorrelation
Spatial analysis offers powerful methods to study the relationship between 
disease and infection. The spatial relationship between disease and infection defined 
over space is termed spatial dependence. This is measured as the existence of 
statistical association (dependence) between disease and infection associated with 
location. To explore spatial dependence measures of spatial autocorrelation are used. 
Spatial autocorrelation assumes that near objects are more related than distant 
objects. In the context of infectious disease, this concept may be applied to explore
the relationship between infection and disease where the spatial distribution can be 
used to define underlying processes such as exposure or transmission. Spatial 
regression models can be used to enhance current understanding of the epidemiology 
infectious disease.
Global spatial autocorrelation statistics are used to describe the overall spatial 
patterns in the data. Local indicators of spatial association take actual values of 
observations in the context of adjacent values allowing mapping and definition of
clusters at exact locations. This allows for the examination of small-scale 
heterogeneity and identification of statistically significant clusters and outliers of 
similar observations in space. 
6.4.2.1 Global Spatial Autocorrelation: Moran’s I
The Moran’s I statistic was used to evaluate global spatial autocorrelation in 
the distribution of the household-level prevalence of disease and infection. The values 
of Moran’s I range between -1 and +1. A value close to -1 indicates negative 
autocorrelation (complete dispersion) whilst a value close to +1 indicates positive 
autocorrelation (clustering) of features. A value close to 0 suggests random 
arrangement. Z-scores and p-values are assigned to ascertain whether spatial 
autocorrelation is statistically significant [5]. Since the Moran’s I statistic can be 
sensitive to skewed distributions, a permutation test was used to verify the results. 
This uses Monte Carlo simulations to generate a Moran’s I sampling distribution [6].
Empirical semivariograms were constructed to obtain the distance range over 
which spatial autocorrelation occurs using the average squared distance between 
paired data values against the distance (or lag) separating the pairs to estimate the 
spatial covariance structure of the data [7].
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6.4.2.2 Local Indicators of Spatial Association 
In this analysis, ‘low’ values include both low values related to low load 
infections and null (zero) values related to uninfected individuals. To explore this, 
these analyses were conducted first on the whole data set, including uninfected 
individuals with a ‘zero’ value for infectious load, and then on infected individuals 
only.
6.4.2.2.1 Local (Anselin) Moran’s I
Clustering and outlier analysis was conducted using the local (Anselin) 
Moran’s I statistic [8]. A positive value for I indicates that a feature has neighbouring 
features with similarly high or low attributable values (a cluster). A negative value for 
I indicates that neighbouring features have dissimilar values and that this feature is an 
outlier. Cluster-Outlier analysis identifies spatial clusters of features with high or low 
values and spatial outliers by calculating Moran’s I, Z-scores, p-values and a code to 
represent the cluster type. Cluster types are defined as clusters of high values (HH, 
High-High), clusters of low values (defined as above) (LL, Low-Low), a high value 
outlier surrounded by predominantly low values (HL, High-Low) and a low value 
outlier surrounded by predominantly high values (LH, Low-High). 
6.4.2.2.2 Getis-Ord Gi*
The Getis-Ord Gi* statistic was used to identify hot and cold spots for
infection [9]. The Getis-Ord Gi* identifies statistically significant ‘hotspots’ 
containing similarly high values and statistically significant ‘cold spots’ containing 
similarly low values, taking into account the spatial dependence of neighbouring
observations [10]. Z-scores and p-values are expressed for each Gi* value in 
comparison with the normal distribution of Gi* calculated by simulation. These 
values represent the statistical significance of the spatial clustering of values given the 
conceptualisation of spatial relationships and scale of analysis described. Statistically 
significant high z-scores show clustering of high load infections, whilst statistically 
significant low z-scores show clustering of low (or zero) load infections.
6.4.3 Geographically weighted spatial regression analysis
Geographically weighted spatial regression allows for modelling of spatially 
variable relationships, such that the statistical model can vary depending on location. 
Linear and logistic mixed effects regression models were applied to examine the 
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covariance structure and compare models with and without a spatial component. The 
log likelihood, Akaike information criterion (AIC) and Bayesian information criterion 
(BIC) were used to compare models [11].
6.5 Chlamydia trachomatis whole genome sequence analysis
In order to obtain the highest quality data set for comparative genomics 
analysis, a data-driven approach is required. This is an iterative process and each 
stage of the pipeline can inform the next in terms of appropriate algorithms employed. 
Interrogation of informatics data can determine the most appropriate downstream 
analysis, therefore for this study we employed this data-driven approach resulting in 
the following pipeline for quality control and analysis to address the research 
hypotheses. Raw sequencing data in fastq format are available from the Wellcome 
Trust Sanger Institute through ftp://ftp.sanger.ac.uk/pub/pathogens/projects/LSHTM. 
6.5.1 Raw Data Quality Assessment (FastQC)
FastQC is a quality control application for high throughput sequence data 
available from the Babraham Bioinformatics Institute 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw fastq files were 
used to obtain results from standard QC checks. FastQC provides detail on basic 
quality statistics of each fastq file, such as total sequence length, GC content (%), read 
length and filtered sequences. It summarizes per base sequence quality, sequence 
length distribution and information on duplicate and overrepresented sequences, 
adapter content and kmer content. 
6.5.2 Raw Data Trimming (Trimmomatic)
Trimmomatic is a flexible pre-processing trimming tool for paired-end 
sequence data. It includes a variety of processing steps for read trimming and filtering 
with the main algorithmic innovations related to identification of adapter sequences 
and quality filtering. This algorithm first removes technical sequences using a simple 
user-supplied technical sequence that is matched to the sequence data, and a 
‘palindromic’ approach where short read lengths of adapter contamination are found 
at the ends of the reads. Quality filtering then employs standard sliding window and 
maximum information approaches. The latter ensures that the trimming process 
becomes increasingly stringent as it progresses through the reads, rather than applying 
a fixed quality threshold, it uses an adaptive approach incorporating a minimum 
length threshold, coverage (based on retained sequence length) and error rate (where 
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error probabilities from read quality socres are used to determine the accumulated 
likelihood of errors over the read). Trimmomatic performs well in challenging 
scenarios with poor quality sequence data [12].
6.5.3 Mapping to reference strains 
Sequences were aligned to publically available reference strains Chlamydia 
trachomatis A/HAR-13 (GenBank Accession Number NC_007429.1), C. trachomatis 
B/Jali20/OT (EMBL Accession Number FM872308), C. trachomatis L2 434 Bu 
(EMBL Accession Number AM884176), C. trachomatis D/13-96 (GenBank 
Accession Number NC_022119) and an assembled C. trachomatis sequence from 
pilot studies (Bijagos_86) using BWA [13]. Results from preliminary mapping to all 
reference strains was similar, therefore C. trachomatis A/HAR-13 was chosen as the 
reference for subsequent analyses (Figure 2). 
Figure 2. C. trachomatis whole genome sequences from study samples mapped to C. 
trachomatis reference strains using BWA
bijagos = assembled C. trachomatis genome from current clinical sample set, dtype = C. trachomatis 
D/13-96, har13 = C. trachomatis A/HAR-13, jali20 = C. trachomatis B/Jali20/OT, l434 = C. 
trachomatis L2 434 Bu
SAMTOOLS/BCFtools (SAMTOOLS) [14] and GATK [15] were used to call 
SNPs and small indels.
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6.5.4 Phylogenetic analysis using RAxML
The best-scoring maximum likelihood phylogenetic trees were constructed 
based on SNPs across the genome using RAxML v7.4.2 [16] using all SNP sites 
spanning the genome.
6.5.5 Recombination analysis using PhiPack and RAxML
Three compatibility-based recombination detection methods were applied to 
detect recombination hotspots using PhiPack [17]: the pairwise homoplasy index 
(Phi) [17], the maximum Chi2 [18] and the neighbour similarity score (NSS) [19] 
across the genome alignment. The confidence in the phylogenetic tree was examined 
by computing RAxML site-based likelihood scores across the genome [16]. Final 
phylogenetic trees were constructed adjusting for recombination [16].
6.5.6 Single Nucleotide Polymorphism (SNP) calling algorithms
Variants were selected as the intersection dataset between those obtained 
using both SNP callers and SNPs were further quality-filtered by mappability and 
uniqueness using the R statistical package v3.0.2 (The R Foundation for Statistical 
Computing, http://www.r-project.org) [20]. Non-unique SNPs with mappability 
values greater than one were filtered and SNP alleles were called using an alternative 
coverage-based approach where a missing call was assigned to a site if the total 
coverage was less than 20x depth or where one of the four nucleotides accounted for 
at least 80% total coverage [20]. There was a clear relationship between the average 
depth of coverage and proportion of missing calls, which provided a further quality 
filtering threshold (Figure 3). Based on these criteria, all sequences with greater than 
10x average depth of coverage over the whole genome were retained.
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Figure 3. Average depth of coverage of reads across the genome compared to the 
proportion of missing calls by SNP calling algorithm
6.5.7 Chlamydial diversity using Tajima’s D
Tajima’s D was calculated using the pegas and ape packages in R. Tajima’s D 
tests the neutral mutation hypothesis by DNA polymorphism such that a negative 
Tajima’s D implies an excess of low frequency polymorphisms suggesting population 
expansion and/or purifying selection and a positive Tajima’s D indicates low levels of 
both high and low frequency polymorphisms indicating a decreasing population size 
and/or balancing selection. A negative Tajima’s D suggests that rare alleles may be 
present at low frequency, indicating a recent population expansion following a 
bottleneck event. A positive Tajima’s D suggests that there are multiple alleles 
present, some at low and some at high frequencies, and sudden population contraction 
causing balancing selection [21].
6.5.8 Chlamydial genome wide association scan (GWAS)
Genome wide association scans (GWAS) are powerful tools to assess the 
excess association between a SNP and defined phenotype. This method is confounded 
by population structure and linkage disequilibrium (LD) [22]. Therefore principal 
component analysis (PCA) was used to elucidate the population structure. Principal 
components from this were included in the GWAS models to adjust for this. Genomic 
inflation was corrected for with the occurrence of a polymorphism in the population 
of over 90% and a minor allele frequency of 5% in binary and linear models (3% in 
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ordinal models). To avoid the occurrence of false positive associations we used a 
conservative Bonferroni correction for multiple testing for genome-wide significance 
based on retaining 759 SNPs in the analysis. This resulted in a threshold p-value for 
genome-wide significance of 6.25xe-05. 
SNP mutations were aggregated by coding and intergenic regions in an n x m 
matrix, where n=number of loci and m=number of sequences. In coding regions only 
non-synonymous mutations were aggregated.
Regression analyses were performed adjusting for age and population 
structure using the first three principal components. Logistic regression models were 
used to assess the association between disease phenotype (binary models for active 
trachoma and ordinal models for conjunctival inflammation) and SNPs across the C. 
trachomatis genome using MASS and glmm packages in R. Linear regression models 
with C. trachomatis load as a continuous outcome were used to assess the association 
between C. trachomatis ocular load and SNPs across the genome. The statistical 
significance of each variable was tested using the Wald test. The standard error for the 
log odds ratio was estimated from the model and used to calculate 95% confidence 
intervals for odds ratios (OR).
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Abstract
Background Trachoma, caused by ocular infection with Chlamydia trachomatis, is 
hyperendemic on the Bijagós Archipelago of Guinea Bissau. An understanding of the 
risk factors associated with active trachoma and infection on these remote and 
isolated islands, which are atypical of trachoma-endemic environments described 
elsewhere, is crucial to the implementation of trachoma elimination strategies.
Methodology/Principal Findings A cross-sectional population-based trachoma 
prevalence survey was conducted on four islands. We conducted a questionnaire-
based risk factor survey, examined participants for trachoma using the World Health 
Organization (WHO) simplified grading system and collected conjunctival swab 
samples for 1507 participants from 293 randomly selected households. DNA 
extracted from conjunctival swabs was tested using the Roche Amplicor CT/NG PCR 
assay. The prevalence of active (follicular and/or inflammatory) trachoma was 11% 
(167/1508) overall and 22% (136/618) in 1-9 year olds. The prevalence of C.
trachomatis infection was 18% overall and 25% in 1-9 year olds. There were strong 
independent associations of active trachoma with ocular and nasal discharge, C. 
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trachomatis infection, young age, male gender and type of household water source. C. 
trachomatis infection was independently associated with young age, ocular discharge, 
type of household water source and the presence of flies around a latrine.
Conclusions/Significance In this remote island environment, household-level risk 
factors relating to fly populations, hygiene behaviours and water usage are likely to be 
important in the transmission of ocular C. trachomatis infection and the prevalence of 
active trachoma. This may be important in the implementation of environmental 
measures in trachoma control. 
Author Summary
Trachoma, caused by ocular infection with Chlamydia trachomatis, is the leading 
infectious cause of blindness worldwide. The World Health Organization elimination 
strategy includes community mass treatment with oral antibiotics, education regarding 
hygiene and facial cleanliness and environmental improvements. Population-based 
trachoma prevalence surveys are essential to determine whether community 
interventions are required. Knowledge of risk factors associated with trachoma and C. 
trachomatis infection in a particular setting may help prioritise trachoma elimination 
activities. We conducted a trachoma prevalence survey to establish the prevalence of 
active (follicular and/or inflammatory) trachoma and C. trachomatis infection on the 
Bijagós Archipelago of Guinea Bissau. We also collected household risk factor data 
from survey participants. Active trachoma prevalence was 11% overall and 22% in 
children aged 1-9 years. C. trachomatis infection prevalence was 18% overall and 
25% in children aged 1-9 years. Active trachoma and the presence of C. trachomatis 
infection were strongly correlated. Risk factors for disease and infection were similar. 
In this environment, measures of facial cleanliness (ocular and nasal discharge) and 
household-level risk factors relating to fly populations, hygiene behaviours and water 
usage are likely to be important in C. trachomatis transmission. This may have 
implications in the implementation of trachoma elimination activities. 
Introduction
Trachoma is caused by ocular infection with Chlamydia trachomatis and is the 
leading infectious cause of blindness worldwide. It manifests as distinct clinical 
syndromes beginning with an acute self-limiting keratoconjunctivitis, which 
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following repeated episodes may progress to a more chronic inflammatory and 
immunofibrogenic process leading to conjunctival scarring and blinding sequelae. 
Trachoma is endemic in 50 countries, with 325 million people at risk of blinding 
disease [1]. Trachoma is responsible for visual impairment in 1.2 million people and
3% of blindness globally [1]. The highest prevalence of active trachoma 
(trachomatous inflammation-follicular (TF) and/or trachomatous inflammation-
intense (TI)) is in sub-Saharan Africa and the distribution of disease is heterogeneous 
[2]. 
Ocular C. trachomatis is probably transmitted between individuals through direct 
spread from eye to eye during close contact, direct or indirect spread of infected nasal 
or ocular secretions on fingers or cloths (fomites) and indirect passive transmission by 
eye seeking flies. There is no known animal reservoir of C. trachomatis in endemic 
environments, the primary reservoir being young children.
Blinding trachoma is usually found in hot, arid, dusty regions. A recent systematic 
review examined studies reporting higher trachoma prevalence in savannah areas and 
areas of lower rainfall, and found weak but consistent evidence supporting anecdotal 
findings that trachoma is associated with semi-arid environments [3].
This study was conducted on the Bijagós Archipelago, a remote group of islands off 
the coast of Guinea Bissau with a total population estimated at 24,000 [4], where 
trachoma is hyperendemic. The climate and environment are not typical of trachoma-
endemic areas. The islands are covered with subtropical forest and altitude does not 
exceed 50m. The climate is tropical, hot and humid. The islands are surrounded by 
mangroves and mudflats. There is significant rainfall (average 400mm/month) from 
May to November [5].
Many studies have suggested that the prevalence of trachoma is associated with 
environmental risk factors such as poor sanitation, access to water and latrine use 
[6,7]. Eye-seeking flies (Musca sorbens) have also been associated with trachoma as 
passive vectors [8] but significant disease exists in areas where fly populations are 
scarce and are therefore less likely to contribute to trachoma transmission [9]. M. 
sorbens preferentially breeds in human faeces and there may be association between 
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fly populations and lack of latrine access or use [6,8]. Social risk factors such as 
migration events and crowded living conditions have also been shown to be important 
in transmission of C. trachomatis and the appearance of active trachoma [10,11]. 
Clustering of disease at the community, household and bedroom levels has been noted 
and is likely to reflect the dynamics of transmission between family members with 
prolonged close contact [6,10-12]. Most transmission events have been shown to 
occur at the household level with more gradual spread within the community [13]. 
The World Health Organization (WHO) advocates the implementation of the SAFE
strategy (Surgery for trichiasis, Antibiotics for active infection, Facial cleanliness to 
prevent disease transmission and Environmental improvement to increase access to 
water and sanitation) for trachoma elimination. The WHO recommends annual mass 
treatment of entire communities with oral azithromycin for three years if the 
prevalence of TF in 1-9 year olds within a district or community exceeds 10%. Mass 
antibiotic treatment aims to clear infection from communities such that transmission 
ceases to be a public health concern [14]. Following this, an assessment is made of A, 
F and E interventions and a decision is taken to continue or cease treatment [15]. 
Despite their inclusion in the SAFE strategy, local environmental factors are not well 
understood, though many are potentially modifiable risk factors for infection and 
disease. The relative importance of these risk factors is not clear and may differ 
between communities. Fewer studies have investigated risk factors for disease and 
infection simultaneously [16-19]. Understanding risk factors associated with trachoma 
and C. trachomatis infection may increase our understanding of disease and 
transmission dynamics allowing for optimization of community-specific 
interventions.
We examined household and individual-level risk factor associations with ocular C. 
trachomatis infection and active trachoma in this unique environment, where 
trachoma is a significant public health problem. Prior to these surveys, these 
communities were treatment-naïve and had not been exposed to any trachoma control 
interventions. 
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Methods
Ethical Approval
This study was conducted in accordance with the declaration of Helsinki. Ethical 
approval was obtained from the Comitê Nacional de Ética e Saúde (Guinea Bissau), 
the LSHTM Ethics Committee (UK) and The Gambia Government/MRC Joint Ethics 
Committee (The Gambia). Verbal consent was obtained from community leaders. 
Written informed consent was obtained from all study participants or their guardians
on their behalf if participants were children. A signature or thumbprint is considered 
an appropriate record of consent in this setting by the above ethical bodies.
Study Design and Population
We conducted a cross-sectional population-based trachoma prevalence survey on four 
islands of the Bijagós Archipelago of Guinea Bissau (Bubaque, Canhabaque, Soga 
and Rubane) in January 2012. Trachoma survey methodology has been described 
previously [20-22]. We randomly sampled one in five households, representing a one 
stage probability sample design satisfying desired criteria for population-based 
prevalence surveys [20,21]. A sample size of 1500 ensured adequate power with 
conservative correction (using a design effect of 4) to account for anticipated 
household clustering. The sample size provides over 90% power to detect an odds 
ratio (OR) of 2 associated with a risk factor found in 20% of subjects without disease 
or infection, or an OR of 3 for a risk factor present in 5% of subjects without disease 
or infection with 95% confidence. The sample size also provides good precision for 
an estimated TF prevalence of  >25% in 1-9 year olds on the four islands of Bubaque 
and Canhabaque (±4%), Soga (±6%) and Rubane (±10%), which is adequate to 
determine whether these communities require mass drug treatment with azithromycin 
in line with WHO policy. 
Household Census
A census of persons resident in randomly selected households was conducted prior to 
the household survey. Residency was defined as living within the household for 
longer than the preceding month or intending to stay resident in the household for 
longer than one month. This was updated to reflect the de facto population (those 
present in the household on the previous night) to limit absenteeism. 
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Household Risk Factor Survey
Demographic, socio-economic and environmental information was collected at 
household and individual levels. Household-level risk factor data were obtained using 
questionnaires administered to the household head or an appropriate responsible adult 
and included items on the level of education of the household head, their socio-
economic status, whether the household had been exposed to any health education or 
promotion within the community, household access to and use of latrines, access and 
use of water and measures of sanitation, waste and presence of flies in the 
environment. The questionnaire was supported through observational data collected 
on water use, latrine use and environmental sanitation. Household size (measured as 
number of members of all ages) and number of children under the age of 10 years 
within the household was recorded. Researchers were masked to trachoma status of 
household members at the time of the household survey.
Trachoma Prevalence Survey
Following the household risk factor survey all individuals from study households 
were invited to attend for clinical examination and conjunctival sampling. 
Individuals’ age, sex and ethnic group and data on facial cleanliness (the presence of 
ocular and/or nasal discharge and whether or not there were flies on the face) were 
collected at the time of examination.
Clinical Assessment
A single trained examiner assessed each participant using the WHO simplified 
grading system where TF (trachomatous inflammation – follicular) and/or TI 
(trachomatous inflammation – intense) constitute active trachoma and TS 
(trachomatous scarring), TT (trachomatous trichiasis) and CO (corneal opacity) are 
trachomatous sequelae which may lead to blindness [23]. A trachoma grade was 
assigned to the upper tarsal conjunctivae of each consenting participant using 
adequate light and a 2.5x binocular magnifying loupe. 
Conjunctival Sampling 
Two sequential samples were taken from the left upper tarsal conjunctiva of each 
participant with Dacron swabs (Fisher Scientific, UK) using a standardised procedure 
[24,25]. The first swab was collected into transport medium for other studies. The 
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second dry swab was collected into a microcentrifuge tube (Simport, Canada) and 
used in this study. Previous work using the Roche Amplicor CT/NG assay (Roche 
Molecular Systems, NJ USA) in a population-based study has shown that there was 
good agreement between first and second swabs with respect to C. trachomatis DNA 
positivity by PCR [26]. Swabs were kept on ice in the field and frozen to -800C within 
8 hours of collection. 
Measures were taken to avoid cross-contamination in the field. Control swabs (pre-
marked swabs drawn at random from the swab dispenser and passed 10cm in front of 
the eye ensuring no contact between the swab tip and participant) were taken to 
ensure field and laboratory quality control. 
Community Mass Treatment 
After survey completion all communities on the study islands were treated with a 
single height-based dose of oral azithromycin in accordance with WHO and national 
protocols.
DNA Extraction
Each swab was suspended in 400!l sterile phosphate buffered saline (PBS) after 
thawing at room temperature. DNA was extracted from the swab/PBS suspension 
using an adapted whole blood protocol on the QIAxtractor (Qiagen, Crawley, UK) 
automated instrument and eluted into a final volume of 50!l DX Elution Buffer 
(Qiagen). 
Detection of infection with C. trachomatis
C. trachomatis DNA was detected using the Roche Amplicor CT/NG assay (validated 
for use with ocular swabs [27]). Required reaction buffer conditions were obtained as 
described previously and used in the standard assay [28]. Positive and negative 
samples were assigned according to the manufacturer’s instructions. In this study, C. 
trachomatis infection is defined as the presence of C. trachomatis DNA by Amplicor 
PCR.
Statistical Analyses
Data were double entered into a customised database (MS Access 2007). 
Discrepancies were resolved through reference to original data forms. Data were 
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further cleaned prior to analysis in STATA 13 (Stata Corporation, College Station, 
Texas USA). 
Random effects logistic regression models were used to assess the variability between 
villages and households assuming a three tier hierarchy to the data (at village, 
household and individual levels). Null models were used to examine the effect of 
cluster variables on the outcome using the likelihood ratio test (LRT), which if 
significant, provided strong evidence that between-village and household variance 
was non-zero. The log likelihood and the LRT were used to compare models.
Univariable associations with active trachoma (TF/TI) and infection with C. 
trachomatis were examined using two-level hierarchical random effects logistic 
regression, accounting for between-household variation. Covariates associated with 
active trachoma or C. trachomatis infection with p<0.10 (using the Wald test) were 
sequentially added to the multivariable model after a priori adjustment for age and 
gender (as categorical variables). Covariates were retained in the final model if the 
Wald p-value 0.05 unless otherwise specified. Further exploration of environmental 
predictor variables was conducted using logistic and hierarchical random effects 
logistic regression models as appropriate using the same criteria. As C. trachomatis
infection is on the causal pathway between several risk factors and active trachoma, 
models with and without C. trachomatis infection were fitted. The model including C. 
trachomatis infection provides estimates of independent associations of other risk 
factors with active trachoma which are not mediated through C. trachomatis infection. 
All statistical analyses were carried out using STATA 13. Statistical significance was 
determined at the 5% level.
Results
Study Population Characteristics
From an estimated total rural population of 5,613 inhabitants on the four study islands 
[4], 1,511 individuals from 293 randomly selected households across 39 villages were 
enrolled. Of these, 1,508 had an ocular assessment and conjunctival swabs were 
obtained from 1,507. The median age of participants was 13 years (range 1 month -
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88 years) and 57% were female. The majority of participants were of the Bijagós 
ethnic group (Table 1). 
Prevalence of Active Trachoma and C. trachomatis Infection 
The prevalence of active trachoma in 1-9 year olds was 22.0% (95% Confidence 
Interval (CI) 18.9-25.5%) (136/618). The prevalence of active trachoma was highest 
in children under the age of 5 years (27.3% (95% CI 23.1-31.9%) (113/416)). Overall, 
11.1% (95% CI 9.4-12.6%) (167/1508) of the study population had active trachoma. 
The relationship between trachoma and infection is shown in Table 2. C. trachomatis
DNA was detected in 18.0% overall (269/1507) and 25.4% of 1-9 year olds 
(157/618). All 15 (~1% of total) control swabs were negative for C. trachomatis
DNA.
Multilevel Clustering of Active Trachoma and C. trachomatis Infection
Null models for both active trachoma and C. trachomatis infection adjusted for age 
and gender showed significant clustering at island, village and household levels. For 
active trachoma, the variance estimated due to between-household clustering was 1.11 
(standard error (SE) 0.17, p<0.0001). The between-village clustering variance was 
0.75 (SE 0.16, p<0.0001) and between-island clustering variance was 0.50 (SE 0.28, 
p=0.0100). For C. trachomatis infection, the variance estimated due to between-
household clustering was 1.37 (SE 0.15, p<0.0001), between-village clustering was 
0.89 (SE 0.14, p<0.0001) and between-island clustering was 0.40 (SE 0.18, 
p=0.0005). The clustering effect was strongest at household level and models 
adjusting for clustering at household level only were a better fit than those including 
adjustment for village and island clustering. Adjusting for clustering at household 
level significantly improved the model versus standard logistic regression analyses 
(p<0.0001). Two-level hierarchical regression models with adjustment for household 
level clustering are presented in this analysis.
Factors associated with active trachoma
Univariable associations with active trachoma are presented in Table 3. The final 
multivariable model showed that active trachoma was strongly independently 
associated with C. trachomatis infection (OR=11.2 (95% CI 6.9-18.1)), ocular 
(OR=2.0 (95% CI 1.0-4.0)) and nasal (OR=2.5 (95% CI 1.5-4.3)) discharge, male 
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gender (OR=1.9 (95% CI 1.2-2.9)) and being aged 0-5 years (OR=10.2 (95% CI 5.1-
20.4) compared to being >15 years of age) (Model 2, Table 4). There was also a 
strong independent association between household water access and active trachoma, 
such that households with access only to a traditional natural spring as a water source 
had an increased risk of active trachoma compared to households with access to 
multiple water sources (OR=1.9 (95% CI 0.9-3.9)). The model without C. trachomatis
infection shows stronger associations, indicating that some effect of these factors is 
mediated through C. trachomatis infection (Table 4). Comparison of the two models 
suggests that some of the effect of younger age and water source is partly mediated 
through C. trachomatis infection, but these remain independently associated with 
trachoma beyond this effect.
Factors associated with C. trachomatis infection
Univariable associations with C. trachomatis infection are presented in Table 5. In the 
final multivariable model C. trachomatis infection was strongly independently 
associated with being aged \HDUV7he presence of ocular discharge (OR=2.3 
(95% CI 1.3-4.4)) and household access only to a traditional natural spring (OR=6.6 
(95% CI 2.8-15.2)) and or access to a single water source only (OR=3.9 (95% CI 1.9-
8.0)) (rather than households who had access to multiple water sources) were strongly 
associated with infection (Table 6). The presence of flies around a latrine was also 
independently associated with infection (OR=2.1 (95% CI 1.1-3.8)). The presence of 
flies around a latrine were strongly associated with the presence of flies in the 
environment surrounding the household (OR=8.3 (95% CI 5.4-12.7), p<0.0001) and 
the presence of visible faeces within the latrine (OR=46.7 (95% CI 28.5-76.6), 
p<0.0001). There was no association between flies in the environment (OR=1.1 (95% 
CI 0.4-3.0), p=0.91) nor flies around the latrine (OR=0.5 (95% CI 0.1-2.6), p=0.43) 
with flies on the face at the time of examination. 
Discussion
We  have shown that there is clustering of both active trachoma and infection at 
household, village and island levels. We found that the most substantial clustering 
was present at household-level, thus the random effects introduced by this are 
adjusted for using two-level hierarchical mixed effects models. Clustering at 
household level has been described in other populations [10,13,29]. We found C. 
GHH
trachomatis infection to be more strongly clustered at the household level than active 
trachoma, which has also been reported in Tanzanian communities [18]. 
Consistent with results from other studies, we found that being aged 0-5 years 
[10,16,29,30-34], the presence of ocular C. trachomatis infection [17] and the 
presence of ocular and nasal discharge [19,32,35,36] were strongly associated with 
active trachoma. We also found that being female was associated with a reduced odds 
of active trachoma, but not infection. The finding of an association between gender 
and active trachoma are contradictory in the literature [36-38]. In this analysis gender 
was included in all models due to a priori assumptions.
At the household level, the only household-level factor independently associated with 
both active trachoma and C. trachomatis infection was access to type and number of 
water sources, where household access to a traditional natural spring as the only water 
source was more strongly associated with active trachoma and C. trachomatis
infection than access to another (single) source or multiple water sources of various 
types. This association is likely to be mediated through the presence of C. trachomatis
infection. A similar association was shown in Ethiopia, where a piped water supply 
was associated with reduced risk of active trachoma compared to spring or river/lake 
water sources [37]. This may have been related to increased distance to the non-piped 
water sources [34] or to volume of water used [33]. In Bijagós communities, every 
household has access to a water source within 15 minutes walking distance. It is likely 
that this association may reflect more subtle hygiene and water use behaviours related 
to allocation of water collected for specific hygiene practices. A greater volume of
water can be obtained with greater ease from an improved well or borehole than is 
possible from a natural spring. Although we found no statistically significant 
association between the volume of water stored in the household and active trachoma, 
it may be that the volume of water specifically allocated for hygiene practices is 
important, as shown in The Gambia [39], and that this finding is a proxy for water use 
allocation. 
Children aged 0-5 years are at increased risk of ocular infection with C. trachomatis. 
In 6-10 year olds the risk is similarly elevated. In contrast, children aged 0-5 years are 
at much greater risk of active trachoma than 6-10 year olds. This supports suggestions 
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that young children are the main reservoir of infection [10,19,32] and demonstrates 
that this reservoir persists beyond pre-school age children in this population. The 
difference found in associations between age and active trachoma and infection may 
be explained by the presumed acquisition of immunity in childhood, which may result 
in reduced prevalence of clinically active trachoma despite the remaining strong 
association with infection. Duration [40] and intensity [41] of active trachoma and C. 
trachomatis infection have been shown to be age-dependent. It may also be that 
clinical signs present in 0-5 year olds are less specific for C. trachomatis infection and 
that other bacteria such as Streptococcus pneumoniae and Haemophilus influenzae
contribute to the clinical phenotype, such that they induce a recall of the follicular 
response in children previously exposed to C. trachomatis, as hypothesised in cross-
sectional studies showing an association between follicular trachoma and these 
bacteria in Tanzania and The Gambia [42,43]. Overall, there is a diminishing 
association with age, indicating that age may also represent a proxy for close contact 
and specific hygiene behaviours, acquired immunity and duration of infection. Whilst 
there were strong univariable associations between infection and ocular and nasal 
discharge, the association with nasal discharge is not significant in the multivariable 
model. Ocular discharge may more specific for C. trachomatis infection than nasal 
discharge, likely representing a consequence of  C. trachomatis infection rather than a 
risk factor for it.
Latrine access was not associated with active trachoma or C. trachomatis infection, 
despite the fact that 60% of individuals do not have access to a latrine. Latrine access 
does not translate into latrine use [44]. We assessed latrine use through observation of 
the latrines in addition to collecting reported data. Although there is high reported use 
of latrines within a household with latrine access, there may be household members 
that do not use the latrine. In these populations children aged 1-9 years are often 
discouraged from using latrines due to caregiver concerns about their safety when 
using latrines (Thompson et al., unpublished data). 
The presence of flies around a household pit latrine was strongly associated with 
infection in the final multivariable model, although there was no association between 
flies on the faces of individuals at the time of examination with either active trachoma 
or infection. The presence of flies on faces has been well-documented as a risk factor 
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for active trachoma in some environments [8,29,45] and there is evidence that the 
eye-seeking flies Musca sorbens (and possibly other domestic muscidae) are passive 
vectors in C. trachomatis transmission[45-48]. One study that examined fly density 
around used household pit latrines in The Gambia found that the majority of flies 
emerging from the latrine were Chrysomya albiceps, rather than M. sorbens [47]. We 
do not have data on the species of flies around pit latrines in Bijagós communities, 
however it is possible that there is ovipositioning by M. sorbens in or around latrines 
in these communities. We found a strong association between flies present in the 
environment and flies around the latrine, although there was no association with flies 
on the face at the time of examination. With decreasing age, there was a trend in 
association between flies on the face and flies around the latrine, but this association 
was non-significant.
M. sorbens have been shown to preferentially breed in human excreta, in addition to 
domestic animal faeces [46]. Although the presence of animal and human excreta 
within 15 metres of the household were not risk factors for active trachoma or C. 
trachomatis infection, they were ubiquitous in the villages. There was a strong 
association noted between flies around a latrine and the presence of visible faeces 
within a latrine. These findings suggest that flies may be important in the transmission 
of trachoma in this environment. Our study was conducted in the cooler dry season, 
possibly explaining the lack of association between flies on faces and in the 
environment and C. trachomatis infection in the regression analysis. Fly populations 
and density have been shown to have seasonality elsewhere [49,50].
The cross-sectional design of this study is a limitation in understanding determinants 
of disease and infection. There may also be some limitations in using stepwise 
regression methods such that models may be overfitted or unstable [51]. Risk factors 
are often difficult to define and despite the presence of statistically significant 
associations, it is likely that the relationship between socio-behavioural and 
environmental risk factors and disease and infection is complex and not fully 
explained by this analysis. It may be that intra- and inter-familial transmission occurs 
in these communities as a consequence of specific hygiene practices and complex 
socio-behavioural factors. These factors are often difficult to define and require 
longitudinal studies beyond the scope of the current study. Further epidemiological 
GH@
studies examining the species and contribution of flies to trachoma transmission and 
water use and specific hygiene behaviours in relation to trachoma and C. trachomatis
infection in this population may be of importance in successful trachoma control 
activities.
Conclusion
We have described individual and household-level risk factor associations with active 
trachoma and ocular infection with C. trachomatis on the Bijagós Archipelago to 
improve our understanding of the relationship between disease and infection in this 
remote treatment-naïve trachoma-hyperendemic population.  
These data suggest that in this environment household-level risk factors relating to fly 
populations, hygiene behaviours and water usage are likely to be important in the 
transmission of ocular C. trachomatis infection. Education about cleanliness, 
sanitation and hygiene practices is likely to be important in reducing transmission of 
infection in these communities. Ensuring the provision of water sources which allow 
adequate water to be allocated for hygiene may assist this, and further studies 
examining specific hygiene practices may be useful. Reducing fly populations around 
the latrines where they exist may be of benefit. These findings may be important in 
the implementation of the F and E components of SAFE in this population. 
In order to fully understand the factors associated with active trachoma and ocular C. 
trachomatis infection in these communities, further epidemiological studies 
examining transmission and clustering of C. trachomatis infection are required. These 
studies should focus on pathogen factors such as the role of infection intensity and 
strain diversity, and socio-behavioural factors such as specific hygiene behaviours.
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Table 1. Study Population Characteristics
aTotal rural population on Bubaque, Canhabaque, Soga and Rubane [4]
bN = total number and % = proportion. IQR = Interquartile range.
Nb (%)
Total rural populationa 5,613
Study population 1,511
Female 869 (57.5)
Children <10 years 618 (40.9)
Bijagos ethnic group 1395 (92.3)
Islands 4
Villages 38
Households 293
Median number of members/household (IQR) 9 (24)
Median number of children < 10 years/household (IQR) 4 (12)
Access to water source all year 1475 (97.6)
Distance to water source < 15 minutes’ walking time 1511 (100)
Access to a latrine 608 (40.4)
Access to private latrine 284 (18.8)
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Table 2. The relationship between trachoma and presence of infection with C. 
trachomatis (Ct) 
Age Group (Na) Clinical Statusb Na(%) Ct +c (%) Ct –c (%)
All ages (1508) No trachoma 999 (66.2) 131 (13.1) 868 (86.9)
Active trachoma (TF and/or TI) 167 (11.1) 103 (61.7) 64 (38.3)
TF 152 (10.1) 97 (63.8) 55 (36.2)
TI 29 (2.0) 24 (82.8) 5 (17.2)
TS 357 (23.7) 51 (14.3) 306 (85.7)
0-5 years (416) No trachoma 298 (72.0) 39 (13.1) 259 (86.9)
Active trachoma (TF and/or TI) 113 (27.3) 69 (61.1) 44 (38.9)
TF 104 (25.1) 66 (63.5) 38 (36.5)
TI 19 (4.6) 16 (84.2) 3 (15.8)
TS 11 (2.7) 2 (18.2) 9 (81.8)
6-10 years (250) No trachoma 220 (88.0) 44 (20.0) 176 (80.0)
Active trachoma (TF and/or TI) 25 (10.0) 20 (80.0) 5 (20.0)
TF 25 (10.0) 20 (80.0) 5 (20.0)
TI 2 (0.8) 2 (100) 0 (0)
TS 7 (2.8) 5 (71.4) 2 (28.6)
aN = total number and % = proportion.
bUsing the WHO Simplified Grading System where TF=trachomatous inflammation-follicular, 
TI=trachomatous inflammation-intense, TS=trachomatous scarring [23]. Individuals may appear in 
more than one clinical category. 
cCt DNA detected (Ct+) or absent (Ct-) by Amplicor PCR.
GG?
Table 3. Multilevel univariable random effects logistic regression analysis of 
factors associated with active trachomaa
Variable N (%) cOR (95% CI)b p-valuec
Individual
Age Group 1504 <0.0001
0-5 years 416 24.02 (12.92-44.65)
6-10 years 250 6.26 (3.11-12.62)
11-15 years 157 3.66 (1.60-8.39)
>15 years 681 1.00 (baseline)
Gender 
Female 854 1.00 (baseline) 0.001
Male 632 1.83 (1.28-2.61)
Presence of C. trachomatis infection by PCR 258 (17.2) 11.19 (7.64-16.40) <0.0001
Presence of ocular discharge 84 (5.6) 8.05 (4.62-14.02) <0.0001
Presence of nasal discharge 261 (17.4) 7.90 (5.14-12.16) <0.0001
Presence of flies on the face 21 (2.6) 2.188 (0.64-7.48) 0.212
Household
Gender of household head (female) 509 (35.1) 0.99 (0.64-1.53) 0.975
Household sized 1.04 (0.99-1.09) 0.068
Number of children <10 years in householdd 1.13 (1.02-1.24) 0.019
Socio-economic status
Access to radio 747 (49.6) 0.94 (0.62-1.44) 0.786
Access to transport 227 (15.1) 1.20 (0.67-2.12) 0.541
Access to mobile phone 635 (42.2) 0.69 (0.45-1.06) 0.090
Relatives living in Bissau or abroad 1069 (71.0) 0.68 (0.43-1.07) 0.090
Access to savings at the end of the month 79 (5.3) 0.78 (0.28-2.13) 0.623
Educational level of household head 0.298
None 883  (58.7) 1.00 (baseline)
Primary 466  (31.0) 1.31 (0.83-2.07)
Secondary and above 156 (10.2) 0.76 (0.36-1.60)
School attendance in children of school age 254 (62.4) 0.48 (0.30-0.76) 0.002
Health education receivede 1054 (70.0) 0.75 (0.48-1.17) 0.201
Water access
Access to water all year 1475 (97.5) 1.08 (0.23-4.99) 0.923
Access to water 0.0002
Multiple water sources 308 (20.5) 1.00 (baseline)
Single water source other than natural spring 913 (60.7) 1.44 (0.87-2.54)
Traditional natural spring only 284 (18.9) 3.37 (1.78-6.37)
Water use within the householde,f 0.359
<1 ‘vasilha’ 67 (4.5) 2.29 (0.40-12.93)
1 ‘vasilha’ 145 (10.0) 3.59 (0.85-15.13)
>1 ‘vasilha’ 1283 (85.8) 2.91 (0.79-10.78)
Latrine access
Access to latrine 608 (40.4) 1.01(0.66-1.55) 0.951
Access to private latrine (vs shared) 284 (18.8) 0.98 (0.75-1.29) 0.903
Latrine usee 0.450
Always 500 (85.3) 0.90 (0.57-1.42)
Sometimes 51 (8.7) 1.00 (0.32-3.20)
Never 35 (6.0) 2.53 (0.75-8.54)
Latrine cleanlinessg 0.471
Very Clean – 1 33 (6.0) 0.24 (0.03-2.30)
2 80 (14.6) 0.49 (0.16-1.50)
3 274 (50.0) 1.09 (0.63-1.89)
4 64 (11.7) 1.24 (0.46-3.32)
Very Dirty - 5 97 (17.7) 1.48 (0.68-3.25)
Flies (ุ20) present around latrineg 251 (16.7) 1.26 (0.74-2.1) 0.391
Faeces visible in latrineg 200 (13.3) 0.89 (0.48-1.65) 0.703
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Environmenth
Flies (ุ20) present 510 (32.6) 1.08 (0.69-1.69) 0.726
Faecal waste (human/animal) 1105 (73.4) 1.07 (0.66-1.73) 0.797
Domestic waste 1175 (78.1) 0.97 (0.58-1.65) 0.922
Animals present 1298 (86.3) 0.66 (0.38-1.17) 0.159
aActive trachoma defined as TF (inflammatory trachoma-follicular) and/or TI (inflammatory trachoma-
intense) using the WHO simplified scoring system [23] bUnadjusted (crude) Odds Ratio (cOR) from 
two-level univariable mixed effects logistic regression analyses; CI=confidence interval cp-value for 
Wald test (Wald’s Chi2); significant associations (where pื0.05) are highlighted in bold dContinuous 
numeric variables ereported by household head fa ‘vasilha’ is a vessel of capacity ~ 30 litres gresearcher 
observed hresearcher observed within 15m of the household
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Table 4. Multilevel multivariable random effects logistic regression analysis of 
factors independently associated with active trachomaa
Model 1b Model 2c
(Final Model)
Variable n aOR(95%CI)d p-valuee aOR (95% CI)d p-valuee
Individual
Age Group 1504 <0.0001 <0.0001
0-5 years 416 13.66 (7.06-26.4) 10.22 (5.13-20.40)
6-10 years 250 3.60 (1.70-7.59) 1.93 (0.88-4.24)
11-15 years 157 3.08 (1.32-7.21) 2.41 (0.93-6.22)
>15 years 681 1.00 (baseline) 1.00 (baseline)
Gender 
Female 854 1.00 (baseline) 0.034 1.00 (baseline) 0.005
Male 632 1.58 (1.03-2.41) 1.89 (1.22-2.94)
Presence of C. trachomatis infection 258 NA NA 11.18 (6.9-18.1) <0.0001
Presence of ocular discharge 84 2.71 (1.39-5.29) 0.003 2.04 (1.04-3.99) 0.036
Presence of nasal discharge 261 2.26 (1.35-3.77) 0.002 2.54 (1.51-4.26) 0.001
Household
Access to water 0.005 0.036
Multiple water sources 308 1.00 (baseline) 1.00 (baseline)
Single water source other than natural spring 913 1.42 (0.70-2.87) 0.90 (0.46-1.75)
Traditional natural spring only 284 3.34 (1.50-7.45) 1.86 (0.89-3.89)
aActive trachoma defined as TF (inflammatory trachoma-follicular) and/or TI (inflammatory trachoma-
intense) using the WHO simplified scoring system [23]
bModel 1 shows the association of predictor variables with active trachoma.
cModel 2 includes the presence of C. trachomatis infection and demonstrates the effect of its inclusion 
on the predictor variables. Some of  the association  in Model 1 is mediated by C. trachomatis
infection.
dAdjusted Odds Ratio (aOR) using multivariable two-level mixed effects logistic regression modelling; 
CI=confidence interval 
ep-value for Wald test (Wald’s Chi2); significant associations (where pื0.05) are highlighted in bold 
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Table 5. Multilevel univariable random effects logistic regression analysis of 
factors associated with ocular C. trachomatis infection 
Variable n cOR (95% CI)a p-valueb
Individual
Ethnicity 1497 0.004
Bijagos 1395 5.05 (1.68-15.17)
Other 102 1.00 (baseline)
Age Group 1504 <0.0001
0-5 years 416 3.28 (2.24-4.80)
6-10 years 250 4.03 (2.59-6.29)
11-15 years 157 1.58 (0.90-2.78)
>15 years 681 1.00 (baseline)
Gender 
Female 854 1.00 (baseline) 0.753
Male 632 1.05 (0.77-1.44)
Presence of ocular discharge 84 (5.6) 4.17 (2.35-7.38) <0.0001
Presence of nasal discharge 261 (17.4) 2.17 (1.48-3.20) <0.0001
Presence of flies on the face 21 (2.6) 2.00 (0.57-7.10) 0.282
Household
Gender of household head (female) 509 (35.1) 0.79 (0.48-1.29) 0.343
Household sizec 1.04 (0.99-1.10) 0.127
Number of children <10 years in householdc 1.09 (0.97-1.22) 0.132
Socio-economic status
Access to radio 747 (49.6) 0.98 (0.61-1.58) 0.945
Access to transport 227 (15.1) 1.14 (0.58-2.24) 0.699
Access to mobile phone 635 (42.2) 0.57 (0.35-0.92) 0.022
Relatives living in Bissau or abroad 1069 (71.0) 0.88 (0.52-1.58) 0.643
Access to savings at the end of the month 79 (5.3) 0.69 (0.22-2.16) 0.527
Educational level of household head 0.200
None 883  (58.7) 1.00 (baseline)
Primary 466  (31.0) 1.26 (0.75-2.12)
Secondary and above 156 (10.2) 0.56 (0.24-1.30)
School attendance in children of school age 254 (62.4) 0.82 (0.56-1.19) 0.289
Health education receivedd 1054 (70.0) 0.78 (0.47-1.30) 0.346
Water access
Access to water all year 1475 (97.5) 0.75 (0.15-3.91) 0.734
Access to water <0.0001
Multiple water sources 308 (20.5) 1.00 (baseline)
Single water source other than natural spring 913 (60.7) 3.69 (1.85-7.38)
Access to natural spring only 284 (18.9) 7.01 (3.11-15.81)
Water use within the householdd,e 0.776
<1 ‘vasilha’ 67 (4.5) 2.21 (0.47-10.43)
1 ‘vasilha’ 145 (10.0) 1.41 (0.39-5.02)
>1 ‘vasilha’ 1283 (85.8) 1.56 (0.54-4.53)
Latrine access
Access to latrine 608 (40.4) 1.21 (0.75-1.97) 0.435
Access to latrine (private vs shared) 284 (18.8) 1.03 (0.76-1.39) 0.840
Latrine used 0.321
Always 500 (85.3) 1.10 (0.67-1.80)
Sometimes 51 (8.7) 0.66 (0.17-2.58)
Never 35 (6.0) 3.73 (0.84-16.6)
Latrine cleanlinessf 0.228
Very Clean – 1 33 (6.0) 0.55 (0.09-3.32)
2 80 (14.6) 0.58 (0.19-1.76)
3 274 (50.0) 1.08 (0.59-1.98)
4 64 (11.7) 1.11 (0.35-3.48)
Very Dirty - 5 97 (17.7) 2.63 (1.13-6.12)
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Flies (ุ20) present around latrinef 251 (16.7) 1.90 (1.05-3.41) 0.033
Faeces visible in latrinef 200 (13.3) 1.15 (0.59-2.24) 0.687
Environmentg
Flies (ุ20) present 510 (32.6) 1.37 (0.84-2.22) 0.209
Faecal waste (human/animal) 1105 (73.4) 0.90 (0.53-1.54) 0.705
Domestic waste 1175 (78.1) 0.65 (0.36-1.17) 0.150
Animals present 1298 (86.3) 0.49 (0.26-0.94) 0.030
aUnadjusted (crude) Odds Ratio (cOR) using two-level univariable mixed effects logistic regression; 
CI=confidence interval bp-value for Wald test (Wald’s Chi2); significant associations (where pื0.05) 
are highlighted in bold cContinuous numeric variables dreported by household head ea ‘vasilha’ is a 
vessel of capacity ~ 30 litres fresearcher observed  gresearcher observed within 15m of the household
GGD
Table 6. Multilevel multivariable random effects logistic regression analysis of 
factors associated with ocular C. trachomatis infection
Variable n aOR (95% CI)a p-valueb
Individual
Age Group 1504 <0.0001
0-5 years 416 3.10 (1.04-4.70)
6-10 years 250 3.83 (2.38-6.16)
11-15 years 157 1.65 (0.92-2.96)
>15 years 681 1.00 (baseline)
Gender 0.377
Female 854 1.00 (baseline)
Male 632 0.86 (0.61-1.21)
Presence of ocular discharge 84 2.33 (1.25-4.35) 0.007
Household
Access to water <0.0001
Multiple water sources 308 1.00 (baseline)
Single water source other than natural spring 913 3.88 (1.88-8.01)
Traditional natural spring only 284 6.57 (2.83-15.23)
Flies (ุ20) present around latrinec 251 2.06 (1.10-3.84) 0.023
aAdjusted Odds Ratio (aOR) using two-level multivariable mixed effects logistic regression modelling; 
CI=confidence interval bp-value for Wald test (Wald’s Chi2); significant associations (where pื0.05) 
are highlighted in bold cresearcher observed
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Spatial clustering of high load ocular Chlamydia trachomatis infection and 
disease severity in trachoma-endemic communities on the Bijagós Archipelago, 
Guinea Bissau
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Abstract 
Trachoma is caused by ocular infection with Chlamydia trachomatis. A population-
based geospatially representative survey conducted in a trachoma-hyperendemic 
treatment-naive population demonstrated that the highest C. trachomatis loads were 
associated with the most severe clinical signs of disease and that the strongest 
associations were with increasing inflammatory scores. Spatial clusters and hotspots, 
independent of age and gender, of individual infections with high bacterial loads were 
detected using local indicators of spatial association. There was no evidence of 
coldspots or clustering of low load infections, suggesting that high load infections 
may be important in transmission of chlamydial infection. These geospatial tools may 
be useful in trachoma surveillance in post-treatment settings to identify clusters of 
infection and thresholds of C. trachomatis bacterial load that may be important foci of 
transmission and may have wider application in monitoring concurrent neglected 
tropical diseases that are targeted for elimination.
Keywords
Chlamydia trachomatis; bacterial load; disease severity; spatial clustering; local 
indicators of spatial association; trachoma
Introduction
Chlamydia trachomatis is the leading infectious cause of blindness globally 
and the most common sexually transmitted bacterium. Trachoma is caused by 
infection with ocular strains of C. trachomatis and manifests as distinct clinical 
syndromes, beginning with an acute self-limiting kerato-conjunctivitis which may 
progress to chronic inflammatory disease with subsequent conjunctival scarring and 
blinding sequelae. A spectrum of disease severity exists, which can be graded 
objectively using validated grading systems (1,2).
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The World Health Organization (WHO) advocates the implementation of the 
SAFE strategy (Surgery for trichiasis, Antibiotics for active infection, Facial 
cleanliness to prevent disease transmission and Environmental improvement to 
increase access to water and sanitation) for trachoma elimination. Mass Drug 
Administration (MDA) of azithromycin aims to clear infection from communities 
such that trachoma ceases to be a public health concern (3). 
Understanding the spatial distribution of disease and infection in trachoma-
endemic regions is increasingly recognized in national trachoma control programme 
planning, enabling the identification of at risk populations and prioritization of target 
areas for control and implementation and optimal scaling of SAFE (4-8). It may also 
be important in understanding transmission, transmission thresholds and the dynamics 
of spread and recovery from infection following intervention.
Spatial analysis offers powerful methods to study the relationship between
active trachoma and ocular infection with C. trachomatis. The spatial relationship 
between disease and infection defined over space is termed spatial dependence. This 
is measured as the existence of statistical association (dependence) between disease 
and infection associated with location. To explore spatial dependence measures of 
spatial autocorrelation are used. Spatial autocorrelation assumes that near objects are 
more related than distant objects. In the context of infectious diseases, this concept 
may be applied to explore the relationship between infection and disease where the 
spatial distribution can be used to define underlying processes such as exposure or 
transmission. Spatial regression models can thus be used to understand the 
epidemiology of active trachoma and C. trachomatis infection. 
Global spatial autocorrelation statistics are used to describe the overall spatial 
patterns in the data. Local indicators of spatial association take actual values of 
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observations in the context of adjacent values allowing mapping and definition of
clusters at exact locations. This allows for the examination of small-scale 
heterogeneity and identification of statistically significant clusters and outliers of 
similar observations in space. In the context of global spatial patterns described 
above, this provides us with a greater understanding of the relationship between 
infection and disease. 
In this study we apply geostatistical tools to investigate the fine-scale 
epidemiology of C. trachomatis infection and clinical signs of active trachoma in a 
population-based study conducted in a trachoma-hyperendemic treatment-naïve 
population from the Bijagós Archipelago of Guinea Bissau in West Africa. Although 
some risk factors have been identified in this population, the reasons why both active 
and scarring trachoma are highly prevalent and severe on these islands remain to be 
elucidated (9). Transmission dynamics, pathogen virulence and C. trachomatis load 
may be contributing factors. This is the first study to use local indicators of spatial 
association using individual-level C. trachomatis load data in the context of spatial 
dependence to investigate the relationship between infection and disease. This may be 
important in understanding disease pathogenesis and transmission dynamics, both of 
which are fundamental to successful trachoma elimination and surveillance strategies.
Methods
Ethical Statement
This study was conducted in accordance with the declaration of Helsinki. 
Ethical approval was obtained from the Comitê Nacional de Ética e Saúde (Guinea 
Bissau), the LSHTM Ethics Committee (UK) and The Gambia Government/MRC 
Joint Ethics Committee (The Gambia). Written (thumbprint or signature) informed 
consent was obtained from all study participants or their guardians as appropriate. 
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After survey completion all communities on the study islands were treated with a 
single height-based dose of oral azithromycin in accordance with WHO and national 
protocols.
Study Area
The Bijagós Archipelago has a total area of more than 10,000 km2 and lies 
between N 11038’19.68” and N 10051’40.32”, W 16029’38.40” and W 15027’17.28”. 
The surface area of exposed land covers approximately 900 km2, of which 350 km2 is 
covered with mangrove forest (10). Altitude does not exceed 50m. The climate is 
humid and tropical, with a prolonged rainy season from May-November, during 
which average monthly rainfall is 400mm3 (11). The mean monthly temperature is 
27.30C (25.1-29.20C), with peak temperatures occurring prior to the rainy season. 
There are 88 islands and islets of which only about 20 are permanently inhabited. The 
remainder are inhabited periodically for seasonal agriculture and traditional initiation 
ceremonies. The study was conducted on four islands of the archipelago (Figure 1). 
These four islands comprise a total rural population of 5,613 (National Population 
Census, 2010, Instituto Nacional de Estatística, Guiné-Bissau). 
Study Design and Study Population
Trachoma survey methodology and this study population have been described 
previously (9,12-15). To satisfy adequate geospatial representation at village-level, 
we included all 38 villages on the four study islands and randomly sampled one in 
five households (with a minimum of five per village) from each. All were sampled if 
there were fewer than six households in the village. Small villages are thus over-
represented by the minimum sampling criteria imposed. Data were geo-coded at 
household and village level using the Garmin eTrex H handheld Global Positioning 
Systems (GPS) unit (Garmin Ltd., UK).
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Clinical Examination and Conjunctival Sampling
A single validated examiner assessed each participant using the WHO 
simplified and modified FPC grading systems (1,2). In the modified FPC system, 
follicles (F), papillae (P) and conjunctival scarring (C) are each assigned a separate 
grade from 0-3. FPC grades of F2/3 or P3 equate to a diagnosis of active trachoma 
(TF (follicular trachoma) or TI (inflammatory trachoma) by the WHO simplified 
system) and a grade of C2/3 (and in some cases C1) equates to a diagnosis of TS 
(trachomatous scarring). A trachoma grade was assigned to the upper tarsal 
conjunctivae of each consenting participant using adequate light and a 2.5x binocular 
magnifying loupe. Both methods were used in order that study data should be 
comparable to data used by trachoma control programmes and research studies 
requiring detailed information related to disease severity and have been used 
previously in similar settings (16,17).   
Samples were taken from the left upper tarsal conjunctiva of each participant 
with Dacron swabs (Fisher Scientific, UK) using a well-tolerated standardized 
procedure described in previous studies (9,12,13,18,19). 
Detection and Quantitation of C. trachomatis 
DNA extraction and droplet digital PCR (ddPCR) (Bio-Rad Laboratories, 
Hemel Hempstead, UK) were conducted as described previously (9,12,13). We used 
C. trachomatis plasmid-based ddPCR to diagnose infection and a single-copy 
pathogen chromosomal gene (omcB) to estimate pathogen load in each plasmid-
positive sample (12,13). Estimated quantities of omcB (C. trachomatis load) and 
plasmid are expressed as copies/swab. 
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Statistical Analysis
C. trachomatis quantitation data were processed as described previously
(12,13). GPS data were downloaded into MapSource v16.16.3 (Garmin Ltd., UK). All 
data were double entered into a customised database (Microsoft Access 2007) and 
discrepancies resolved through reference to source documents. Data were cleaned and 
analysed in STATA 13 (Stata Corporation, College Station, Texas USA). Statistical 
significance was determined at the 5% level. 
Mixed effects linear regression models of C. trachomatis load and Clinical Phenotype
C. trachomatis load data were log(e) transformed where indicated. The 
geometric mean of load, respective standard error (SE) and 95% confidence intervals 
(CI) were calculated. An analysis of variance (ANOVA) with pair-wise comparisons 
was used to compare load across detailed clinical phenotypes. Assessment of group 
differences and multiple comparisons were adjusted for using the Scheffé correction 
(20). Associations between load and detailed clinical phenotype were examined using 
univariable and multivariable mixed effects linear and logistic regression models 
accounting for household-level clustering detected in previous studies (9). 
Geostatistical Analyses
Geocoded data were projected into UTM Zone 28N. ArcGIS 10.1 (ESRI Inc., 
USA) and the R statistical package v3.0.2 (The R Foundation for Statistical 
Computing, http://www.r-project.org using spdep, automap and nlme packages) were 
used for all geostatistical analyses (21-23). In the following analyses, the zone of 
indifference is used to define adjacency. This method assumes that each observation 
has local influence that decreases with distance beyond a critical distance cut-off, 
resulting in an adapted model of impedance, or distance decay, such that all features 
have an impact on all other features, but this impact decreases with distance. This 
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method is appropriate for point data and takes into account the extent of spatial 
autocorrelation in selecting data-driven threshold cut-offs (24). 
Spatial Autocorrelation
The Moran’s I statistic was used to evaluate global spatial autocorrelation in 
the distribution of the household-level prevalence of disease and infection. The values 
of Moran’s I range between -1 and +1. A value close to -1 indicates negative 
autocorrelation (complete dispersion) whilst a value close to +1 indicates positive 
autocorrelation (clustering) of features. A value close to 0 suggests random 
arrangement. Z-scores and p-values are assigned to ascertain whether spatial 
autocorrelation is statistically significant (25). Since the Moran’s I statistic can be 
sensitive to skewed distributions, a permutation test was used to verify the results. 
This uses Monte Carlo simulations to generate a Moran’s I sampling distribution (26). 
Empirical semivariograms were constructed to obtain the distance range over 
which spatial autocorrelation occurs using the average squared distance between 
paired data values against the distance (or lag) separating the pairs to estimate the 
spatial covariance structure of the data (27). 
Linear and logistic mixed effects regression models were also applied to 
examine the covariance structure and compare models with and without a spatial 
component. The log likelihood, Akaike information criterion (AIC) and Bayesian 
information criterion (BIC) were used to compare models (28).
Local Indicators of Spatial Association: Hotspot and Cluster-Outlier Analyses
The Getis-Ord Gi* statistic was used to identify hot and cold spots for
infection (29). The Getis-Ord Gi* identifies statistically significant ‘hotspots’ 
containing similarly high values and statistically significant ‘cold spots’ containing 
similarly low values, taking into account the spatial dependence of adjacent 
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observations using the zone of indifference described previously (30). Z-scores and p-
values are expressed for each Gi* value in comparison with the normal distribution of 
Gi* calculated by simulation. These values represent the statistical significance of the 
spatial clustering of values given the conceptualisation of spatial relationships and 
scale of analysis described. Statistically significant high z-scores show clustering of 
high load infections, whilst statistically significant low z-scores show clustering of 
low (or zero) load infections.
Clustering and outlier analysis was conducted using the local (Anselin) 
Moran’s I statistic using the zone of indifference to define adjacency (31). A positive 
value for I indicates that a feature has adjacent features with similarly high or low 
attributable values (a cluster). A negative value for I indicates that adjacent features 
have dissimilar values and that this feature is an outlier. Cluster-Outlier analysis 
identifies spatial clusters of features with high or low values and spatial outliers by 
calculating Moran’s I, Z-scores, p-values and a code to represent the cluster type. 
Cluster types are defined as clusters of high values (HH, High-High), clusters of low 
values (defined as above) (LL, Low-Low), a high value outlier surrounded by 
predominantly low values (HL, High-Low) and a low value outlier surrounded by 
predominantly high values (LH, Low-High). 
In this analysis ‘low’ values include both low values related to low load 
infections and null (zero) values related to uninfected individuals. To explore this, 
these analyses were conducted first on the whole data set, including uninfected 
individuals with a ‘zero’ value for infectious load, and then on infected individuals 
only. 
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Results
Trachoma and C. trachomatis infection prevalence is hyperendemic in this 
population and is described elsewhere in detail (9,12,13). C. trachomatis load was 
skewed, with the majority of cases having low copy numbers (<1000 copies/swab). 
Log-(e) transformation removed the skew (skewness -0.106, p=0.5454) in these 
analyses.  
C. trachomatis bacterial load and clinical phenotype in individuals with C. 
trachomatis infection
The geometric mean of estimated omcB copies/swab present in clinically 
normal conjunctivae (F0/P0/C0) was 294 copies/swab (95% C.I. 165-524). In 
clinically active trachoma it was 8562 copies/swab (95% C.I. 5412-13546). 
Significantly higher loads were detected in individuals with increasing F and P scores 
(Table 1). C. trachomatis load by age and clinical phenotype is shown in Figure 2. 
The majority of infections with high loads were in children under 10 years of age with 
active trachoma.
Spatial structure of active trachoma and C. trachomatis infection
Significant positive spatial autocorrelation was evident for C. trachomatis
infection (Moran’s I=0.19, p<0.0001) but not active trachoma (Moran’s I=0.07, 
p=0.0659). Semi-variograms demonstrate that autocorrelation in infection is 
negligible in distances greater than 1719m (Figure 3). We found no evidence of 
spatial autocorrelation in the distribution of C. trachomatis load (Moran’s I=0.05, 
p=0.4464). 
C. trachomatis load was the strongest predictor of clinically active trachoma. 
In accordance with the semi-variograms, including spatial structure in multivariable 
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mixed effects regression analyses for active trachoma and C. trachomatis infection 
improves the fit of the models (Table 2).
Inflammatory and follicle scores were strongly associated with bacterial load. 
Inclusion of the spatial structure in models predicting C. trachomatis load improved 
the fit, but the effect of spatial dependence becomes undetectable when age and 
disease severity scores are included, thus resolving residual spatial variation (Table 
3). 
Hotspot analysis (Getis Ord Gi*) of C. trachomatis infection (Figure 4)
Intense clustering (statistically significant high z-scores), or hotspots, of high 
load infections was identified. There was no evidence of coldspots, or intense 
clustering of low load infections or zero-value uninfected individuals. There was no 
apparent difference between analyses conducted on the whole data set (infected and 
non-infected individuals) versus those conducted on infected individuals only.
Cluster and outlier analysis (local (Anselin) Moran’s I) of C. trachomatis infection 
(Figure 5)
High load infections were clustered with other high load infections (HH 
clusters). Outliers where there was a single low load infection amidst predominantly 
high load infections (HL) were also demonstrated. There was no clustering of low
load infections (or zero-values from uninfected individuals) (LL clusters) and there 
were no statistically significant outlying high loads surrounded by predominantly low 
loads (LH). Analyses were conducted on the whole data set and infections only as 
described above.
There were no individuals with infections below 10,000 omcB copies/swab 
noted within a HH cluster or as a HL outlier.
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Discussion
The majority of ocular C. trachomatis infections occur in children, who have 
the highest loads and most severe active trachoma. However, infection predominantly 
occurs at low bacterial loads in the population overall. Similar findings have been 
observed in other studies (17,32,33), though we found a greater prevalence of 
infection across all age groups typical of hyperendemic settings. Almost half the 
individuals with quantifiable infection had a normal clinical phenotype, though the 
mean C. trachomatis load was significantly lower than in those with active trachoma, 
which is consistent with other studies in meso and hyperendemic settings (32,34).
In this population C. trachomatis load increases with disease severity (for both 
follicular (F) and inflammatory (P) scores), the strongest association being with
increasing P-scores. The association between ocular C. trachomatis load and disease 
severity in trachoma is supported by findings from other studies (16,17,32,35). The 
association between C. trachomatis load and high F-scores is in part due to 
collinearity between F and P, where with high F-scores there is likely to be 
inflammation present. Inflammation has previously been found to be associated with 
high C. trachomatis loads and persistence of infection in children (36).  This is 
consistent with the high prevalence of infection and the spectrum of load and 
phenotype observed in this age group but may also be associated with pathogen 
virulence if there are different C. trachomatis strains in circulation. Further analysis is 
underway to investigate associations between pathogen genotype, clinical phenotype 
and geospatial clustering of strains.
There is spatial dependence in the distribution of C. trachomatis infection, 
demonstrated by positive spatial autocorrelation. The distance over which this occurs 
(1719m) equates to that of village boundaries. We have shown that the highest burden 
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of infection (and load) is in children under 10 years of age. There are usually only one 
or two children of this age group within a household in these communties (9). These 
data are supportive of transmission occurring at village level in this population. 
Although household and village-level clustering is evident in active trachoma 
and ocular C. trachomatis infection (9,37-39), the inclusion of this spatial structure in 
regression models for active trachoma and C. trachomatis infection further improves 
model fit and demonstrates underlying spatial processes in the relationship between 
infection and disease, such that cases of active trachoma may represent recent 
exposure to C. trachomatis infection. The effect of spatial dependence in infection is 
greater than in active trachoma, perhaps reflecting the complexity of the disease 
process, where host-pathogen interactions contribute. 
C. trachomatis bacterial load is not globally spatially autocorrelated, likely 
reflecting the stronger influence of underlying social and biological rather than spatial 
processes. However, using local indicators of spatial association to examine fine-scale 
spatial clustering we have identified hotspots and clustering of high load infections.
Spatial clusters, independent of age and gender, of individual infections with high 
bacterial loads (HH) and high load outliers that cluster with other low loads (HL) 
exist. Furthermore, there is no evidence of coldspots or clustering of low load 
infections (LL), suggesting that high load infections may be important in transmission 
of chlamydial infection. There appears to be a threshold of C. trachomatis load below 
which HH clustering (and being a HL outlier) does not occur. The same phenomena 
were observed in data including infected and uninfected individuals and data with 
infected individuals only suggesting that low load infection may represent a negligible 
risk of transmission. This supports the described Allee effect, which hypothesizes that 
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a reduction in chlamydial fitness due to reduced pathogen population size or density 
results in its disappearance from a population (40).
We did not find a threshold effect within hotspots demonstrated using Getis-
Ord Gi*. This may be explained by differences in the underlying methodology, where 
the Getis-Ord Gi* includes the value of each feature examined in an average value in 
its analysis, whereas the local Moran’s I statistic takes each feature but includes only 
adjacent features’ values in the average value in its analysis. This is particularly 
evident where the scale of the analysis is small. The local Moran’s I statistic may be 
more useful in this context as it provides greater detail on clustering and outliers, 
which may have application in disease surveillance. 
There are a limited number of studies that have assessed the spatial 
distribution of trachoma (5,7,41) and ocular C. trachomatis infection (42,43). Broman 
et al. did not find clustering of active trachoma in children under the age of 10 years, 
but found clusters of households with high bacterial loads (defined as the household 
mean load) in treatment-naïve communities, supporting the findings in this study (42). 
Yohannan et al. examined binary household-level data using a K-function nearest 
neighbours analysis (43). The methodology for cluster detection in these studies was 
heterogeneous and measures of spatial dependence were not included in these 
analyses.
Longitudinal study is required to fully investigate the dynamics of C. 
trachomatis bacterial load in transmission. This study is limited in the assumption of 
load and clinical disease severity as a steady state. There are few data addressing 
stability of C. trachomatis load and disease phenotype (36). Bobo et al. conducted 
weekly surveys for three months in hyperendemic communities, finding that 62% of 
children had at least one infection during that time and of those 64% were persistently 
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infected and had higher mean C. trachomatis loads and more severe disease than 
those who were sporadically infected (36). Additionally, host conjunctival immune 
response and duration of infection add complexity to the interaction between C. 
trachomatis infection and disease severity (33,44).
Conclusion
This is the first study to use individual-level quantifiable C. trachomatis
infections from a geospatially representative population-based sample to investigate 
spatial clustering of C. trachomatis infection. These data show that increasing C. 
trachomatis load is related to increasing disease severity in active trachoma, 
particularly with respect to inflammation. We have provided a global statistical 
measure for spatial autocorrelation in infection and disease and used local indicators 
of spatial association to describe the location and nature of the clusters in relation to 
C. trachomatis load.
These data suggest that high load C. trachomatis infections cluster spatially 
and may be important in transmission. C. trachomatis strain diversity may be 
associated with bacterial load, the spectrum of disease severity and the clustering of 
high load infections within these communities. Further epidemiological and in vitro
studies are required to provide a more complete picture of the relationship between 
disease severity and chlamydial load.
We are currently developing mathematical models to investigate transmission 
dynamics of C. trachomatis and the effect of high load infections in these 
communities. Such models, in conjunction with geospatial tools may be useful as 
tools for post-MDA trachoma surveillance. Using these methods, it may be possible 
to identify clusters of infection and thresholds of C. trachomatis bacterial load that 
may be important foci of transmission and may improve our understanding of disease 
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pathogenesis and transmission. These methods may also have wider application in 
monitoring concurrent neglected tropical diseases that are targeted for elimination. 
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Table 1. Estimated Chlamydia trachomatis load (omcB copies/swab) and analysis of variance (ANOVAa) by detailed clinical phenotype in 
infected individuals 
Clinical Phenotype nb omcB
copies/swab 
(Geometric
Mean)
95% C.I.
(SE 
geometric mean)
p-Value
(ANOVA)
Median Min Max
Normal (F0P0C0) 71 294 165, 524 Baseline 176 15 96333
Active Trachoma 
(TF and/or TI)
92 8562 5412, 13546 p<0.00001 14236 17 274835
Scarring Trachoma 
(TS)
19 928 280, 3074 p=0.4069 2142 17 49125
Follicular Score 
(F)
0 91 438 251, 762 Baseline 227 15 202632
1 20 1288 448, 3697 p=0.324 Baseline 1710 34 96333
2 27 3212 1264, 8165 p=0.002 p=0.624 Baseline 3203 27 140693
3 46 19870 2832, 25927 p<0.0001 p<0.0001 p=0.018 22767 323 274835
Inflammatory Score 
(P)
0 46 122 68, 218 Baseline 67 15 41059
1 70 1534 871, 2702 p<0.0001 Baseline 1469 16 202632
2 46 10413 5461, 19857 p<0.0001 p<0.0001 Baseline 18569 17 274835
GA?
3 22 14053 5550, 35581 p<0.0001 p<0.0001 p=0.964 21864 34 158548
Scarring Score 
(C)
0 155 1902 1207, 2996 Baseline 2095 15 274835
1 11 449 111, 1816 p=0.438 Baseline 204 34 11556
2 9 990 192, 5111 p=0.927 p=0.941 Baseline 589 76 54651
3 9 2475 253, 24192 p=0.995 p=0.608 p=0.923 7023 17 49125
aScheffé correction used for multiple comparisons bn=number of individuals with quantifiable C. trachomatis bacterial load
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Table 2. Multivariable mixed effects logistic regression analysis showing the effect of spatial dependence on clinically active trachoma and 
ocular Chlamydia trachomatis infection
aAIC=Akaike information criterion bWith household or village as cluster variables cIncluding of spatial structure ddefined as TF/TI using the WHO simplified grading system 
(2)  edefined as log-(e) omcB copies/swab.
Model Predictor Variables n AICa
C. trachomatis infection
No spatialb
Spatialc
age 1426 854.8
801.8
No spatial
Spatial
age 
active trachomad
1426
163
546.4
495.6
Active trachoma
No Spatial
Spatial
age 1426 697.9
659.0
No Spatial
Spatial
age
C. trachomatis infection
1426
224
389.5
362.3
No Spatial
Spatial
age
C. trachomatis loade
1426
180
251.2
232.7
GAA
Table 3. Multivariable mixed effects linear regression analysis of factors predictive of Chlamydia trachomatis load (omcB copies/swab) in 
infected individuals
Model Variable n ORa 95% C.I. p-Value AICb BICc loglikd
Nulle
884.8 894.3 -439.4
Clustering
Householdf
Villagef
Spatialg
884.3
882.1
799.7
893.8
892.0
834.8
-439.1
-438.2
-388.8
Finalh
Including age and disease severity
Spatial
No spatial
802.6
797.7
844.1
829.6
-388.3
-388.8
Age 0-5 years 87 2.60 0.99, 6.87 0.052
6-10 years 45 0.70 0.24, 2.05 0.509
11-15 years 15 1.77 0.43, 7.20 0.427
>15 years 37 1.00 -- --
GAB
Disease Severity Inflammatory Grade (P)
0 46 1.00 -- --
1 70 7.54 3.12, 18.20 <0.0001
2 46 22.8 8.15, 63.9 <0.0001
3 22 30.9 9.39, 101.50 <0.0001
Follicular Grade (F)
0 91 1.00 -- --
1 20 1.29 0.43, 3.84 0.649
2 27 2.20 0.82, 5.88 0.114
3 46 7.78 3.16, 19.15 <0.0001
C. trachomatis load is defined as log-(e) omcB copies/swab. There was no evidence of heteroscedasticity of residuals (Breusch-Pagan/Cook Weisberg test for 
heteroscedasticity in the final model. (Chi2 = 0.44, p=0.5079)) aExponentiated coefficient bAIC=Akaike information criterion cBIC=Bayesian information criterion 
dloglik=Log likelihoood eNull model with dummy cluster variable fIncluding household or village as cluster variables on outcome  gIncluding spatial structure hFinal model 
including covariates with and without adjustment for spatial structure
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Figure 1. The Bijagós Archipelago, Guinea Bissau 
The islands of Bubaque, 
Canhabaque, Rubane and Soga 
(circled in red) were included in the 
current study. © 2009 Ezilon.com
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Figure 2. Chlamydia trachomatis load by age and clinical phenotype in infected individuals
  
y-axis shows the natural logarithmic scale of C. trachomatis bacterial load (omcB copies/swab)
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Figure 3. Empirical semivariograms and fitted models for household prevalence of (a) ocular Chlamydia trachomatis infection and (b) active 
trachoma and the distribution of (c) ocular Chlamydia trachomatis bacterial load 
(a) (b) (c) 
(a) Unadjusted household prevalence of C. trachomatis infection
(b) Household prevalence of active trachoma in 1-9 year olds
(c) Ocular C. trachomatis bacterial load
(d)Prevalence data were log transformed (ln(ln+1)) due to significant negative skew. Active trachoma is defined as TF/TI by the WHO 
simplified grading system (2) (F2/3 or P3 by the modified FPC grading system (1)). Distance is indicated in metres. Model fit with the 
smallest residual sum of squares (Matern, M.Stein’s parameterization (Ste)). All values of Kappa (smoothing parameter of the Matern 
model) tested. Nugget, sill, range and Kappa are all estimated from the data.
GAF
Figure 4. Hotspots of high load ocular Chlamydia trachomatis infections
C. trachomatis load was log transformed (ln(ln+1)) due to significant negative skew. 
Stastistically significant Getis-Ord Gi* Z-scores identify ‘hotspots’ containing similarly 
high values, taking into account the spatial dependence of neighbouring observations. There 
are no ‘coldspots’ (statistically significant clusters of similarly low values). Adjacency is 
defined by the zone of indifference.
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C. trachomatis load was log transformed (ln(ln+1)) due to significant negative skew. 
Statistically significant positive values for the Local Moran’s I statistic indicate clustering 
with similarly high (H-H) or low (L-L) values. Negative values indicate that neighbouring 
observations have dissimilar values and that this observation is an outlier (H-L or L-H). H-
H clusters and H-L outliers are observed. There are no L-L clusters. Observation values 
represent C. trachomatis load. Adjacency is defined by the zone of indifference.
Figure 5. Clusters and outliers of high load ocular Chlamydia trachomatis infections
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Abstract
The Chlamydia trachomatis (Ct) plasmid is a virulence factor. Plasmid copy number, Ct load and 
disease severity were assessed in a trachoma-hyperendemic treatment-naïve population. Using 
droplet digital PCR plasmid copy number was found to be stable (median 5.34 (1-18)) and there 
were no associations with Ct load or disease severity.
KEYWORDS Chlamydia trachomatis; trachoma; disease severity; plasmid copy number; 
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Trachoma is caused by infection with ocular strains of Chlamydia trachomatis. The 
7.5-kb C. trachomatis plasmid has been shown to function as a virulence factor in 
animal models (1,2). Phenotypic differences exist between plasmid-cured and wild-
type C. trachomatis strains with respect to infectivity, glycogen accumulation, 
induction of inflammation and activation of toll-like receptor pathways (3,4). Plasmid 
deletion mutagenesis studies showed that deletion of the plasmid-encoded pgp4 gene 
results in an in vitro phenotype identical to that of a plasmid-free strain (5). This
supports bacterial transcriptome analysis showing a decrease in transcript levels of a 
subset of chromosomal genes in a naturally occurring plasmid-free strain of C. 
trachomatis, demonstrating that the plasmid is a transcriptional regulator of virulence-
associated genes (6).
There is little information in the literature relating plasmid copy number (per genome) 
to virulence (7-9). The mechanisms of plasmid virulence are not clearly defined, 
particularly in naturally occurring infections. We assessed plasmid copy number 
variation and its association with disease severity in ocular C. trachomatis infection 
from a trachoma-hyperendemic treatment-naïve population on the Bijagós 
Archipelago of Guinea Bissau.
Individuals from 300 randomly selected households from 38 villages on four islands 
were examined by a single trained examiner using the WHO simplified and modified 
FPC grading systems (10,11). In the FPC system, follicles (F), papillae (P) and 
conjunctival scarring (C) are separately scored 0-3. Active disease (TF (follicular 
trachoma) or TI (inflammatory trachoma) by the WHO simplified system) equates to 
F2/3 and P3 respectively. C2/3 (and in some cases C1) is equivalent to TS
(trachomatous scarring).  Both systems were used to provide detailed phenotypic 
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information and comparability with other studies. Individuals’ age, sex and ethnicity 
were recorded. 
Swabs were taken from the left upper tarsal conjunctiva of each participant using a 
validated procedure (12,13). Swabs were collected dry into microcentrifuge tubes 
(Simport, Canada), kept on ice in the field and frozen to -800C within 8 hours of 
collection. Measures were taken to avoid cross-contamination in the field and in the 
laboratory (13).
DNA extraction and droplet digital PCR (ddPCR) for detection of C. trachomatis
plasmid were conducted as described previously (14). A second duplex assay was 
used to estimate plasmid and chromosome (omcB) target concentrations within the 
same reaction in plasmid positive samples. We used published primer-probe target 
sequences appropriate for quantitation of all genovars of C. trachomatis (7,14). We 
used a modified omcB probe to improve quenching efficiency and reduce background 
fluorescence (Table 1). Methods for mastermix preparation, droplet generation, 
thermal cycling conditions, droplet reading, target DNA concentration calculation and 
re-testing of saturated samples are described elsewhere (14). Estimated quantities of 
omcB and plasmid are expressed as copies/swab. C. trachomatis load refers to omcB
copies/swab. Plasmid copy number (per genome) was calculated using the 
plasmid:genome ratio. 
Raw quantitation data were processed as previously described (14). Geometric mean
omcB load and linear and logistic regression analyses (with odds ratios (OR)) were 
conducted in STATA 12 (Stata Corporation, College Station, Texas USA) to examine 
associations between plasmid copy number, load and detailed clinical phenotype. C. 
trachomatis load and plasmid copy number data were log-(e) transformed and robust 
standard error used where indicated. 
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Of 1,511 individuals enrolled, 1,508 individuals consented to ocular assessment and 
1,507 conjunctival swabs were obtained. The median age of participants was 13 years 
(1 month-88 years) and 57% were female. Most participants were of the Bijagós 
ethnic group. The prevalence of active trachoma (TF/TI) in 1-9 year olds was 21% 
(136/660) (95% CI 17.89-24.11%). Overall, 11% had clinically active trachoma 
(164/1508) (95% CI 9.42-12.58%). C. trachomatis plasmid DNA was detected in 
16% overall (233/1507) (26% of 1-9 year olds). All samples were adequate by criteria 
described previously (14).
C. trachomatis load was estimated in 79% (184/233) of plasmid positive samples. In 
21% of samples where plasmid load was very low, omcB was below the level of 
detection. 
The geometric mean estimated omcB copies/swab varied by clinical phenotype (294
copies/swab (95% C.I. 165-524) in 73 with normal conjunctivae, 8562 copies/swab 
(95% C.I. 5412-13546) in 92 with active trachoma and 928 copies/swab (95% C.I. 
280-2074) in 19 with scarring. 
The median plasmid copy number was 5.34 (1-18.03) (Figure 1). Plasmid copy 
number was stable in infections across the four study islands (Kruskall Wallis H 
(Chi2)=4.5001(df=3,p=0.2123)). Plasmid copy number was not associated with the 
presence of active trachoma (OR 1.00, 95% CI 0.88-1.12, p=0.960), severity of 
inflammatory (OR 1.04, 95% CI 0.927-1.162, p=0.515) or follicular (OR 1.03, 95% 
CI 0.922-1.159, p=0.572) disease or C. trachomatis load (Table 2). At lower load the 
variance was highly heterogeneous (Levene’s W0=55.3, df=2, p<0.000000001) 
(Figure 2).
The theoretical advantages of ddPCR are presented by Hindson et al. (15). These 
include nanolitre-sized droplet partitioning of the reaction, which promotes optimal 
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primer-template interaction conditions robust to variation in PCR efficiency, thus 
enabling accurate estimation of both plasmid and omcB copy numbers within the 
same reaction. We have discussed the precision and accuracy of our diagnostic 
ddPCR assay elsewhere (14).
There are a few published studies examining plasmid copy number in reference 
strains of C. trachomatis (7-9,16-17). Pickett et al. showed that across 12 C. 
trachomatis serovars the plasmid copy number was not significantly different but 
there were variations depending on growth phase and condition during in vitro culture 
(7). Seth-Smith et al. showed an increased plasmid copy number in ocular relative to 
urogenital strains (8). We demonstrate a stable plasmid copy number distribution in 
naturally occurring ocular C. trachomatis infection that does not vary with geographic 
location, clinical phenotype or C. trachomatis load. Our data show that ddPCR may 
have limitations in measuring plasmid copy number at very low load infections (<200 
omcB copies/swab) where plasmid copy number variance is greatest. This observation 
may reflect a breakdown in the assumptions required to apply the Poisson distribution
to accurately estimate load with ddPCR. Despite the caveats, our data suggest plasmid 
copy number stability in naturally occurring ocular C. trachomatis infection.
Maintenance of the plasmid at low copy number carries inherent risk during cell 
partition (18) but naturally occurring plasmid-free strains are rare (19-21). A lower 
risk higher copy number system is metabolically expensive but may confer a ‘fitness’ 
advantage. Thus, the maintenance of 5-6 plasmids per genome may maximise 
infectivity or intracellular survival whilst provoking minimal host immune response. 
Though there is convincing evidence that the chlamydial plasmid is a virulence factor 
(3,4,6,22-24) our data suggest that plasmid copy number is not associated with 
disease severity and that additive gene dosage effects do not appear to correlate with 
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pathogen virulence in vivo. This supports in vitro work showing no association 
between plasmid copy number and tissue tropism (9). Previous work in vitro and in 
animal models suggests that subtle genomic differences between chlamydial isolates 
are associated with differences in growth kinetics, immune responses and pathology 
(25,26). Further epidemiological and in vitro studies using comparative pathogen 
genomics to examine these associations are required to fully understand the 
relationship between disease severity and chlamydial virulence. 
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Table 1. Primer and probe sequences for control and C. trachomatis targets using the ddPCR system 
Molecular Target Nucleotide Sequence and Modifications
Internal Control
Homo sapiens RPP30 (encoding ribonuclease 
P/MRP 30kDa subunit)a
Forward (RPP30-F) 5’ AGA TTT GGA CCT GCG AGC G 3’
Reverse (RPP30-R) 5’ GAG CGG CTG TCT CCA CAA GT 3’
Probe (RPP30_HEX_BHQ1)a 5’ HEX-TTC TGA CCT GAA GGC TCT GCG CG-BHQ1-3’
Target One
C. trachomatis cryptic plasmid pLGV440 
(circular; genomic DNA; 7500bp)
Forward (Ct-plasmid-F) 5’ CAG CTT GTA GTC CTG CTT GAG AGA 3’
Reverse (Ct-plasmid-R) 5’ CAA GAG TAC ATC GTT CAA CGA AGA 3’
Probe (Ct-plasmid_FAM_BHQ1)a,b 5’ 6FAM-CCC CAC CAT TTT TCC GGA GCG A-BHQ1-3’
Probe (Ct-plasmid_HEX_BHQ1)c 5’ HEX-CCC CAC CAT TTT TCC GGA GCG A-BHQ1-3’
Target Two
C. trachomatis (Serovar A) omcB gene
Forward (Ct-omcB-F) 5’ GAC ACC AAA CGC AAA GAC AAC AC 3’
Reverse (Ct-omcB-R) 5’ ACT CAT GAA CCG GAG CAA CCT 3’
Probe (Ct-omcB-FAM-BHQ1) 5’6FAM-CCA CAG CAA AGA GAC TCC CGT AGA CCG-BHQ1-3’
aMRP, mitochondrial RNA processing endoribonuclease; HEX, hexachlorofluorescein reporter; BHQ, black hole quencher; 6FAM, 6-carboxyfluorescein reporter
bC. trachomatis plasmid probe used in screening (first) assay
cC.trachomatis probe used in quantitative (second) assay
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Table 2. The relationship between plasmid copy number and C. trachomatis load 
(omcB copies/swab)
OmcB 
(copies/swab)
n
Variance
Plasmid
Min
Copy
Median
Numbera
Max
<100 41 19.8139 1 4.1514 18.0291
100-10000 82 2.7136 1 5.3421 9.2819
>10000 62 1.0814 3.6164 5.4261 8.3947
Kruskall Wallis H (Chi2) = 4.58, df=2, p=0.10. 
aPlasmid Copy Number = plasmid copies/genome
Figure 1. Distribution of plasmid copy number variation in naturally occurring 
ocular infection with C. trachomatis within the study population
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ABSTRACT
This is the first population-based genome-wide association scan (GWAS) for 
Chlamydia trachomatis performed on whole genome sequence data obtained directly 
from conjunctival samples taken from treatment-naïve trachoma-endemic communites 
in West Africa. Whole genome sequence data were obtained directly from clinical 
samples using novel DNA-bait sample enrichment. We analysed the sequence data in 
the context of detailed in vivo conjunctival phenotypes and ocular C. trachomatis load 
(omcB load by droplet digital PCR). We identified a total of 1050 SNPs in coding
regions, representing greater than expected genomic diversity. GWAS was performed 
on 759 non-synonymous SNPs in coding regions. A number of associations were 
identified at genome-wide significance (p=6.25xe-05). The strongest association was 
between incE and conjunctival inflammation (OR=2.51, p=5.16xe-08). Two other 
loci (mutY and CTA_0271) were associated with C. trachomatis ocular load. These 
findings were supported by the presence of other synonymous SNPs in close 
proximity within these genes and loci. These data inform us about host-pathogen 
interactions that are likely to be important in C. trachomatis pathogenesis and may 
also be important vaccine and therapeutics targets. 
KEYWORDS
Ocular Chlamydia trachomatis, bacterial load, conjunctival inflammation, genome 
wide association scan, virulence, pathogenesis
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INTRODUCTION
Chlamydia trachomatis is an obligate intracellular human pathogen and is the 
leading infectious cause of blindness and the most common sexually transmitted 
bacterial infection contributing to significant global morbidity and mortality (Mabey 
2003, Hu 2010). Chlamydial strains are differentiated into biovars based on 
pathobiological characteristics and serovars based on serospecificity for the major 
outer membrane protein (MOMP) encoded by the ompA gene (Rodriguez 1991). 
Serovars fall into biological groups associated with trachoma (A-C), sexually 
transmitted non-invasive disease (D-K) and lymphogranuloma venereum (LGV) (L1-
3). Despite the diverse biological phenotypes (tissue tropism and disease outcome), C. 
trachomatis strains share near genomic synteny, suggesting that minor genetic 
changes determine pathogen-host and tissue-specific infection characteristics 
(Caldwell 2003, Jeffrey 2010, Nunes 2013).
Underlying host and pathogen factors responsible for such diverse clinical 
outcomes are unclear. Strain-specific differences have been described related to 
clinical presentation in trachoma (Hayes 1992, Bailey 1994, Kari 2008, Andreason 
2010). Comprehensive genomic analysis of a limited pool of laboratory and clinical 
isolates of the major trachoma serotypes found subtle genetic differences relating to in 
vitro and in vivo pathogenic properties in the different isolates (Kari 2008). Whole 
genome sequencing has also been used to identify regions of likely recombination in 
recent clinical strains, demonstrating that whole-genome sequencing and comparative 
genomics is an effective approach for discovering variable loci in C. trachomatis that 
are associated with clinical presentation (Jeffrey 2010). Putative virulence factors 
identified through whole genome sequence analysis and subsequent in vitro and 
animal studies include the polymorphic outer membrane protein family (Stephens 
1998, Longbottom 1998, Stothard 2003, Gomes 2006), type III secretion apparatus 
and effectors (Rockey 1995, Hsia 1997, Hefty 2007), genes involved in tryptophan 
(Caldwell 2003, Wood 2003, Carlson 2006) and glycogen (O’Connell 2011, Wang
2011) biosynthesis, members of the incA (Hackstadt 1999, Suchland 2000) and 
phospholipase D (Nelson 2006, Taylor 2010) families, genes from the heat shock 
protein family (LaVerda 2000, Kol 2000), the chlamydial cytotoxin (Carlson 2004)
and plasmid-encoded genes implicated in the regulation of chromosomal virulence 
factors (Carlson 2008, Frazer 2012, Song 2013).
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Basic research into C. trachomatis has long been hampered by significant 
technical barriers due to its obligate intracellular life cycle. Only recently has genetic 
manipulation of the chlamydial plasmid been possible, allowing for in vitro
transformation and modification studies (Wang 2011, Wang 2013). Despite these 
advances there are limited genomic data available for current clinical strains, 
rendering it difficult to relate genetic changes to functional relevance and virulence 
factors in vivo.
In the current study we used a genome-wide approach to investigate 
associations with disease and chlamydial load in naturally occurring ocular C. 
trachomatis infections from treatment-naïve communities in a trachoma-endemic 
region in West Africa. We have previously published data from this population 
showing strong associations between ocular C. trachomatis load and disease severity, 
particularly in relation to inflammation (Last 2014a). We have also demonstrated 
spatial clustering of high load ocular C. trachomatis infections, suggesting that 
bacterial load may be important in pathogenesis and transmission (Last 2014a). This 
is the first study to use this approach to examine whole genome sequence data 
obtained directly from a cross-sectional collection of current clinical samples with C. 
trachomatis infection in the context of detailed clinical, epidemiological and spatial 
metadata.
METHODS
Survey and Sample collection
Survey, clinical examination and sample collection methods have been 
described previously (Last 2014a, Last 2014b, Last 2014c). Briefly, we conducted a 
cross-sectional population-based survey in trachoma-endemic communities on the 
Bijagós Archipelago of Guinea Bissau. The upper tarsal conjunctivae of each 
consenting participant were examined, two digital photographs were taken and a 
clinical grade was assigned using both the WHO simplified grading system (Thylefors 
1981) and the modified FPC system (Dawson 1987). The modified FPC system 
allows detailed scoring of the conjunctiva for the presence of follicles (F), papillary 
hypertrophy (inflammation) (P) and conjunctival scarring (C), receiving a grade of 0-
3 for each parameter. For this study we define the clinical phenotypes as active 
trachoma (where the conjunctiva receives a grade of follicular trachoma (TF) and/or 
intense inflammatory trachoma (TI) by the WHO grading system (F2 and/or P3 by the 
modified FPC system)) and as a scale of conjunctival inflammation (P0-P3). The 
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inflammatory phenotype (P score) was chosen as a phenotype on the basis of previous 
studies showing strong association between inflammation and C. trachomatis
bacterial load (Burton 2006, Faal 2006, Last 2014a). Conjunctival swabs were 
obtained and DNA extracted and quantified using droplet digital PCR (ddPCR) as 
described previously (Roberts 2013, Last 2014c). C. trachomatis load refers to omcB 
(genomic) copies/swab.
Pre-sequencing sample enrichment
Whole genome sequence (WGS) data were obtained direct from clinical 
samples. DNA baits spanning the length of the C. trachomatis genome were compiled 
by SureDesign and synthesized by SureSelectXT (Agilent Technologies, UK). C. 
trachomatis DNA extract from clinical samples was quantified and carrier human 
genomic DNA added to obtain a total of 3 !g input for library preparation. DNA was 
sheared using a Covaris E210 acoustic focusing unit. End-repair, non-templated 
addition of 3’ –A adapter ligation, hybridisation, enrichment PCR and all post-
reaction clean-up steps were performed according to the SureSelectXT Illumina 
Paired-End Sequencing Library protocol (V1.4.1 Sept 2012). All recommended 
quality control measures were performed between steps.
Whole genome sequencing and sequence quality filtering
DNA was sequenced by the Wellcome Trust Sanger Institute using Illumina 
paired-end technology (Illumina GAII or HiSeq 2000). Sequences were aligned to the 
Chlamydia trachomatis A/HAR-13 reference genome (GenBank Accession Number 
NC_007429.1) and plasmid (GenBank Accession Number NC_007430.1) using BWA 
(Langmead 2009). SAMTOOLS/BCFtools (SAMTOOLS) (Li 2009) and GATK 
(McKenna 2010) were used to call SNPs and small indels. Variants were selected as 
the intersection dataset between those obtained using both SNP callers and SNPs were 
further quality-filtered by mappability and uniqueness (Coll 2014). Non-unique SNPs 
with mappability values greater than one were filtered and SNP alleles were called 
using an alternative coverage-based approach where a missing call was assigned to a 
site if the total coverage was less than 20x depth or where one of the four nucleotides 
accounted for at least 80% total coverage (Coll 2014). There was a clear relationship 
between the average depth of coverage and proportion of missing calls, which 
provided a further quality filtering threshold. Based on this we retained all sequences 
with greater than 10x average depth of coverage over the whole genome. 
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Comparative genomics analyses
The best-scoring maximum likelihood phylogenetic trees were constructed 
using RAxML v7.4.2 (Stamatakis 2008) using all SNP sites spanning the genome. 
Recombination is known to occur in C. trachomatis (Jeffrey 2010, Harris 2012) and 
can be problematic in constructing phylogeny. We applied three compatibility-based 
recombination detection methods to detect recombination hotspots using PhiPack 
(Bruen 2006): the pairwise homoplasy index (Phi) (Bruen 2006), the maximum Chi2 
(Smith 1992) and the neighbour similarity score (NSS) (Jakobsen 1996) across the 
genome alignment. We also examined the confidence in the phylogenetic tree by 
computing RAxML site-based likelihood scores (Stamatakis 2008). Final 
phylogenetic trees were constructed adjusting for recombination (Stamatakis 2008). 
Tajima’s D was calculated to assess DNA polymorphism in the context of the neutral 
mutation hypothesis (Tajima 1989).
Genome wide association scan analyses
A genome wide association scan (GWAS) is a powerful tool to assess the 
excess association between a SNP and defined phenotype. In general this method is 
confounded by population structure and linkage disequilibrium (LD) (Thomas 2011). 
Therefore we used principal component analysis (PCA) to elucidate the population 
structure and included principal components to adjust for population structure. We 
also corrected for genomic inflation for the occurrence of a polymorphism in the 
population of over 90% and a minor allele frequency of 5% in binary and linear 
models (3% in ordinal models). To avoid the occurrence of false positive associations 
a conservative Bonferroni correction was applied for to adjust for multiple testing in 
genome-wide significance analysis. 
SNP mutations were aggregated by coding and intergenic regions in an n x m 
matrix, where n=number of loci and m=number of sequences. In coding regions only 
non-synonymous mutations were aggregated.
Regression analyses were performed adjusting for age, population structure 
and LD, using the first three principal components. Logistic regression models were 
used to assess the association between disease phenotype (binary models for active 
trachoma and ordinal models for conjunctival inflammation) and SNPs across the C. 
trachomatis genome using MASS and glmm packages in the R statistical package 
v3.0.2 (The R Foundation for Statistical Computing, http://www.r-project.org). Linear 
regression models with C. trachomatis load as a continuous outcome were used to 
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assess the association between C. trachomatis ocular load and SNPs across the 
genome. The statistical significance of each variable was tested using the Wald test. 
The standard error for the log odds ratio was estimated from the model and used to 
calculate 95% confidence intervals for odds ratios (OR).
RESULTS
From a total of 184 C. trachomatis infections quantifiable by ddPCR, we were 
able to obtain whole genome sequence data for 126 using SureSelectXT. We retained 
83 high quality sequences for the final analyses following application of stringent 
filtering criteria. There were no differences between the 83 retained and the 43 
excluded with respect to demographic characteristics, bacterial load, disease severity 
scores or geographical location. 
Phylogenetic Reconstruction and Population Structure 
This collection of population-based ocular C. trachomatis whole genome 
sequences reveals substantial genetic diversity compared to the global chlamydial 
diversity previously published (Harris 2012). Tajima’s D for the sequence data set 
was -2.50 (p=0.01) suggesting an excess of low frequency polymorphisms indicating 
population expansion and/or purifying selection. After stringent filtering, we found 
759 and 10 unique non-synonymous SNP sites in non-repetitive coding regions of the 
genome and plasmid respectively, relative to the reference strain C. trachomatis 
A/HAR-13. Recombination was extensive and hotspots across the genome are shown 
in Figure 1(A). It was not possible to remove all recombinant SNPs for phylogenetic 
reconstruction, but removal of SNPs in regions were there was most likely to be 
greatest recombination (using Phi) had no effect on phylogenetic relationships. 
Additionally, a site-wise log likelihood plot demonstrated that there was no 
significant lack of confidence in the tree construction due to recombination (Figure 
1(B)). 
Figure 2 shows radial cladograms for the plasmid and genome for all 
sequences in the final data set with published C. trachomatis reference strains, rooted 
on Chlamydia muridarum Nigg (GenBank Accession Numbers NC_002182.1 
(plasmid) and NC_002620.1 (genome)). Figure 3 shows the genomic diversity of 
these data in the context of ompA genotyping. There does appear to be clustering by 
serovar (A or B) but SNP phylogeny demonstrates greater diversity than that defined 
by ompA genotyping that may be useful in strain classification. Furthermore, whole 
genome sequence typing has shown that despite conforming to ocular ompA
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genotypes, there are a number of sequences whose genomes cluster with urogenital 
strains (Figure 2(Aii)). Principal component analysis demonstrated that the first three 
principal components captured the majority of this structural variance, and were 
included in the final GWAS (Figure 4). Polymorphic loci on the C. trachomatis
genome are shown in Figure 5. 
Identifying genes and loci associated with disease severity
We conducted two GWAS analyses on the 759 unique non-synonymous SNPs 
in coding areas found in the 83 ocular C. trachomatis sequences (Figure 6). A critical 
p-value threshold was defined as 0.05/759 = 6.25xe-05. Using conjunctival 
inflammatory phenotype (P score) in ordinal logistic regression analysis we identified 
a single gene (incE) that was strongly associated with papillary hypertrophy (Odds 
Ratio (OR)=2.51, p=5.16xe-08) (Figure 6(B)). This finding was supported by the 
presence of other synonymous and non-synonymous SNPs within incE and at 
adjacent positions on the chromosome (Figure 7). We also identified a negative 
association between level of conjunctival inflammation and the locus CTA_0165
(OR=0.44, p=1.66xe-12). Further genes and loci were associated with clinical 
phenotype but did not reach this threshold for genome-wide significance. Additional 
genes and loci that reached significance at the 1% level are detailed in Table 1.
tolB and rpoA were also strongly associated with conjunctival inflammation 
but did not reach genome-wide significance (p=0.0017 and p=0.0062 respectively) 
(Table 1).
Identifying genes and loci associated with C. trachomatis ocular load
On the same set of whole genome sequences we conducted a linear GWAS 
analysis with C. trachomatis load (log-(e) omcB copies/swab) as the outcome (Figure 
8). We found that mutY and CTA_0271 were strongly associated with C. trachomatis
load (p=2.10xe-05 and p=4.68xe-05 respectively). pmpE, pmpF and pmpB were 
strongly associated, almost reaching genome-wide significance (p=0.0002, p=0.0004
and p=0.0022 respectively). Additionally, association with tyrP and tarP were 
approaching significance (p=0.0036 and p=0.0037 respectively) (Table 1). Other 
genes and loci of interest that did not reach genome-wide significance are included at 
the 1% level in Table 1. The same GWAS analyses were conducted for the plasmid 
but no associations were found. 
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DISCUSSION
This is the first population-based GWAS analysis conducted for C. 
trachomatis. We have used high quality sequence data obtained direct from clinical 
samples in conjunction with an objective detailed clinical phenotype and accurate 
estimation of C. trachomatis ocular load. We investigated C. trachomatis genotypic 
associations with disease severity and bacterial load in a treatment-naïve population-
based sample collection. 
In this population incE had the strongest positive association with conjunctival 
inflammation. There were non-synonymous SNPs up and downstream to incE (in 
genes clpB, araD, efp_1 and loci CTA_0121 and CTA_0127) and within the same 
operon (incD, incF and incG), however these did not reach genome-wide 
significance. Further analysis of SNPs within the operon (presented as a regional view 
in Figure 7) showed a frequent non-synonymous SNP at position 136633 (TG) 
surrounded by other supporting synonymous SNPs forming a peak in the regional 
manhattan plot. 
IncE is an inclusion membrane protein. There has been increasing interest in 
the role of this family of proteins since the characterization of incD-G. A study using 
RT-PCR showed that these four inclusion membrane proteins (IncD - IncG) are co-
transcribed within the first two hours of internalization of C. trachomatis, suggesting 
that they are required for modification of the nascent inclusion in early chlamydial 
infection (Scidmore-Carlson 1999). Soon after development of inclusions, homotypic 
fusion occurs, allowing the fused inclusions to escape degradation through host 
endolysosomal pathways and promote fusion with each other to sustain higher 
bacterial loads, thus promoting infection. The role of the Inc family in naturally 
occurring fusing and non-fusing variants has been described (Suchland 2000). 
Serotyping studies showed that strains lacking the IncA serotype were non-fusogenic. 
Subsequent genotyping of incA showed that there were two non-synonymous SNPs 
within incA rendering it non-fusogenic (Suchland 2000, Fields 2002). Others reported 
that non-fusogenic strains unable to express incA had a greater tendency to cause 
subclinical infection in natural human genital tract infection (Giesler 2001). 
Inclusion membrane proteins are type III effector proteins, which are secreted 
from within the parasitophorous vesicle and insert in the inclusion membrane. They 
are exposed on the cytosolic face of the inclusion where they can interact with host 
cells. They are expressed as a family and individually have an inherent property to 
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form vesicular structures. They appear to be important in inclusion membrane 
structure and biogenesis and are thought to play a role in virulence and pathogenesis 
(Carlson 2005, Mital 2013). 
The locus CTA_0165 was negatively associated with conjunctival 
inflammation at genome-wide significance level. This locus codes for a 
phosphatidylcholine-hydrolysing phospoholipase D, which is part of the chlamydial 
phospholipase D (PLD) family. The PLD loci and chlamydial cytotoxin are located 
within the plasticity zone (PZ). This is one of the most polymorphic regions in the 
genome. In the current study, other PLD loci were also highly polymorphic 
(CTA_0163, CTA_0164 and CTA_0167) but did not reach genome-wide significance 
in the association analysis. The PZ PLDs are transcribed during normal and persistent 
infection and corresponding PLD proteins are located on the inclusion membrane of 
reticulate bodies. There is some evidence from in vitro studies that these PLDs may 
be involved in reactivation of C. trachomatis from a gamma interferon-induced 
persistent state (Nelson 2006). The functions of the PZ PLDs are not well defined, but 
they may be important, strain-specific pathogenic factors in vivo (Nelson 2006, Taylor 
2010).
tolB and rpoA were approaching genome-wide significance in their association 
with conjunctival inflammation. tolB encodes a translocation protein and is located 
close to ompA. In Pseudomonas aeruginosa TolB is a periplasmic component of the 
TolB-Pal trans-envelope protein complex of Gram-negative bacteria. TolB is essential 
for P. aeruginosa growth in vitro and in vivo and TolB-deplete cells are defective in 
cell envelope integrity, resistance to human serum and some antibiotics, and in the 
ability to establish infection (Lo Sciuto 2014). There may be a role for TolB in growth 
and pathogenicity. rpoA has been shown to be strongly upregulated during chlamydial 
persistence in Chlamydia pneumoniae infections (Bunk 2010). RpoA, along with 
certain pmp, ompA, porB and groEL-encoded antigens, was suggested as an 
immunodominant marker in persistent C. pneumoniae infections (Bunk 2008). 
mutY was associated with C. trachomatis bacterial load at genome-wide 
significance. mutY is described extensively in studies on Escherichia coli as a mutator 
locus involved in GC to TA transversions (Nghiem 1988). mutY is normally involved 
in mismatch corrections, removing adenines from mismatch situations and 
maintaining genomic stability (Manuel 2004). E. coli carrying mutY mutations lack 
the mismatch correction glycosylase. It is also thought to promote tryptophan-
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independent mutants, with small in-frame deletions and transversions in the trpA23
operon in other chlamydial species (Bridges 1997). The presence of mutY mutations 
has been documented in a hypervirulent C. trachomatis strain causing LGV 
(Somboonna 2011). 
CTA_0271 encodes a 12kDa hypothetical membrane-associated protein of 116 
amino acids in length from position 281,737-282,087. It is flanked by glgP
(CTA_0270) and yidC (CTA_0273). Though neither of these loci reached genome-
wide significance, an association was demonstated with C. trachomatis ocular load. 
glgP is involved in carbohydrate and glycogen metabolism and encodes GlP, an 
antigen encoded on the chlamydial genome but transcriptionally regulated by the 
plasmid (Li 2012). In mice, these antigens are thought to be associated with C. 
muridarum pathogenesis. Intravaginal GlP in mouse models produced protective 
immunity in terms of decreased vaginal shedding of C. muridarum 14 days after 
introduction (Li 2012). There was good correlation of protection with C. muridarum-
specific antibody and a Th1 dominant T cell response, suggesting that GlP may be 
considered as part of a multi-subunit vaccine (Li 2012).
yidC is thought to be required for the maintenance of the translocation-
competent state of certain autotransporters in the periplasm in E. coli (Jong 2010). 
Autotransporters are an important family of virulence factors secreted by Gram-
negative bacteria. They translocate across the membrane and are eventually secreted 
into the extracellular environment. The role of two yidC insertases were examined in 
Streptococcus mutans, showing that yidC contributes to cell surface biogenesis and 
protein secretion in S. mutans (Palmer 2012).
Although below the genome-wide significance threshold, pmp E, pmpF, 
pmpB, tyrP and tarP were also associated with C. trachomatis load. The Pmp family 
have been linked to chlamydial virulence previously (Stothard 2003, Gomes 2006). 
They are surface-expressed, exhibit autotransporter characteristics and are involved in 
transmembrane transport as type III secretion effectors (Tan 2006, Swanson 2009). 
Specifically pmpE and pmpF are highly variable and are detected on the chlamydial 
elementary body surface (Tan 2006). PmpB (and PmpD and H) are strongly 
immunogenic and elicit a pro-inflammatory cytokine response (Tan 2006). They are 
strong candidates for a putative role in virulence via modulation of inflammation and 
adherence to host cells. In mouse models, PmpE-H have been identified as CD4 T cell 
vaccine candidates (Yu 2014). In C. muridarum genital tract infection, CD4 T cells 
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are the foundation for protective immunity, with antibodies playing a secondary role. 
In mice, each of these proteins was found to individually confer protection, measured 
by accelerated clearance of C. muridarum infection from the murine genital tract (Yu 
2014). Combining multiple outer membrane components (PmpE-H + the major outer 
membrane protein (MOMP)) provided broader immunogenicity against chlamydial 
infection (Yu 2014). In our analysis, ompA (encoding MOMP) was polymorphic but 
not associated with inflammation or ocular C. trachomatis load. 
tyrP is linked to tyrosine phosphorylation, occurring early in pathogen-host 
interactions (Clausen 1997). This species-specific mechanism of pathogen entry to 
host cells is thought to involve specific ligands and host cell co-receptors. The
phenomenon was observed in C. trachomatis cell culture using McCoy cells and is 
hypothesized as a species-specific mechanism in the pathogenesis of chlamydial 
infection (Clausen 1997). 
tarP is highly polymorphic between chlamydia strains (Carlson 2005, 
Thomson 2008). TarP is thought to be involved in pathogen-directed phagocytosis 
during the initial attachment phase of uptake of the chlamydial elementary body 
(Jewett 2006). Intra-serovar recombination is thought to play a role in the diversity of 
these genes (Gomes 2007, Harris 2012). Given the diversity in these genes between 
pathobiotypes, associations with ocular C. trachomatis load are not surprising and 
they may be associated with chlamydial virulence. 
Although there were a number of polymorphic genes and loci identified, they 
did not reach the stringent genome-wide significance level stipulated using GWAS. 
This GWAS approach has been shown to be a robust approach for discovering novel 
loci in other pathogens (Laabei 2014, F Coll [unpublished data]). The current study 
has identified strong associations with putative virulence genes and loci, 
contextualizing these associations in currently circulating C. trachomatis strains. The 
data are validated in the findings of putative disease severity associations with inc, 
pmp and PLD genes. The chlamydial GWAS provides compelling evidence that these 
are important and relevant associations, and we have been able to associate them with 
detailed clinical phenotype and an accurate estimate of C. trachomatis load in vivo. 
We have also found associations with novel loci that are linked to virulence in other 
Gram-negative bacteria (mutY, tolB, rpoA and yidC) and a locus for a hypothetical 
membrane protein whose function is currently unclear (CTA_0271), suggesting these 
as putative virulence factors in C. trachomatis. Additionally, the results from this 
GDF
study support findings of virulence-associated genes identified in murine models 
(glgP and pmpE-H). 
Interestingly, there were no genome-wide associations with disease severity or 
C. trachomatis load found in genes or loci on the plasmid. However there were 
associations with genes on the chromosome that are thought to be regulated by 
plasmid-encoded genes (such as glgP). It is clear that the plasmid has an important 
role in chlamydial pathogenesis, but the mechanisms behind this remain unclear.
We were able to obtain high quality whole genome sequence data from 
samples with loads above 1000 omcB copies/swab (126/184 (68%) samples with 
quantifiable C. trachomatis DNA by ddPCR) from this population-based study. We 
further applied stringent quality control filters on WGS data obtained and retained 83 
samples in the final analysis. Despite these limitations, we have generated a large 
archive of ocular C. trachomatis WGS data with corresponding detailed clinical and 
epidemiological metadata. These data are unique in their completeness in the global 
collection of C. trachomatis WGS data.
These samples were collected from a spatially representative population-based 
survey in treatment-naïve trachoma-endemic communities, thus offering further 
opportunity for association analysis at genome scale resolution with spatial 
phylodynamics. We identified a number of genes associated with ocular clinical 
phenotype and C. trachomatis bacterial load from this trachoma-endemic population 
in West Africa and intend to test these associations in other populations and 
replication cohorts. Through validating these findings in other populations we may be 
able to address limitations of the statistical power of GWAS analysis in which it is 
necessary to adjust for population structure and LD (Type I error) by using PCA 
(which may increase Type II error). We have attempted to counteract this by using a 
conservative p-value threshold for genome wide significance by applying a 
Bonferroni correction for multiple comparisons. 
The associations with conjunctival inflammation and C. trachomatis load 
detailed in this study highlight genes involved with specific biological characteristics 
of C. trachomatis and its early interactions with host cells. These data inform us about 
these early interactions that are likely to be important in C. trachomatis pathogenesis 
and may also be important putative vaccine candidates. Pathogen GWAS, particularly 
in conjunction with a detailed in vivo phenotype and accurate estimation of C. 
trachomatis load, is a powerful approach to identifying multiple targets for further 
GEH
study in pathogenesis and directed study of potential vaccine candidates, allowing a 
greater understanding of association and interaction of genes on a genome-wide scale.
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Figures
Figure 1. Recombination hotspots on the Chlamydia trachomatis genome
Figure 2. Maximum likelihood phylogenetic tree showing population structure of 
ocular Chlamydia trachomatis sequences included in the analysis
Figure 3. Maximum likelihood phylogenetic tree showing serovar clustering of ocular 
Chlamydia trachomatis
Figure 4. Principal Component Analysis of ocular Chlamydia trachomatis sequences
Figure 5. Polymorphic loci on the Chlamydia trachomatis genome
Figure 6. Genome-wide association scan to identify genes and loci of Chlamydia
trachomatis associated with clinical disease phenotype in trachoma1#<2+)'DO':2..4+/#$<':[K*'&%+4**'()*+ &$7'()*,+-. 4.)+4$
Figure 8. Genome-wide association scan to identify genes and loci associated with 
ocular Chlamydia trachomatis bacterial load in trachoma
Figure Legends
Figure 1. Statistically significant hotspots of recombination using (A) the pairwise 
homoplasy index (Phi) (B) the site-wise log likelihood support for the best-scoring 
maximum likelihood tree are demonstrated along the Chlamydia trachomatis genome 
Figure 2. (Ai) RAxML maximum likelihood phylogenetic tree including all sequences 
retained in the analysis after quality filtering (n=83, colour-coded blue). Radial 
phylogram representation of the best-scoring maximum likelihood tree using RAxML 
software. Sequences are shown with published C. trachomatis reference strains 
(black), mapped to reference strain C. trachomatis A/HAR-13 (red) and rooted on C. 
muridarum Nigg (green). (Aii) Ocular C. trachomatis sequences (blue) clustering 
with urogenital strains (black). Radial cladograms produced representing the best-
scoring maximum likelihood trees using RAxML software for (B) C. trachomatis
genome (C) C. trachomatis plasmid. 
Figure 3. RAxML maximum likelihood phylogenetic tree including all sequences 
retained in the analysis after quality filtering (n=83). Radial phylogram representation 
of the best-scoring maximum likelihood tree using RAxML software. Sequences are 
colour-coded by ompA genotype showing clustering of A (A/HAR-13 (red), A7249 
(orange)) and B (B/JALI-20 (blue), B/TZ1A828 (purple)) ocular serovars.. 
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Figure 4. The 83 ocular C. trachomatis sequences are plotted against principal 
components (PC) 1 – 4. Sequences are colour-coded by ompA genotype. PC 1-3 best 
capture this clustering by genotype, identifying the underlying population structure.  
Figure 5. Highly polymorphic loci across the C. trachomatis genome are represented 
by SNP density per kb. 
Figure 6. Locus GWAS for non-synonymous SNPs in coding regions for (A) Active 
trachoma (TF/TI) and (B) Conjunctival inflammation (P score; P0-3) in trachoma 
using binary and ordinal logistic regression models adjusting for age, population 
structure and linkage disequilibrium with Bonferroni correction for multiple testing 
(p=5xe-05). A log10 p-value of 2 is equivalent to a p-value of 0.01. Genes with an 
association significant at the 1% level are labeled. 
Figure 7. Frequency of synonymous (black) and non-synonymous (red) SNPs shown 
across the incE and incDEFG operon (chromosomal position shown on x axis) in 83 
isolates (y axis).
Figure 8. Locus GWAS for non-synonymous SNPs in coding regions for ocular C. 
trachomatis load (defined as log-(e) omcB copies/swab) linear regression models 
adjusting for age, population structure and linkage disequilibrium with Bonferroni 
correction for multiple testing (p=6.25xe-05). A log10 p-value of 2 is equivalent to a 
p-value of 0.01. Genes with an association significant at the 1% level are labeled.
Tables
Table 1. Genes and loci associated with disease severity and ocular Chlamydia 
trachomatis load in trachoma
Table Legends
Table 1. Active trachoma is defined as TF/TI by the WHO simplified grading system 
(Thylefors 1981). Conjunctival inflammation is defined by a P score (0-3) using the 
modified FPC grading system (Dawson 1987). C. trachomatis ocular load is defined 
as the log-(e) omcB copies/swab. Genome-wide significance using a Bonferroni 
correction is defined as p=6.25xe-05. Represented here are associated genes and loci 
significant at the 1% level to account for false discovery rates. *Odds Ratio=0.03 
suggesting a negative association.
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Figure 1. Recombination hotspots on the Chlamydia trachomatis genome
  
(A) (B)
Statistically significant hotspots of recombination using (A) the pairwise homoplasy index (Phi) and (B) the site-wise log likelihood support for the best-scoring maximum 
likelihood tree are demonstrated along the Chlamydia trachomatis genome.
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Figure 2. Maximum likelihood phylogenetic trees showing population structure of 
ocular Chlamydia trachomatis sequences included in the analysis
(Ai)
(Aii)
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(B) (C)
(Ai) RAxML maximum likelihood phylogenetic tree including all sequences retained in the analysis after quality filtering (n=83, colour-coded blue). Radial phylogram 
representation of the best-scoring maximum likelihood tree using RAxML software. Sequences are shown with published C. trachomatis reference strains (black), mapped to 
reference strain C. trachomatis A/HAR-13 (red) and rooted on C. muridarum Nigg (green). (Aii) Ocular C. trachomatis sequences (blue) clustering with urogenital strains
(black). Radial cladograms produced representing the best-scoring maximum likelihood trees using RAxML software for (B) C. trachomatis genome (C) C. trachomatis
plasmid. 
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Figure 3. Maximum likelihood phylogenetic tree showing serovar clustering of ocular Chlamydia trachomatis
RAxML maximum likelihood phylogenetic tree including all sequences retained in the analysis after quality filtering (n=83). Radial cladogram representation of the best-scoring maximum 
likelihood tree using RAxML software. Sequences are colour-coded by ompA genotype showing clustering of A (A/HAR-13 (red), A7249 (orange)) and B (B/JALI-20 (blue), B/TZ1A828 
(purple)) ocular serovars. 
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Figure 4. Principal Component Analysis of ocular Chlamydia trachomatis sequences
GFD
The 83 ocular C. trachomatis sequences are plotted against principal components (PC) 1 – 4. Sequences are colour-coded by ompA genotype. PC 
1-3 best capture this clustering by genotype, identifying the underlying population structure.
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Figure 5. Polymorphic genes and loci on the Chlamydia trachomatis genome
Highly polymorphic loci across the C. trachomatis genome are represented by SNP density per kb.
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Figure 6. Genome-wide association scan to identify genes and loci of Chlamydia trachomatis associated with clinical disease phenotype in 
trachoma
(A) Active trachoma
?HH
(B) Conjunctival inflammation
Locus GWAS for non-synonymous SNPs in coding regions for (A) Active trachoma (TF/TI) and (B) Conjunctival inflammation (P score; P0-3) in trachoma using binary and 
ordinal logistic regression models adjusting for age, population structure and linkage disequilibrium with Bonferroni correction for multiple testing (p=5xe-05). A log10 p-
value of 2 is equivalent to a p-value of 0.01. Genes with an association significant at the 1% level are labeled.
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Frequency of synonymous (black) and non-synonymous (red) SNPs shown across the incE and incDEFG operon (chromosomal position shown on x axis) in 83 isolates (y 
axis).
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Figure 8. Genome-wide association scan to identify genes and loci associated with ocular Chlamydia trachomatis bacterial load in trachoma
Locus GWAS for non-synonymous SNPs in coding regions for ocular C. trachomatis load (defined as log-(e) omcB copies/swab) linear regression models adjusting for age, 
population structure and linkage disequilibrium with Bonferroni correction for multiple testing (p=5xe-05). A log10 p-value of 2 is equivalent to a p-value of 0.01. Genes with 
an association significant at the 1% level are labeled.
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Active trachoma is defined as TF/TI by the WHO simplified grading system (Thylefors 1981). Conjunctival inflammation is defined by a P score 
(0-3) using the modified FPC grading system (Dawson 1987). C. trachomatis ocular load is defined as the log-(e) omcB copies/swab. Genome-
wide significance using a Bonferroni correction is defined as p=6.25xe-05. Represented here are associated genes and loci significant at the 1% 
level to account for false discovery rates. *Odds Ratio=0.03 suggesting a mildly protective association.
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ABSTRACT
Background
Trachoma is caused by ocular infection with Chlamydia trachomatis (Ct). The Bijagós 
Archipelago of Guinea Bissau is trachoma-hyperendemic. The WHO recommends three 
annual rounds of community mass drug administration (MDA) of azithromycin if the 
prevalence of follicular trachoma (TF) in 1-9 year olds > 10% at district level to achieve an 
elimination target of TF < 5%. Prior to this survey these communities were treatment-naïve 
and there had been no trachoma control activities.
Methods
We conducted a population-based trachoma survey on four islands. Left and right upper tarsal 
conjunctivae of each participant were assessed for trachoma using the WHO simplified and 
modified FPC grading systems. Swabs were taken from the left upper tarsal conjunctiva. 
After the survey mass MDA was undertaken in all communities on the study islands in line 
with WHO and national policy. We used a droplet digital PCR assay to diagnose and 
quantitate Ct infection. Repeat ocular examination and conjunctival swabs were obtained on 
the treated cohort one year following MDA.
Results
At baseline TF prevalence in 1-9 year olds was 22.0% (136/618). The overall prevalence of 
infection was 18.6% (25.4% in 1-9 year olds). Treatment coverage was estimated at 70%. At 
one year, TF in 1-9 year olds was significantly reduced (7.4% (29/394), p<0.001). Overall 
prevalence of infection was significantly reduced to 3.3% (34/1029), p<0.001) (6.6% in 1-9 
year olds, p<0.001)). The median ocular Ct load had reduced from 2038 to 384 genomic 
copies/swab (p<0.001). There was greater clustering of infection following MDA,
demonstrated by local indicators of spatial association, though the number of clusters of high 
load infections was reduced. Inflammatory disease was less severe following MDA, and most 
infection was present in children under the age of 10 years with active trachoma. 
Conclusions
Despite initial high rates of disease and infection and lower than recommended MDA 
coverage, elimination of trachoma may be achieved with fewer than three rounds of MDA in 
this setting. The reduction in Ct load, disease severity and presence of high load Ct infection 
clusters following MDA inform about Ct infection transmission dynamics and suggest that 
transmission may be coming under control. These data may be useful in understanding the 
epidemiology of trachoma in endemic communities and have subsequent implications for the 
national trachoma control programme in Guinea Bissau. 
KEYWORDS: Chlamydia trachomatis, bacterial load, trachoma, disease severity, 
community mass treatment
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Chlamydia trachomatis is the leading infectious cause of blindness globally 
(1-3). Trachoma is caused by infection with ocular strains of C. trachomatis and 
manifests as distinct clinical syndromes, beginning with an acute self-limiting kerato-
conjunctivitis which may progress to chronic inflammatory disease with subsequent 
conjunctival scarring and blinding sequelae. 
The World Health Organization (WHO) advocates the implementation of the 
SAFE strategy (Surgery for trichiasis, Antibiotics for active infection, Facial 
cleanliness to prevent disease transmission and Environmental improvement to 
increase access to water and sanitation) for trachoma elimination. Mass Drug 
Administration (MDA) of azithromycin aims to clear infection from communities 
such that trachoma ceases to be a public health concern (4). The WHO currently 
recommends three annual rounds of MDA if the prevalence of follicular trachoma 
(TF) in 1-9 year olds is > 10% (at district level) to achieve a reduction in TF to < 5%
(4). Following three rounds of MDA an impact survey is recommended, based on 
which decisions about continuing treatment or conducting surveillance are made. 
There are conflicting data from trachoma-endemic communities on the optimal 
duration and mode of administration required to achieve this target. 
There are modest data from countries with hypo and mesoendemic trachoma 
suggesting that between one and three rounds of single dose MDA are sufficient. Oral 
azithromycin, even as a single dose delivered as a mass administration to 
communities, has significantly reduced the burden of active disease, and in some 
populations has eliminated infection with C trachomatis entirely (5). Often, disease 
(and infection) returns to communities, despite mass treatments, necessitating 
continued surveillance and repeat treatments. The evidence-base relating to optimal 
frequency of mass drug administration that will be effective in eliminating trachoma 
is not fully understood and may vary between settings (6).
In trachoma-hyperendemic populations, despite high coverage of MDA under 
research study conditions, levels of infection and disease, although reduced, can 
persist or re-emerge (7). Longitudinal studies in Tanzania suggest that with present 
WHO protocols, hyperendemic countries may need yearly mass treatment for over ten 
years, which has significant economic and logistic impact on national trachoma 
programmes, non-government organisations and pharmaceutical donors of 
azithromycin (8). Good coverage without elimination of disease at 18 months and re-
emergence of disease within families has been demonstrated in other studies (9). 
?G?
Studies in Ethiopia suggest that prevalence of disease and infection can be 
reduced with multiple annual mass treatments, but that on cessation of treatment, 
disease and infection re-emerge. In some regions where annual treatment appears to 
have had little impact, even biannual treatment that has been implemented under 
research study conditions in this setting has failed to reduce TF prevalence in 1-9 year 
olds to under 5% (10). 
The dynamics of trachoma transmission, particularly in the context of MDA,
are complex and not well understood. Trachoma endemicity is likely to be important, 
such that in hypoendemic populations disease can spontaneously disappear (11-14) or 
disappear after a single round of community mass treatment with antibiotics (5,15). In 
mesoendemic populations disease prevalence may stabilize following community 
mass antibiotic treatment (9), and in hyperendemic populations disease and infection 
persist despite continued rounds of community mass treatment (16).  
At baseline (prior to MDA) trachoma was endemic on the remote Bijagós 
Archipelago of Guinea Bissau. In this population we found a strong association 
between C. trachomatis bacterial load and disease severity. We demonstrated spatial 
clustering of high load infections (17). Following the initial survey we sought to 
assess the impact of a single round of MDA on the prevalence of active trachoma and 
ocular C. trachomatis infection, with particular emphasis on the effect on C. 
trachomatis load, disease severity and spatial clustering of C. trachomatis infection 
one year following MDA.
Methods
Ethical Statement
This study was conducted in accordance with the declaration of Helsinki. 
Ethical approval was obtained from the Comitê Nacional de Ética e Saúde (Guinea 
Bissau), the LSHTM Ethics Committee (UK) and The Gambia Government/MRC 
Joint Ethics Committee (The Gambia). Written (thumbprint or signature) informed 
consent was obtained from all study participants or their guardians as appropriate. 
Following this study all communities on the study islands received further treatment 
with oral azithromycin in accordance with WHO and national protocols.
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Study Design and Study Population
Trachoma survey methodology and this study population have been described 
previously (17-22). Briefly, we used first stage cluster random sampling with 
geospatial representation at village-level to randomly select households for inclusion 
in the survey at baseline. Data were geo-coded at household and village level as 
described previously (17). One year following MDA we sought to follow up members 
of all households enrolled at baseline. 
Clinical Examination and Conjunctival Sampling
Clinical examination and conjunctival sampling were conducted at baseline 
and one year following treatment. A single validated examiner assessed each 
participant using the WHO simplified and modified FPC grading systems as described 
previously (4,17,20,23). In the modified FPC system, follicles (F), papillary 
hypertrophy (inflammation) (P) and conjunctival scarring (C) are each assigned a 
separate grade from 0-3. FPC grades of F2/3 or P3 equate to a diagnosis of active 
trachoma (TF (Trachoma-Follicular) or TI (Trachoma-Intense Inflammatory) by the 
WHO simplified system) and a grade of C2/3 (and in some cases C1) equates to a 
diagnosis of TS (trachomatous scarring). Clinical grading of the upper tarsal 
conjunctivae was conducted in the field as described previously (17-20). Samples 
were taken from the left upper tarsal conjunctiva of each participant using a well-
tolerated standardized procedure described in previous studies (17-20).
Community Mass Treatment
A single height-based dose of oral azithromycin was offered to all individuals 
in all communities participating in the study in accordance with WHO and national 
policy. Alternative treatment with tetracycline eye ointment was offered if there were 
contraindications to treatment with azithromycin. 
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Detection and Quantitation of C. trachomatis 
DNA extraction and droplet digital PCR (ddPCR) (Bio-Rad Laboratories, 
Hemel Hempstead, UK) were conducted as described previously (17,19,20). C. 
trachomatis plasmid-based ddPCR was used to diagnose infection and a single-copy 
pathogen chromosomal gene (omcB) to estimate pathogen load in each plasmid-
positive sample (19,20). Estimated quantities of omcB (C. trachomatis load) are 
expressed as copies/swab. 
Statistical Analysis
C. trachomatis quantitation data were processed as described previously
(19,20). Data were double entered into a customised database (Microsoft Access 
2007) and discrepancies resolved through source documents. Data were cleaned and 
analysed in STATA 13 (Stata Corporation, College Station, Texas USA). Statistical 
significance was determined at the 5% level. 
We examined trachoma and C. trachomatis infection prevalence data at 
baseline and follow-up using a Chi2 test of proportions. C. trachomatis load data were 
log-(e) transformed where indicated. Median load comparisons were made between 
baseline and follow-up using Kruskall-Wallis Chi2. Associations between load and 
detailed clinical phenotype were examined using multivariable mixed effects linear 
and logistic regression models accounting for clustering detected in previous studies 
(17,18). 
Geocoded data were projected into UTM Zone 28N and analysed in ArcGIS 
10.1 (ESRI Inc., USA) as described previously (17). Briefly, Moran’s I was calculated 
at baseline and follow-up to evaluate the effect of MDA on the global spatial 
distribution of active trachoma and C. trachomatis infection. A local indicator of 
spatial association (local (Anselin) Moran’s I) was used to identify clusters and 
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outliers of C. trachomatis infection by load at baseline and follow-up. This method 
detects statistically significant clusters or outliers related to C. trachomatis load based 
on the calculation of z-scores for the distribution. Cluster types identified (relative to 
their z-score and p-value) include H-H (high loads associated with other high loads), 
L-L (low loads associated with other low loads), H-L (a high load outlier associated 
with other predominantly lower loads) and L-H a low load outlier associated with 
other predominantly high loads). The methods underlying these geostatistical tools 
and their application are discussed fully elsewhere (17).
Results
Prevalence of trachoma and C. trachomatis infection
Participant enrolment and follow-up are illustrated in Figure 1. MDA was 
conducted following the baseline survey and was estimated at 70% overall across the 
study islands. Characteristics at baseline and follow-up were not significantly 
different, nor were population-based estimates of scarring trachoma (TS) and 
trachomatous trichiasis (TT) (Table 1). The prevalence active trachoma (TF/TI) and 
ocular C. trachomatis infection was statistically significantly reduced following 
treatment (Table 2). The prevalence of TF in 1-9 year olds was reduced from 22.0% 
(95% CI (Confidence Interval) 18.9-25.5) (136/618) to 7.4% (95% CI 4.8-9.9) 
(29/394) (p<0.001). The prevalence of TI in this age group was also reduced (from 
2.9% (95% CI 1.4-4.1) (18/618) to 1.5% (95% CI 0.3-2.7) (6/394)). The prevalence of 
ocular C. trachomatis infection was reduced in the population from 18.6% (280/1502) 
to 3.3% (34/1029) (p<0.001) and in 1-9 year olds from 25.4% (157/618)) to 6.6% 
(26/395) (p<0.001). 
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Clustering of active trachoma and C. trachomatis infection
There was some evidence for increased clustering of active trachoma and C. 
trachomatis infection at village-level at follow-up. There was also increased 
clustering of infection at household level at follow-up (Table 3). The Moran’s I for C. 
trachomatis infection at baseline was 0.06 (z=2.10, p=0.0353) and 0.27 (z=3.85, 
p=0.0001) at follow-up indicating increased clustering following MDA. 
C. trachomatis ocular load and disease severity
Median estimated load of C. trachomatis infection was significantly reduced 
from 2038 omcB copies/swab to 348 omcB copies/swab (Chi2 = 6.21, p=0.0127) 
(Figure 2). At follow-up almost all infections occurred in children under the age of 10 
years, with 59% (20/34) occurring in children aged 0-5 years. At baseline a greater 
proportion of individuals with TS or normal conjunctivae were infected, indicating 
that infection was more widely spread in the population (Figure 3). 
Disease severity with infection was also reduced from baseline to follow-up, 
most markedly with respect to conjunctival inflammation. There was a shift from 
higher proportions of P2 and P3 scoring disease at baseline to greater proportions of 
P0 and P1 scoring disease at follow-up (Figure 4). Conversely, the proportions of 
high scoring follicular disease (F2 and F3) were greater in the infected cohort at 
follow-up (Figure 4). The association between C. trachomatis load and disease 
severity is demonstrated in age-adjusted mixed effects linear regression models 
accounting for household clustering (Table 4). A strong association remains between 
C. trachomatis load and conjunctival inflammation (P score), though the association 
is weaker at follow-up. The association with F3 scores is maintained and is stronger at 
follow-up. 
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Age-adjusted mixed effects logistic regression analysis accounting for 
household clustering examining associations between disease severity and C. 
trachomatis infection showed that P scores were the strongest predictors at baseline. 
At follow-up there was stronger association between F scores and infection, although 
an association between infection and P scores remains evident (Table 5). 
Interestingly, there was a very strong association between F3 and the presence of 
infection at follow-up, independent of effects of collinearity with P scores.  
Spatial clustering of high load C. trachomatis infections
Maps were generated using the local Moran’s I statistic. These demonstrated 
clustering of C. trachomatis infection by load and found that at baseline there were a 
larger number of clusters of high load infections (H-H clusters) than at follow-up. 
High load outliers (H-L) were not present at follow-up. The H-H clusters present at 
follow-up were at different locations compared to baseline. One H-H cluster at 
follow-up was present in a location where there was a H-L outlier prior to MDA. A 
second H-H cluster was located where there was previously no clustering related to 
bacterial load. Clustering of low load (L-L clusters) infections was not evident at 
either time point. Cluster-outlier maps at baseline and follow-up are presented in 
Figure 5. The threshold C. trachomatis load for membership of a H-H cluster is 
~10,000 omcB copies/swab irrespective of time point.
Discussion
These data suggest that in this island population, despite initial high rates of 
disease and infection and relatively low MDA coverage, reduction of TF to <5% in 1-
9 year olds may be achievable with fewer than three rounds of MDA. The WHO 
recommends that MDA aim for 100% coverage to be considered adequate for 
trachoma control programmes (4). However, due to the significant logistic challenges 
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that exist in this remote area it was only possible to achieve an estimated 70% 
coverage. 
Despite this, following MDA there was a significant reduction in the 
prevalence of both disease and infection following MDA. At both time points active 
trachoma and C. trachomatis infection (particularly those with the highest bacterial 
loads) were most prevalent in children under 10 years of age. Following MDA C. 
trachomatis infection has virtually disappeared in adults, and is reduced in those with 
scarred or normal conjunctivae. The ubiquitous presence of C. trachomatis infection 
across all age groups and clinical phenotypes at baseline is likely to represent the 
distribution typical of chronic hyperendemicity of trachoma before MDA (24). The 
reduction in the prevalence of infection and change in distribution by age and disease 
suggests a shift in the epidemiology of ocular C. trachomatis infection and may mark 
the beginning of control of transmission in these communities. 
The median ocular C. trachomatis load was significantly lower in the 
population following MDA. This is consistent with findings from other studies 
suggesting that from 2-12 months following MDA the prevalence and load of 
infections remain low (9). 
The number of clusters of high load infections detected using local spatial 
statistics was reduced and there was an absence of high load outlying infections 
amidst other low load infections after MDA. This supports the previous suggestion of 
bacterial load being important in transmission of infection and its maintenance in the 
population (14,17). This phenomenon may be due to reduced chlamydial diversity in 
the population following MDA. The role of chlamydial strain diversity in 
transmission is unclear but greater diversity is likely to represent more successful 
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transmission. There is some evidence that following MDA the number of strains by 
ompA genotyping was substantially reduced (25). 
At both time points the threshold value for membership in a H-H cluster is 
~10,000 omcB copies/swab, suggesting that there may be a threshold load important 
in transmission. The change from a H-L outlier prior to MDA to a H-H cluster 
following treatment suggests that there may be ongoing transmission at this location. 
Additionally a new H-H cluster is apparent where there was previously none. This 
particular location has a mobile population, being populated by fishermen and their 
families from Guinea Conakry, Sierra Leone and other islands on the archipelago. 
There are limited amenities in this settlement and it is possible that infection has been 
reintroduced. Introduction of infection following migration events has been 
documented in The Gambia (7). These data provide insight into the dynamics of 
transmission and the micro-epidemiology of C. trachomatis infection in these 
populations and support findings suggesting the importance of C. trachomatis
bacterial load in transmission (14,17).
Clustering of disease and infection was more apparent following MDA. The 
strongest clustering was present at village level following MDA. This may be relevant 
in the context of previous spatial analyses conducted in this population suggesting 
that the village may be an important unit of transmission in these communities (17). 
An increase in clustering and size of clusters of infection in treated communities has 
been described (26). 
Additionally, in this study were able to use the detailed conjunctival grading 
system to investigate associations between infection, bacterial load and disease 
severity following MDA. A strong association between C. trachomatis load and 
inflammatory trachoma has been described previously (17,24,27). Associations 
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between C. trachomatis genotype, using pathogen genome-wide association scans, 
and inflammatory phenotype have been shown (Last et al., in preparation (Chapter 
10). The reduced association between infection and P score following MDA may 
reflect the decreased burden of circulating infection and decreased infection loads. It 
is likely that repeated episodes of infection are reduced following MDA due to a 
decrease in circulating C. trachomatis and subsequently reduced transmission. 
Moreover, in populations undergoing MDA there is evidence that clinical signs of 
trachoma become less specific for C. trachomatis infection (28), suggesting that only 
the more severe phenotypes remain predictive of C. trachomatis infection. 
Although a single grader standardised against a trachoma-grading expert using 
the WHO simplified grading system was employed at both time points to minimise 
inter-observer bias, this may not eliminate all bias with respect to the use of the non-
standardised modified FPC grading system and the associations noted between 
phenotype and bacterial load. However, the concurrent use of the WHO simplified 
system supports these associations and this study supports data from other studies
(17,24,27).
There was some loss to follow-up during the course of this study due to the 
fluctuating nature of these communities. The characteristics of the population in terms 
of age distribution, gender and chronic sequelae (trachomatous trichiasis) suggest that 
the follow-up cohort is adequately representative of the baseline cohort. However, the 
prevalence of conjunctival scarring in the cohort at follow-up was higher, indicating 
that there may be selective drop out of less severely affected individuals. This may 
affect the overall prevalence of C. trachomatis infection found at follow-up, as the 
prevalence of infection in conjunctival scarring may be higher than in those with no 
clinical signs of trachoma (18). There may also be responder bias within the follow-
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up cohort. Further longitudinal study is underway in a larger randomly selected 
population to verify prevalence data from this study
We are currently developing mathematical models to investigate transmission 
dynamics of C. trachomatis and the effect of high load infections in these 
communities. Such models, in conjunction with ongoing work on pathogen genomics 
to define C. trachomatis strain diversity and geospatial analysis may improve our 
understanding of disease pathogenesis and transmission and may be useful in 
trachoma surveillance in post-MDA settings to identify clusters of infection and 
thresholds of C. trachomatis bacterial load that may be important foci of transmission. 
In summary, through investigating the micro-epidemiology of C. trachomatis
infection and its relationship with bacterial load and disease severity, these data 
suggest that MDA is having an impact on transmission of ocular C. trachomatis in 
these communities. However, further monitoring is required, as our geospatial 
analyses suggest that that there may be on-going transmission and risk of 
reintroduction of infection to communities despite MDA. Further longitudinal study, 
utilising mathematical models, high resolution chlamydial genotyping and geospatial 
analysis, is necessary to provide a more complete picture of the relationship between 
disease severity, chlamydial load, transmission and elimination thresholds in 
communities undergoing MDA.
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Figure 1. Enrollment of participants at baseline and follow-up one year after 
community mass treatment for trachoma control
Community mass treatment was distributed in accordance with WHO and national trachoma control 
policies. Zithromax® was donated by Pfizer Inc. through the International Trachoma Initiative.
Table 1. Study population characteristics at baseline and follow-up at one year
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Table 2. The effect of community mass treatment with azithromycin on the 
prevalence of active trachoma and ocular C. trachomatis infection
aCI = Confidence Interval bTF1-9 = TF (Trachoma-Follicular) in 1-9 year olds; TI1-9 = TI (Trachoma-
Intense Inflammatory) in 1-9 year olds cCt = C. trachomatis infection in the population overall and in 
1-9 year olds *p<0.001 (Chi2)
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aCE = Cluster Estimates obtained from age-adjusted mixed effects regression models for active 
trachoma and Ct (C. trachomatis) infection at baseline and follow-up. 95% CI (Confidence Intervals) 
of the s.e. (standard error) are quoted. Mixed effects models including all three cluster levels showed 
household to have the strongest effect. All cluster estimates were significant at the 1% level (Wald 
Chi2).
Figure 2. Reduction in median C. trachomatis load in ocular C. trachomatis infection 
following community mass treatment with azithromycin
Box-whisker plot showing the median C. trachomatis load (omcB copies/swab) from individuals with 
conjunctival infection at baseline and follow-up.
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Figure 3.  The effect of community mass treatment with azithromycin on ocular C. trachomatis load by age and clinical phenotype TPU '' TaU
(A) Baseline (B) Follow-up. Clinical phenotype defined using the WHO simplified grading system (22).
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Figure 4. The effect of community mass treatment with azithromycin on disease severity in individuals with ocular C. trachomatis infection T&U'$mGEA T>U'$m@A
T%U'$mGEA T7U'$m@A
Proportion of infected individuals with conjunctival inflammation (P score) at (a) baseline and (b) follow-up. Proportion of 
infected individuals with conjunctival follicles (F score) at (c) baseline and (d) follow-up. F and P scores according to the modified 
FPC grading system (4).
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Table 4.  The effect of community mass treatment with azithromycin on associations between disease severity and C. trachomatis bacterial load
in individuals with ocular C. trachomatis infection
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Age-adjusted multivariable mixed effects linear regression analysis accounting for household clustering with log-(e)-transformed C. trachomatis load (omcB copies/swab). F 
and P scores according to the modified FPC grading system (4). Individuals may appear in multiple clinical grading categories. p-value is for the Wald Chi2.
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Table 5. The effect of community mass treatment with azithromycin on associations between clinical phenotype and the presence of ocular C. 
trachomatis infection 
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Age-adjusted multivariable mixed effects logistic regression analysis accounting for household clustering. Two models examining clinical phenotype were used: Model 1 
summarised using TF (Trachoma-Follicular ) and TI (Trachoma-Intense Inflammatory) according to the WHO simplified grading system (22) and Model 2 using more 
detailed F and P scores according to the modified FPC grading system (4). Individuals may appear in multiple clinical grading categories. p-value is for the Wald Chi2.
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Figure 5. Cluster-Outlier maps showing the effect of community mass treatment on clusters of high load ocular C. trachomatis infections 
''''''''TPU TaU
C. trachomatis load was log transformed (ln(ln+1)) due to significant negative skew. Statistically significant positive values for the Local Moran’s I statistic indicate clustering 
with similarly high (H-H) or low (L-L) values. Negative values indicate that adjacent observations have dissimilar values and that this observation is an outlier (H-L (a high load 
outlier) or L-H (a low load outlier)). Maps are presented at (A) baseline and (B) follow-up after MDA. H-H clusters are observed at both time points. H-L outliers are observed at 
baseline only. There are no L-L clusters. Observation values represent C. trachomatis load. 
Cluster Type
?@?
Chapter 12 Study Summary, Limitations and Conclusions 
12.1 Summary of Study Findings
12.1.1 Trachoma is hyperendemic on the Bijagós Archipelago (Chapters 7 and 11).
Table 1 summarises trachoma and ocular C. trachomatis infection prevalence 
data from the baseline survey using WHO indicators.
Table1. Prevalence of trachoma and ocular C. trachomatis infection in treatment-
naïve communities on the study islands of the Bijagós Archipelago
Prevalence (%) 
[95% Confidence Interval]
n
Follicular Trachoma (TF1-9b) 22.0[18.9-25.5] 136/618
Inflammatory Trachoma (TI1-9b) 2.9[1.4-4.1] 18/618
C. trachomatis infectionallc 18.6[16.7-20.6] 280/1502
C. trachomatis infection1-9c 25.4[22.0-28.8]] 157/618
Conjunctival Scarring (TSb)
Overall 
By Age Group
0-5 years
6-10 years
11-15 years
>15 years
23.8 [21.6-25.9]
2.7[1.1-4.2]
2.8[0.8-4.8]
11.5[6.5-16.4]
47.2[43.5-51.0]
357/1502
11/414
7/250
18/157
321/680
Trachomatous Trichiasis (TT>15b) 3.5[2.1-4.9] 24/680
From the baseline survey of 1507 individuals with complete clinical examination and 
infection data. bPrevalence data presented according to the WHO simplified grading 
system [1]. TF1-9 = Trachoma-Follicular (TF) in 1-9 year olds; TI1-9 = Trachoma-
Intense Inflammatory (TI) in 1-9 year olds; TS = Trachomatous scarring; TT>15 = 
Trachomatous Trichiasis in those >15 years of age. cC. trachomatis DNA positivity
by ddPCR in all (the population overall) and 1-9 (1-9 year olds).
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12.1.2 Water access reflecting specific hygiene behaviours and the presence of flies 
around latrines are associated with the presence of ocular C. trachomatis infection 
in communities on the Bijagós Archipelago (Chapter 7).
Knowledge of risk factors associated with trachoma and C. trachomatis
infection in a particular setting may help prioritise trachoma elimination activities. In 
this study, household-level clustering was adjusted for in all models examining risk 
factor associations. Active trachoma and the presence of C. trachomatis infection 
were strongly correlated. Risk factors for disease and infection were similar. In this 
environment, individual measures of facial cleanliness (ocular and nasal discharge) 
and household-level risk factors relating to fly populations, hygiene behaviours and 
water usage are likely to be important in C. trachomatis transmission. 
There was a strong association between type of water source and both active 
trachoma and C. trachomatis infection. The association with active trachoma is likely 
to be mediated through C. trachomatis infection. In Bijagós communities, every 
household has access to a water source within 15 minutes walking distance. It is 
therefore likely that this association may reflect more subtle hygiene and water use 
behaviours related to allocation of water collected for specific hygiene practices.
Latrine access was not associated with active trachoma or C. trachomatis
infection, despite the fact that 60% of individuals did not have access to a latrine.
However, the presence of flies around a household pit latrine was strongly associated 
with infection in final multivariable models. There was a strong association between 
flies around a latrine and the presence of visible faeces within a latrine. These 
findings suggest that flies may be an important risk factor in the transmission of 
trachoma in this environment.
12.1.3 There is spatial clustering of high load ocular C. trachomatis infection
(Chapter 8).
Spatial clusters and hotspots, independent of age and gender, of individual 
infections with high bacterial loads were detected using local indicators of spatial 
association. There was no evidence of coldspots or clustering of low load infections, 
suggesting that high load infections may be important in transmission of chlamydial 
infection. 
These data suggest that there may be a threshold of C. trachomatis load below 
which clustering of high loads does not occur. Equally, these data suggest that having 
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a low load infection may be similar to being uninfected with respect to transmission, 
since those with no infection behaved similarly to those with low load infections in 
terms of clustering. This supports the proposed Allee effect, which hypothesizes that a 
reduction in chlamydial fitness due to reduced pathogen population size or density 
results in its disappearance from a population [2].
Measures of spatial dependence in the distribution of C. trachomatis infection, 
supported by household demographics, suggest that village-level transmission is
important in this population. 
12.1.4 High load ocular C. trachomatis infections were associated with the most 
severe inflammatory disease in active trachoma (Chapter 8).
The highest C. trachomatis loads were associated with the most severe clinical 
signs of disease and the strongest associations were with increasing inflammatory 
scores. The majority of ocular C. trachomatis infections occur in children, who have 
the highest loads and most severe active trachoma. 
In this population C. trachomatis load increases with disease severity (for both 
follicular (F) and inflammatory (P) scores), the strongest association being with 
increasing P scores. The association between C. trachomatis load and high F scores is 
in part due to collinearity between F and P, such that individuals with high F scores 
are likely also to have some degree of inflammation present. Inflammation has 
previously been found to be associated with high C. trachomatis loads and persistence 
of infection in children [3].
12.1.5 The (virulence) plasmid copy number (per genome) is stable in naturally 
occurring ocular C. trachomatis infection and there is no association with disease 
severity or ocular C. trachomatis load (Chapter 9).
The C. trachomatis plasmid is a virulence factor. This is the first study to 
document plasmid copy number variation in naturally occurring ocular C. trachomatis
infection, demonstrating its stability and that it does not vary with geographic 
location, clinical phenotype or C. trachomatis load.
Nanolitre-sized droplet partitioning of the ddPCR reaction, promotes optimal 
primer-template interaction conditions which are robust to variation in PCR 
efficiency, and enabled the accurate estimation of both plasmid and genome (omcB)
copy numbers within the same reaction. 
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This study found the plasmid copy number to be stable, with a median copy 
number per genome of 5.34 (range 1-18 copies/genome) and there were no 
associations with C. trachomatis bacterial load or disease severity.
There is clearly a selective advantage in maintaining this extra-chromosomal 
element, and though there is convincing evidence that the chlamydial plasmid is a 
virulence factor [4-9], these data suggest that plasmid copy number is not associated 
with disease severity and that additive gene dosage effects do not appear to correlate 
with pathogen virulence in vivo.
12.1.6 Naturally occurring ocular C. trachomatis genomic diversity was greater 
than anticipated in the context of global C. trachomatis diversity (Chapter 10).
In the context of the global collection of published laboratory reference and 
clinical urogenital, lymphogranuloma venereum and ocular C. trachomatis strains
[10], this study shows greater than anticipated phylogenetic diversity amongst these 
C. trachomatis infections. This is the first population-based prospective collection of 
naturally occurring ocular C. trachomatis strains obtained direct from clinical 
samples. Whole genome sequence analysis has demonstrated the extent of this 
diversity, summarized in phylogenetic trees in Chapter 9. The Tajima’s D at whole 
genome sequence level (D=-2.50, p=0.01) suggests an excess of low frequency 
polymorphisms, indicating population expansion and/or purifying selection [11]. This 
is supported by evidence of widespread recombination demonstrated using the 
pairwise homoplasy index and previous studies showing evidence of purifying 
selection using ompA genotyping [12,13].
12.1.7 incE was associated with conjunctival inflammation at a genome-wide 
significance level (Chapter 10).
In this population, the C. trachomatis incE gene was strongly associated with 
conjunctival inflammation at genome-wide significance level using pathogen genome 
wide association scan (GWAS) with ordinal logistic regression analysis. There were 
supporting synonymous and non-synonymous SNPs within the incE-D operon. IncE 
is part of the inclusion membrane protein family. Inclusion membrane proteins are 
type III effector proteins, secreted from within the parasitophorous vesicle and 
inserted in the inclusion membrane. They are thus exposed on the surface of the 
inclusion, where they may interact with host cells. They appear to be important to 
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inclusion membrane structure and biogenesis, and are thought to play a role in 
virulence and pathogenesis [14,15].
12.1.8 Novel genes and loci (mutY and CTA_0271) were associated with C. 
trachomatis ocular load at a genome-wide significance level (Chapter 10). 
Linear GWAS models showed that the strongest associations at genome-wide 
significance with C. trachomatis ocular load were with mutY and CTA_0271. mutY
has been identified in a hypervirulent C. trachomatis strain causing lymphogranuloma 
venereum [16] and in other chlamydial species causing tryptophan-independent 
mutants [17]. In E. coli this gene has been extensively described as a mutator locus 
involved in mismatch corrections and the maintenance of genomic stability. 
CTA_0271 is a novel loci coding for a hypothetical membrane protein. 
Other genes (pmpE, pmpF, pmpB, tyrP and tarP) were also associated with C. 
trachomatis load, but below the stringent threshold set for genome-wide significance 
correcting for multiple testing. The polymorphic membrane proteins (pmps), tyrP 
(causing tyrosine phosphorylation) and tarP (involved in actin skeleton 
reconfiguration and pathogen-directed phagocytosis) are thought to be associated with 
chlamydial virulence [14,19,20].
12.1.9 There were no associations between genes and loci on the C. trachomatis 
plasmid and disease severity or ocular C. trachomatis load (Chapter 10).
Ordinal and linear GWAS regression models did not show any association 
between plasmid genes and loci with conjunctival inflammation or ocular C. 
trachomatis load. However there were associations with genes on the chromosome 
that may be regulated by plasmid-encoded genes (such as glgP) [21]. It is clear that 
the plasmid has an important role in chlamydial pathogenesis, but the mechanisms 
behind this remain unclear.
12.1.10 A single round of community mass treatment with oral azithromycin 
significantly reduces the prevalence of active trachoma and ocular C. trachomatis 
infection (Chapter 11).
There was a significant reduction in the prevalence of both disease and 
infection following community mass distribution of azithromycin (MDA). Most 
infection, in particular those with the highest loads, was concentrated in children 
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under the age of 10 years with active trachoma. Following MDA C. trachomatis
infection virtually disappeared in adults, and is markedly reduced in those with 
scarred or normal conjunctivae. The baseline distribution of infection and disease is
representative of hyperendemicity of trachoma in this population before MDA [22]. 
The reduction in the prevalence of infection and change in distribution by age and 
disease after MDA may mark the beginning of control of transmission in these 
communities. 
12.1.11 Following a single round of community mass treatment with oral 
azithromycin there is a significant reduction in median ocular C. trachomatis load 
and conjunctival inflammation (Chapter 11).
The median ocular C. trachomatis load was significantly lower in the 
population following MDA. This is consistent with findings from other studies 
suggesting that following MDA the prevalence and load of infections can remain low 
[23].
This study used a detailed conjunctival grading system to investigate 
associations between infection, bacterial load and disease severity following MDA. 
Following MDA there was weaker association between infection and P score than at 
baseline. Clinical signs of trachoma become less specific for C. trachomatis infection
once MDA has been initiated [24]. This may reflect the overall decrease in circulating 
C. trachomatis and probable reduction in repeated episodes of infection. This may 
represent reduced transmission within these communities. 
12.1.12 Following a single round of community mass treatment with oral 
azithromycin there is increased spatial clustering of ocular C. trachomatis infection
(Chapter 11).
Clustering of disease and infection was more apparent following MDA using 
mixed effects regression models and measures of global spatial autocorrelation. The 
strongest clustering was present at village level following MDA. This may be relevant 
in the context of previous spatial analyses conducted in this population suggesting 
that the village may be an important unit of transmission in these communities [25]. 
The phenomenon of increased clustering of infection in treated communities has been 
described previously [26]. 
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The number and size of clusters of high load infections detected using local 
spatial statistics was reduced and there was an absence of high load outlying 
infections amidst other low load infections after MDA. These disparate remaining 
small clusters of high load infections following MDA may represent isolated islands 
of infection rather than the larger clusters of high load infection present at baseline.
This supports the previous suggestion of bacterial load being important in 
transmission of infection and its maintenance in the population and supports they 
hypothesis that transmission is beginning to come under control with MDA [2,25]. 
12.2 Study Limitations
Many of the findings from this study were based on cross-sectional data. A 
cross-sectional study has inherent limitations, providing a ‘snap-shot’ view of the 
epidemiology of trachoma and C. trachomatis infection. Cross-sectional data is 
limited to demonstration of associations rather than determination of causality. It is 
also difficult to make inferences about transmission of C. trachomatis infection based 
on cross-sectional data, particularly as the study is limited in the assumption of load 
and clinical disease severity as a steady state. Longitudinal study is required to fully 
investigate the dynamics of C. trachomatis bacterial load in transmission, but they are 
often time-consuming, expensive and logistically challenging.  Some of these issues 
are currently being addressed through the development of predictive mathematical 
models that can be modified and validated using follow-up data. 
Although a single grader standardised against a trachoma-grading expert using 
the WHO simplified grading system was employed at each data collection time point 
to minimise inter-observer bias, this may not eliminate intra-observer bias with 
respect to the use of the non-standardised modified FPC grading system. However, 
concurrent use of the WHO simplified system supports the associations between 
detailed clinical phenotype and bacterial load. Moreover these data support findings 
from other studies using the modified FPC grading system. Conjunctival digital 
photographs taken will be independently graded using the modified FPC system to 
further validate these findings.
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There was some loss to follow-up in the cohort following MDA. This was 
largely due to unavoidable losses due to mobility within the population. The follow-
up cohort were demographically similar to the baseline cohort, therefore it was 
assumed that they were representative of the population. However, to confirm the 
post-treatment findings there has been a further impact survey conducted in these 
communities, with new random selection of households to remove any cohort bias 
and ensure an adequate sample size to detect a reduction in prevalence of disease and 
infection in the context of MDA.
For the GWAS analysis it was only possible to obtain high quality whole 
genome sequence data for 68% of samples with quantifiable C. trachomatis DNA by 
ddPCR. Further application of stringent quality control filters on sequence data 
obtained resulted in 83 (66% of sequenced samples (45% of total quantifiable C.  
trachomatis positive samples)) samples being retained in the final analysis. This is 
likely to reduce the power of the study to adequately detect less extreme associations 
with disease severity or C. trachomatis load. Despite these limitations, these data 
represent a unique and sizeable archive of ocular C. trachomatis whole genome 
sequence data with corresponding detailed clinic-epidemiological metadata. Future 
validation of these findings in other populations (described in Chapter 12) may 
address the limitations of the statistical power of GWAS analysis. Additionally a 
conservative p-value threshold for genome wide significance was applied using a 
Bonferroni correction for multiple comparisons, to reduce the detection of ‘false 
positive’ associations.
12.3 Study Conclusions
The Bijagós Archipelago is a unique setting where trachoma is hyperendemic, 
and at the time of the baseline survey communities were treatment-naïve. This is the 
first study of its kind to be conducted in this remote and challenging environment. 
This study has established the prevalence of trachoma and ocular C. trachomatis
infection, and socio-environmental risk factors have been identified that may be 
important in the implementation of trachoma elimination activities in these 
communities. 
The primary aims of this study were to use novel molecular, bioinformatic and 
geostatistical approaches in conjunction with population-based clinical and 
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epidemiological metadata to investigate the micro-epidemiology of ocular C. 
trachomatis and active trachoma in this population.
C. trachomatis ocular load was estimated using a next generation ddPCR 
assay that was optimized and evaluated for this study. The accurate estimation of C. 
trachomatis load for individual infections allowed detailed analysis of load and 
disease severity data. There was a strong association between C. trachomatis ocular 
load and disease severity, in particular with the level of conjunctival inflammation. 
Geostatistical analysis suggests that ocular C. trachomatis load may be important in 
transmission, through demonstration of the presence of spatial clusters of high load 
infections and the absence of spatial clusters of low load infections.
Whole genome sequence data was obtained directly from clinical samples 
using cutting edge genome-wide DNA-bait sample enrichment technology for the first 
time in ocular C. trachomatis infection. Next generation Illumina sequence 
technology and stringent bioinformatics algorithms were applied to obtain high 
quality whole genome sequence data for comparative genomics analysis. This study 
includes the first pathogen GWAS for C. trachomatis, identifying putative genes and 
loci associated with disease severity and C. trachomatis ocular load. Pathogen GWAS 
affords a powerful analysis allowing for adjustment of population structure and 
linkage disequilibrium. The associations with conjunctival inflammation (incE) and 
C. trachomatis load (mutY and CTA_0271) highlight genes involved with specific 
biological characteristics of C. trachomatis. The functions of these molecules suggest
that early interactions with host cells are important in C. trachomatis pathogenesis. 
This is consistent with results from host GWAS studies examining conjunctival 
scarring in trachoma which suggest that host genes and pathways involved in early 
interactions in intracellular parasitism are important determinants of later fibrotic 
conjunctival pathology [Ch Roberts, unpublished data]. Pathogen GWAS, particularly 
in conjunction with a detailed in vivo phenotype and accurate estimation of C. 
trachomatis load, is a powerful approach to identifying multiple targets for further 
study in pathogenesis and directed study of potential vaccine candidates, allowing a 
greater understanding of association and interaction of genes on a genome-wide scale.
As part of this study, the first mass distribution of azithromycin (MDA) 
campaign was conducted in conjunction with the Programa Nacional de Saúde de 
Visão. Following a single round of MDA the prevalence of active trachoma and 
ocular C. trachomatis were significantly reduced. Individual (and median) load of C. 
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trachomatis was reduced and the highest burden of disease and infection were 
concentrated in young children. Spatial clustering of infection identified using 
geostatistical tools was intensified following MDA, but clusters of high load 
infections were reduced. The absence of low load clusters was evident at baseline and 
following MDA. Disease severity was reduced following MDA, particularly in 
relation to conjunctival inflammation. 
In summary, spatial clustering of high load ocular C. trachomatis infections 
and a strong association with severe inflammatory trachoma suggests the importance 
of chlamydial load in disease pathogenesis and transmission. Geospatial tools may be 
useful in trachoma surveillance in post-treatment settings to identify clusters of 
infection and thresholds of C. trachomatis bacterial load that may be important foci of 
transmission. The association between conjunctival inflammation and C. trachomatis
load may reflect pathogen virulence, highlighted by the presence of associations with 
C. trachomatis load and conjunctival inflammation identified by pathogen GWAS. 
Further epidemiological and in vitro studies are required to provide a more complete 
picture of the relationship between disease severity and chlamydial load.
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Chapter 13 Future Studies
Work is ongoing to develop mathematical models (in collaboration with the 
University of California, San Francisco) to investigate the transmission dynamics of 
C. trachomatis and the effect of high load infections in these communities, based on 
the findings of the current study suggesting that C. trachomatis load is important in 
pathogenesis and transmission. Such models, in conjunction with geospatial tools may 
be useful as tools for trachoma surveillance in post-MDA settings to identify clusters 
of infection and thresholds of C. trachomatis bacterial load that may be important foci 
of transmission and may improve our understanding of disease pathogenesis and 
transmission. These methods may also have wider application in monitoring 
concurrent neglected tropical diseases that are targeted for elimination. 
The associations with conjunctival inflammation and C. trachomatis ocular 
load evident on pathogen GWAS analysis warrant further study. Further validation of 
these findings will be established through sequence-typing over incE in a replication 
cohort in conjunction with detailed clinical and immunological metadata. A full 
examination of synonymous and non-synonymous SNPs in adjacent regions, 
including over the incD-G operon, will be conducted. There is ongoing work 
examining allele frequency and linkage disequilibrium across these SNPs in 
association with conjunctival inflammation.  Operon-based analysis, gene interaction 
studies and epistasis can be examined in silico to explore these associations further. In 
vitro analysis expressing IncE from open reading frame clones will be conducted 
following results from this study. 
Comparative genomics analysis will be undertaken looking for signatures of 
selection and towards the development of a high-resolution SNP-based typing tool, 
allowing for the meaningful definition of strain-dependent virulence and its 
subsequent use in studies into the pathogenesis and epidemiology of C. trachomatis
infection. 
Further epidemiological and in vitro studies using comparative pathogen 
genomics to examine these associations are required to fully understand the 
relationship between disease severity and chlamydial virulence and identify potential 
vaccine candidates. The molecular, geostatistical and bioinformatics tools employed 
in these study have further application in the study of C. trachomatis infection, 
?AC
pathogenesis, transmission and disease surveillance in the context of MDA in 
trachoma-endemic communities.
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Appendix V. Consent Information and Forms 
Information for Participants
Study: Mapping Trachoma on the Bijagos Archipelago of Guinea Bissau
Principal Investigator: Dr Anna Last
London School of Hygiene & Tropical Medicine (UK) and the Programa
Nacional da Saúde Visao (PNSV) (Guinea Bissau)
What is trachoma and why is it important?
Trachoma is a common cause of blindness in many African countries, 
including Guinea Bissau. This disease is caused by infection (with a 
bacterium called chlamydia) which is passed from eye to eye.  After people 
have had the infection many times, it can cause scarring of the upper eyelid, 
which pulls the eyelashes inwards, causing damage to the eye. This is very 
painful and in a significant number of cases results in blindness.
At certain stages of the disease it is possible to treat the infection using topical 
eye medication or antibiotics by mouth. In other studies conducted in Africa, 
we have discovered that treatment with an antibiotic called azithromycin 
works well to clear the infection even after a single dose. The World Health 
Organization (WHO) recommends that all communities where trachoma is a 
significant problem should be treated with this medication each year to 
eliminate trachoma. If the infection has already damaged your eyelids, you 
may need surgery to prevent blindness.
What is this study about?
We know that trachoma is a big problem on the Bijagos Islands. We do not 
know why there is such a big problem here. This study will help us to 
understand why this might be through identifying different strains of infection 
in relation to the disease in the community. The study will also help us learn 
how many people on the islands have infection, which will allow us to work 
with the Programa Nacional da Saúde Visao to offer you important treatment 
with antibiotics or surgery.
Who is conducting this study?
The London School of Hygiene & Tropical Medicine (UK) together with the 
Programa Nacional da Saúde Visao (Guinea Bissau).
Whose help do we need?
We need the help of approximately 2500 people living in communities on the 
islands.
What will we ask you to do?
We will conduct a census in your community. We will visit you in your 
community. If you agree to participate in the study, we will ask you some 
questions about yourself and where you live. We will then ask you if we can 
examine your eyes and take 2 samples (with cotton swabs) to test for the 
presence of infection. These swabs will be tested in the laboratory in The 
Gambia. We would also like to take a photo of each eye that we examine. We 
will return one year later and ask you to do the same again (eye examination, 
eye swabs and photos).
What are the benefits of participating in this study?
Trachoma is a huge problem on the Bijagos Islands. Trachoma can be treated 
effectively with the oral antibiotic, azithromycin. This treatment can cure the 
infection and prevent blindness caused by trachoma. Together with the PNSV 
?C?
we will treat your communities with trachoma with antibiotics and provide 
surgery for those of you who need it to prevent blindness.
Are there any risks involved in participating in this study?
The eye examination is a little uncomfortable but will not harm your eye in any 
way. The examination takes only a few moments to complete. There are no 
risks associated with taking swab samples. This examination has been carried 
out in many countries without problem. Azithromycin is a safe medication and 
is used widely in Guinea Bissau and other African countries in the control of 
trachoma, as part of the work of the WHO and national eye care programmes 
to prevent blindness from this disease. 
What tests will be done on the samples?
We will test the swabs in the laboratory in The Gambia and in the UK to 
improve our knowledge of the disease. The tests will show whether or not 
there is infection with chlamydia and will tell us how much infection is there. 
What will happen to the records and photos we take of your eyes?
All the information that we collect is confidential. Only the organisers of the 
study will have access to them.
Do I have to take part in this study?
No, it is completely voluntary. It is your decision whether or not to participate. 
You may discontinue your participation in the study at any time without 
reason. This will not affect your access to health care or treatment for 
trachoma or any other disease in any way.
Thank you very much for considering your involvement in this important study. 
If you have any further questions, please ask us.
Dr Anna Last (Doctor and Study Coordinator) 00245 650 6554
Mrs Eunice Cassama (Ophthalmic Nurse) 00245 628 8282
Dr Meno Nabicassa, PNSV, Ministry of Public Health, Bissau
Dr Jose Nakutum, Regional Hospital ‘Marcelino Banca’, Bubaque
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Informações para participantes
Estudo: Mapeamento do Tracoma no Arquipélago dos Bijagós na Guiné Bissau
Responsável: Dra Anna Last
Escola de Higiene e Medicina Tropical de Londres no Reino Unido com o Programa 
Nacional da Saúde da Visão (PNSV) da Guiné Bissau
O que é o tracoma e por que é importante?
O tracoma é uma causa comum de cegueira em muitos países Africanos, incluindo 
Guiné-Bissau. A doença é causada por uma infecção (por uma bactéria chamada
clamídia) que se espalha de olho a olho. Depois que as pessoas tiveram a infecção 
muitas vezes, pode deixar cicatrizes na pálpebra superior, que puxa os cílios para 
dentro de forma a causar danos aos olhos. Isso é muito doloroso e muitas vezes 
leva à cegueira. 
Em alguns estágios iniciais da doença, o tracoma pode ser tratado com pomada 
aplicada no olho, ou com comprimidos. Em estudos realizados em África, 
descobrimos que o comprimido antibiótico chamado azitromicina funciona bem até 
mesmo quando apenas uma dose é administrada. A Organização Mundial de Saúde 
(OMS) recomenda que todos os distritos onde o tracoma é comum tomem este 
medicamento a cada ano para eliminar tracoma . Se a infecção já prejudicou suas 
pálpebras, você pode precisar de cirurgia para prevenir a cegueira.
A respeito do que é este estudo?
Sabemos que o tracoma é um grande problema nas ilhas Bijagós. Nós não sabemos 
porque   o problema é tão grande. A fim de compreender porque é que há um 
problema tão grande através da identificação de diferentes tipos de infecção com 
relação a doença de olho na comunidade. Nós também precisamos saber o número 
de pessoas infectadas na comunidade para que possamos trabalhar com o Projecto 
Nacional para a Saúde da Visão e poder dar a você um bom tratamento com 
comprimidos ou cirurgia. 
Quem está fazendo este estudo?
Escola de Higiene e Medicina Tropical de Londres no Reino Unido juntamente com o 
Programa Nacional da Saúde da Visão (PNSV) da Guiné Bissau.
Da ajuda de quem precisamos?
Precisamos da ajuda de cerca de 2500 pessoas que vivem em comunidades nas 
ilhas.
O que vamos pedir-lhe para fazer?
Vamos fazer um recenseamento na sua comunidade. Vamos visitá-lo em sua 
comunidade. Se você concorda em participar do estudo, vamos fazer algumas 
perguntas sobre si mesmo e onde você vive.
Depois precisamos examinar seus olhos e tomar 2 amostras (com um cotonete) 
para testar a presença da infecção. As amostras serão testadas em laboratório na 
Gâmbia. Vamos tomar uma foto de cada olho que examinarmos. 
Vamos voltar um ano mais tarde e pedir-lhe para fazer o mesmo novamente (exame 
oftalmológico, colheita de amostras e fotos)
Quais são os benefícios de participar deste estudo?
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O tracoma é um grande problema nas ilhas Bijagós. O tracoma pode ser tratado 
eficazmente com o antibiótico azitromicina, um comprimido. Este tratamento pode 
curar a infecção e prevenir a cegueira por tracoma. Nós, juntamente com o PNSV, 
vamos a tratar comunidades com tracoma e fazer a cirurgia de triquíase para 
prevenir a cegueira.
Existem riscos causados por participar neste estudo?
O exame e a lavagem são apenas um pouco desconfortáveis mas não vão danificar 
o olho de maneira nenhuma. Vai demorar apenas poucos minutos. Não há riscos no 
processo de colheita de amostras. Já foi feita sem problemas em muitos países. 
Azitromicina é um medicamento seguro e é utilizada freqüentemente na Guiné-
Bissau e outros países Africanos para o controle do tracoma, como parte do trabalho 
da OMS e programas nacionais para impedir a cegueira por esta doença.
Que testes serão feitos com as amostras?
Vamos testar as amostras em laboratório na Gâmbia e no Reino Unido para 
aumentar a nossa compreensão do tracoma. Os testes vão diagnosticar se há 
infecção por clamídia e verificar a quantidade e que tipo de clamídia está presente.
O que vamos fazer com os registos e as fotos que fazemos sobre seus olhos?
Todas as informações que coletamos serão confidenciais. Somente os 
organizadores do estudo terão acesso a elas.
Sou obrigado a participar deste estudo?
Não, a participação é completamente voluntária. É sua decisão participar deste 
estudo. Você pode negar-se a participar do estudo quando quiser sem dar 
explicação. E em caso de nao querer participar, isso nao afectara o seu 
relacionamento com o hospital ou seu tratamento de tracoma ou outras doenças de 
maneira nenhuma.
Muito obrigada por considerar estar envolvido neste trabalho importante. Se você 
tiver alguma dúvida, pergunte-nos.
Dra Anna Last (Médica e Coodenadora do Estudo) 00245 650 6554
Sra Eunice Cassama (Enfermeira ofthalmológica) 00245 628 8282
Dr Meno Nabicassa, Programa Nacional da Saúde da Visão, Ministério da Saúde 
Pública, Bissau
Dr Jose Nakutum, Hospital Regional da Bubaque ‘Marcelino Banca’
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Form 5: Consent Form for Participants
Study: Mapping Trachoma on the Bijagos Archipelago of Guinea Bissau
London School of Hygiene & Tropical Medicine (UK) and the National Programme for 
Visual Health (PNSV) (Guinea Bissau)
Forename    __________________________ Surname    
_________________________
HID       __________________________ UID
I have read/had explained to me the information about the study. The Field Assistant 
has answered all my questions about the study. 
I understand the information and will participate Yes No
Certification of Participant (or parent/guardian if child under 13 years of age)
Signature/Thumbprint    __________________________________
Name      __________________________________
Date                                                __________________________________
Certification of Field Assistant
I have explained the objectives of the study and I am satisfied that he/she 
understands and agrees to participate voluntarily.
Signature    __________________________________
Name      __________________________________
Date                                                 __________________________________
Witness declaration if the participant is unable to read the consent information
I am witness to the study explanation and informed consent of the aforementioned 
participant .
Signature/Thumbprint    __________________________________
Name __________________________________
    
Date                                                 __________________________________
Identification
Sticker
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Formulário 5: Consentimento para Participantes
Estudo: Mapeamento do Tracoma no Arquipélago dos Bijagós na Guiné Bissau
Escola de Higiene e Medicina Tropical de Londres no Reino Unido com o Programa 
Nacional da Saúde da Visao (PNSV) da Guiné Bissau
Nome Próprio  _________________________ Apelido    
___________________________
Número de identificação (UID)   
Eu   li  /  recebi explicações sobre o estudo. O assistente respondeu todas as minhas 
perguntas sobre o estudo. 
Eu entendo as informações e aceito participar Sim
Não
Confirmação do Participante (Ou pai / responsável se a criança tiver menos de 13 
anos)
Assinatura/Impressão digital   __________________________________
Nome      __________________________________
Data                                                __________________________________
Confimação do Assistente
Eu expliquei o objetivo do estudo e estou convencido de que ele/ela concorda em 
participar voluntariamente.
Assinatura    __________________________________
Nome      __________________________________
Data                                                 __________________________________
Declaração de testemunha se o participante não puder ler as informações de 
consentimento
Eu sou testemunha das explicações fornecidas ao participante e do consentimento 
dado do participante acima mencionado para o estudo.
Assinatura/Impressão digital   __________________________________
Nome  __________________________________
    
Data                                                 __________________________________
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Appendix VII. Ocular Assessment Forms
U(0,%-a03( fb""!F/-3/gh("&( $0/.(,/"GD03,+0/"D+#`%3#/HWV&0#$&74+b&']]]]]]]]]]]]]'P**#*/)$/)'7)'9&>4+&/q+#4']]]]]]]]]]]]'14/q<+&54b&]]]]]]]]]]]]]]]86-''']]]''']]]'' !6-'' ]]]'']]]''b']]]'']]]'']]][z0)+4'f6-
U(0,%-a03("&+".(1#+1$3,+1$("20++1.*3&(i" L3,
Mh(:)'Mh(L'CjLTLS!y'K+))$%,& 4'54+02"u+#4'7)'%4$*)$/#0)$/4O[40)'']]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]] P.)"#74]]]]']]]]]]]]]]]]]]]]]]]]]]]]67&7)''''''''''''''''''''''''''''''''''''''''''''' &$4*'')'0{*)*'-&/&'7)'[&%#0)$/4'' T77b00b&&&&U:)V4 =&*%2"#$4''b''1)0#$#$4W/$#& |G}'a#S&<q* |?}'a&"&$/& |@}'12"& |A}'=&$7#$R&|B}'=&$S&%4 |C}'K&.)" |D}'1&"2.) |E}'=&$%&$,&|F}'=&$*4&$%)|GH}'[&"2 |GG}':&+&%2") |G?}'J2/+4'94%&" 7) $&*%#0)$/4 ]]]]]]]]]]]]]]]]]]]]]]]]]]94%&" 7) #$5É$%#& ]]]]]]]]]]]]]]]]]]]]]]]K&**&'0&#*'7)'20'0{*'"4$<)'7)'%&*&'.4+'&$4v |G}':#0 |?}'[w4c&#'Ä')*%4"& |G}':#0 |?}'[w4h2&"v']]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
+V"1%&/$_)(*6P%2#7&7)'c#*2&"
CT<jTS\
jLkEj<C!
!"&**#5#%&w4 1&%#&" |G}'[&*&"|?}'J%2"&+|@}'=4*%&*
!1("""""""""""""""""""""J{#
]]]'']]]''b']]]'']]]'']]]''b'']]]'']]]'']]]'']]]
?DH
PN&"#&w4'74 8+&%40&
CT<jTS\ [ 81 86 8: 88 !J1'''' K ![z0)+4* 74*'54/4*
jLkEj<C! [ 81 86 8: 88 !J1'''' K ![z0)+4* 74*'54/4*
W/#_2)/&'P7)*#N&'7)'P=J:8(P'G G?@W/#_2)/&'P7)*#N&'7)'P=J:8(P'?
W/#_2)/&'P7)*#N&'7)'P=J:8(P'GW/#_2)/&'P7)*#N&'7)'P=J:8(P'?
G?@
P=J:8(P'rP6(s'4'P=J:8(P'r:K6ZW-s
P=J:8(P'rP6(s'4'P=J:8(P'r:K6ZW-s
?DG
U(0,%-a03( fb""!F/-3/gh("&( $0/.(,/"GL+7%1&/"D+#`%3#/HWV&0#$&74+b&']]]]]]]]]]]]]'P**#*/)$/)'7)'9&>4+&/q+#4']]]]]]]]]]]]'14/q<+&54b&]]]]]]]]]]]]]]]86-''']]]''']]]'' !6-'' ]]]'']]]''b']]]'']]]'']]][z0)+4'f6-
U(0,%-a03("&+".(1#+1$3,+1$("20++1.*3&(i" L3,
Mh(:)'Mh(L'CjLTLS!y'K+))$%,&'4'54+02"u+#4'7)'%4$*)$/#0)$/4O[40)'']]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]] P.)"#74]]]]']]]]]]]]]]]]]]]]]]]]]]]]67&7)''''''''''''''''''''''''''''''''''''''''''''' &$4*'')'0{*)*'-&/&'7)'[&%#0)$/4'' T77b00b&&&&U:)V4 =&*%2"#$4''b''1)0#$#$4
+V"1%&/$_)(*6P%2#7&7)'c#*2&"
CT<jTS\
jLkEj<C!
!"&**#5#%&w4 1&%#&" |G}'[&*&"|?}'J%2"&+|@}'=4*%&*
!1("""""""""""""""""""""J{#
]]]'']]]''b']]]'']]]'']]]''b'']]]'']]]'']]]'']]]
?D?
PN&"#&w4'74 8+&%40&
CT<jTS\ [ 81 86 8: 88 !J1'''' K ![z0)+4* 74*'54/4*
jLkEj<C! [ 81 86 8: 88 !J1'''' K ![z0)+4* 74*'54/4*
W/#_2)/&'P7)*#N&'7)'P=J:8(P'G G?@W/#_2)/&'P7)*#N&'7)'P=J:8(P'?
W/#_2)/&'P7)*#N&'7)'P=J:8(P'GW/#_2)/&'P7)*#N&'7)'P=J:8(P'?
G?@
P=J:8(P'rP6(s'4'P=J:8(P'r:K6ZW-s
P=J:8(P'rP6(s'4'P=J:8(P'r:K6ZW-s
?D@
Appendix VIII. Conjunctival Digital Photography Protocola473x'[#R4$'-AHb-CHb-@HHH 9)$*x'c('P1':'=#%+4'[#R4$'GHB00'Gx?OE\:I='c('W-'=#%+4'61'GxG'C? ()_2#+)*'C?00'7#&0)/)+'fc'7#<#/&"'5#"/)+
9+1+0/-
x =&R)'*2+)'>&//)+3'T&$7'>&%R'2.'>&//)+3'#*'%,&+<)7U
x =&R)'*2+)'/,)'5#"/)+'")$*'.+4/)%/4+'#*'#$'."&%)'T&$7'*.&+)U
x K+)*)+N)'>&//)+#)*'>3'*M#/%,#$<'%&0)+&'455'M,)$'$4/'#$'2*)
x !,)%R'*)//#$<*'>)54+)'2*)
K/,+0/"L+$$317#GO 6$*)+/'>&//)+3'&$7':-'0)04+3'%&+7?O 82+$'%&0)+&'4$@O K+)**'r6$54s'&$7'%,)%R'/,&/'>&//)+3'#*'52""3'%,&+<)7'&$7'/,&/'0)04+3'%&+7'#*')0./3AO !,)%R'/,&/'")$*'&$7'5#"/)+'&+)'*)%2+)BO :)/'/4'=P[fP9'1J!f:x'r=s'4$'")$*CO :)/'/4'r12""s'4$'")$*DO :)/'")$*'/4'G'G'HO@GA'T*,42"7'*,4M'1BD'4$'04$#/4+UEO :)/'/,)'7#&"'/4'&.)+/2+)'rPs'4$'/,)'7#&"FO K+)**'r=)$2sO'a3'.+)**#$<'2.'&$7'74M$'&++4M'R)3*'342'%&$'$&N#<&/)'/,)'/&>*'4$'/,)'")5/O':)")%/'/,)'%&0)+&'#%4$'T:;JJ86[\'=W[fUO f*)'/,)'+#<,/'&++4M'R)3'&$7'/,)$'2.b74M$'/4'*)")%/'#/)0*'5+40'/,)'*,44/#$<'0)$2O':)")%/'6=P\W'hfP968Ñ'^j'JZ'^j'ÇKW\'[4+0&"'T*)")%/'M#/,'&++4M'R)3*U'^j'JZO':)")%/'6=P\W':6ÖW'^j'JZ'^j'9&+<)'^j'JZO':)")%/'6:J':W[:686c68Ñ'^j'AHH'^j'JZOGHO WV#/'>3'.+)**#$<'r=)$2s 2$/#"'>&%R'/4'04$#/4+'+)&73'/4'/&R)'.#%/2+)O
S/O317"/"D*($(GO I+#/)'/,)'7&/)'&$7'342+'$&0)'&/'/,)'/4.'45'/,)'.,4/4'"4<'54+0?O I+#/)'.&+/#%#.&$/'f6-'#$'*.&%)'.+4N#7)7'4$'.,4/4'"4<'54+0@O =&R)'*2+)'5"&*,'#*'4$AO f*)'/,)'")$*'/4'54%2*'/4'/&R)'.#%/2+)'45'/,)'f6-BO 8,)$ /&R)'?'.#%/2+)*'45'/,)'")5/ )3)14%2*'#$'4$'/,)')3)=&R)'*2+)'/,)'%4$S2$%/#N&'#*'#$'/,)'!W[8(WPN4#7'<"&+)b"#<,/'&+/)5&%/8+3'/&R#$<'5+40'7#55)+)$/'&$<")*'/4'&N4#7'"#<,/'&+/)5&%/')/%OPN4#7'<"4N)7'5#$<)+*-4'$4/'.,4/4<+&.,'/,)'%4+$)&CO ().)&/'54+'/,)'")5/')3)DO !;W!Z'WP!;'K;J8J'P:'68'6:'8PZW[O'65'#/'#*'$4/'*&/#*5&%/4+3'7)")/)'2*#$<'/,)'/+&*,'%&$'#%4$O'()/&R)'.,4/4*O'
?DA
Appendix IX. Conjunctival Digital Photo Log Form
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Appendix X. Conjunctival Specimen Log Form
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1. DEFINITIONS AND ABBREVIATIONS 
Abbreviations
CT Chlamydia trachomatis
MRC Medical Research Council; representing Medical 
Research Council Laboratories (UK) Unit, The Gambia
MWP Microwell Plate
NG Neisseria gonorrhoeae
PRET Partnership for the Rapid Elimination of Trachoma
SOP Standard Operating Procedure
2. BACKGROUND 
The AMPLICOR® CT/NG Test is an in vitro multiplex 
diagnostic test that can detect Chlamydia trachomatis (CT) 
and/or Neisseria gonorrhoeae (NG) in clinical specimens, 
including ocular swabs. This test utilizes polymerase chain 
reaction nucleic acid amplification and nucleic acid 
hybridization.
The AMPLICOR® CT/NG Test offers: 
x High sensitivity without a loss of specificity;
x Increased sensitivity over traditional culture or DNA direct 
probe tests; 
x An ideal screening application (high sensitivity in low 
prevalence populations, including asymptomatic and 
symptomatic patients); and 
x Optional co-amplified internal control enabling inhibition 
control.
3. PURPOSE 
This Standard Operating Procedure (SOP) describes the 
protocol for testing ocular swabs for the presence or absence 
?EG
of Chlamydia trachomatis DNA using the commercially 
available AMPLICOR® CT/NG test.
4. SCOPE 
This SOP applies to the testing of all ocular swabs collected 
in the framework of the Partnership for the Rapid Elimination 
of Trachoma (PRET) programme and to the testing of all 
internal and external quality control samples processed by 
the PRET team in The Gambia. 
5. RESPONSIBILITIES 
Laboratory Management is responsible for ensuring that time 
and resources are available to conduct the procedures as 
outlined in this SOP.
The Research Fellow is responsible for ensuring that all staff 
is properly trained in performing the test and that all staff 
are read and follow this SOP.
The Senior Lecturer may at any time perform a quality check 
on how the procedures are conducted, administered, and 
recorded.
6. HEALTH & SAFETY 
All practices must be carried out in accordance with the 
Unit’s health and safety regulations.
a. 6.1 Precautions
x Personal protective equipment (laboratory coat and 
gloves) is to be worn at all times.
x Safety cabinet is to be cleaned with 70% ethanol before 
work and with 2% hycolin followed by 70% ethanol after 
work.
x Guidelines for using Pre & Post PCR rooms are to be 
followed.
7. MATERIALS AND REAGENTS
Reagents are to be properly preserved and monitored 
for their purity. Store all reagents and plates at 2-8ºC, 
do not freeze.
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The batch number and expiry date of all reagents used on a 
given day must be documented using form T4 Reagent batch 
and expiry log.
b. 7.1 CT/NG Specimen Preparation Kit
x CT/NG Urine Wash: Tris HCl Buffer, 300 mM Sodium 
Chloride, 0.1% Detergent
x CT/NG Lysis Buffer: Tris-HCL Buffer, 1% Solubilizer, 
0.09% Sodium Azide.
x CT/NG Specimen Diluent: Tris HCL Buffer, 6mM 
Magnesium Chloride, 25 % Detergent, 0.05% Sodium 
azide. 
c. 7.2 AMPLICOR® CT/NG Amplification Kit
x CT/NG Master Mix: Tris HCl Buffer, EDTA, 100 mM 
Potassium Chloride, Glycerol, 0.01% AmpliTaq®, 0.016% 
dUTP, 0.005% dATP, 0.005% dCTP, 0.005% dGTP, 0.01% 
Amperase, 0.00004% Biotinylated Primers SS01, SS02, 
CP24 and CP27, Sodium Azide.
x CT/NG Internal Control: Tris HCl Buffer, 0.001% Non-
Infectious Plasmid  containing C. trachomatis primer 
binding sequences and a unique probe binding region; 
0.005% Poly rA RNA, EDTA, Amaranth dye, 0.05% Sodium 
azide. 
x C. trachomatis Control: Tris HCl Buffer, 0.001% Non-
infectious plasmid DNA containinf C. trachomatis 
sequences; 0.005% non-specific carrier DNA, 0.5% 
Detergent, EDTA, 0.05% Sodium Azide.
x N. gonorrhoeae Control: Tris HCl Buffer, Non infectious 
plasmid DNA containing N. gonorrhoeae sequences, 
0.005% Non-specific carrier DNA, EDTA, 0.05% Sodium 
Azide.
d. 7.3 AMPLICOR® Chlamydia trachomatis Detection Kit
x CT MWP: Microwell Plate Chlamydia trachomatis coated
with CT-Specific DNA Probe.  96 wells in one resealable 
pouch. 
x [1] DN (Denaturation Solution): 1.6% Sodium Hydroxide, 
EDTA, Thymol Blue. IRRITANT!
x [2] CT/NG HYB (CT/NG Hybridization Solution): Sodium 
Phosphate Solution, 0.2% Solubilizer, 32.4% Sodium 
Thiocyanate. HARMFUL!
x [3] AV-HRP (Avidin-Horseradish Peroxidase Conjugate): 
Tris HCl Buffer, 0.001% Avidin-horseradish peroxidase 
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conjugate, Bovine Gamma Globulin, Emulsit 25, 0.1% 
Phenol1% ProClin® 150 preservative. 
x [4A] SUB A (Substrate A): Citrate Solution, 0.01% 
Hydrogen Peroxide, 0.1% ProClin 150 preservative.
x [4B] SUB B (Substrate B): 0.1% TMB, 40% 
Dimethylformamide (DMF).  TOXIC!
x [5] STOP (stop Reagent): 4.9% Sulfuric Acid.
x 10X WB (10X Wash Concentrate): 2% Phosphate Buffer, 
9% Sodium Chloride, EDTA, 2% Detergent, 0.5% 
ProClin® 300 preservative.
8. PROCEDURES 
All procedures are carried out in the Trachoma Lab (Whittle
Building) and the Post PCR room as indicated below.
8.1 Principle of the Test
The AMPLICOR CT/NG test is based on PCR amplification of 
target DNA using biotinylated primers (CP24 & CP27). After 
PCR amplification, the amplicon is chemically denatured to 
form single stranded DNA by adding a Denaturation solution. 
Detection of the amplified product is done by ELISA, which is 
achieved by hybridization of the amplified products to MWP 
coated with oligonucleotide probes specific to the CT target 
(CP35) and detection of the probe-bound amplified products 
by colour formation.
An Internal Control (IC) is added in the Amplicor test as an 
option to check for inhibition of the test that may be due to 
certain substances present in the samples. The IC is 
noninfectious plasmid DNA and has a randomized internal 
sequence of similar length and base composition as the 
target sequence and in addition has a unique probe binding 
region that differentiates the IC amplification products from 
the target amplification products. The master mix used in the 
test contains biotinylated primers specific for the target and 
for the IC and therefore allows the IC to be co- amplified 
with the target DNA from samples. Detection is done on a 
separate MWP coated with oligonucleotide probes specific for 
IC (SK535). After completion of the ELISA, this results in 
colour formation in the MWP. 
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8.2 Specimen Preparation
8.2.1 DNA Extraction (to be done in the Safety Cabinet)
To prevent cross-contamination, always recap tubes 
and change gloves frequently.
x Using a sterile filter tip, pipette 500 !l AMPLICOR CT/NG 
lysis buffer into sterile DNA free 2 ml polypropylene screw 
cab tubes. Make sure tubes are properly closed to avoid 
any evaporation. Store tubes at 2-8ºC until use.
x Label the tubes containing the lysis buffer with the sample 
IDs to be extracted. Organize the samples in the same 
order in the racks as the labeled tubes with lysis buffer. 
This step can be done on the laboratory bench.
x Using a new, clean wooden stick, remove the specimen 
(swab) from the transport tube and place it into the tube 
containing lysis buffer. Verify that the ID on the tube 
with lysis buffer is identical to the sample’s ID.
x Elute the DNA by vortexing the swab in lysis buffer for 10 
seconds. Be sure to change gloves every 20 samples or 
whenever needed to avoid cross-contamination.
x Gently squeeze out the lysis buffer from swab by pressing 
it against the side of the tube. Replace the swab in the 
transport tube. Store the extracted swabs in a self-seal 
plastic bag. Label the bag with study number, date of 
extraction, and number of samples.  
x Recap the tube containing eluted DNA and incubate for 15 
min at room temperature.
x Change gloves and add 300 !l of AMPLICOR CT/NG 
Specimen Diluent to each lysed sample. Recap the tube.
x Mix by vortexing for 10 seconds. Incubate samples at 
room temperature for 5 min.
x Heat the prepared specimen, containing extracted DNA at 
95°C for 10 min.  Before proceeding to amplification, store 
extracted samples at 2-8°C for at least 12 hours to help in 
inactivating inhibitors. Samples should be tested within 7 
days of extraction. Store DNA samples at -20°C if 
amplification will not be done within this period.
8.2.2 Preparation of controls (to be done in the Safety Cabinet)
Prepare NG controls first to avoid contamination with 
C. trachomatis DNA.
Working NG Control
x Pipette 1 ml of Specimen Diluent into a sterile 2 ml screw 
cap tube.
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x Add 100 !l of NG positive control, recap and mix well by 
vortexing or pipetting. Label the tube as Working NG 
control. 
Processed NG Control
x Pipette 250 !l of CT/NG lysis buffer into a sterile 2 ml 
tube. Add 250 !l of Working NG control, recap and mix by 
vortexing or pipetting. 
x Incubate at room temperature for 10 min. Label the tube 
as Processed NG control.  
x This control will be the negative control for the CT 
amplification and detection.
Note: New working and processed controls must be 
prepared for each PCR set during a working day
Working CT Control
x Pipette 1 ml of Specimen Diluent into a sterile 2 ml tube 
screw cap tube.
x Add 100 !l of CT positive control, recap and mix well by 
vortexing or pipetting. Label tube as Working CT control. 
Processed CT Control
x Pipette 250 !l of CT/NG lysis buffer into a sterile 2 ml 
tube. Add 250 !l of Working CT control, recap and mix by 
vortexing or pipetting. 
x Incubate at room temperature for 10 min. Label the tube 
as CT processed control.  
x This control will be the positive control for the CT 
amplification and detection.
Note: New working and processed controls must be 
prepared for each PCR set during a working day. 
8.2.3 Preparation of Master Mix (to be done on Pre-PCR bench)
x Using a sterile filter tip add 100 !l of CT/NG Internal 
control (Red) to CT/NG Master Mix (clear), recap  the 
tube.
x Mix well by inverting 15 times. [3 master mix for each 96 
samples].  
x Aliquot 50 !l of master mix in the PCR strip tubes. Prepare 
only the required number of tubes. Label each strip of 
tubes. Any remaining amplification mix must be labeled 
with the date of preparation and stored at 2-8°C for 
further use, up to 7 days.
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x Place the PCR tubes containing the master mix in a self-
seal bag to be transferred to the area where the DNA 
samples are going to be loaded. In a separate bag, place 
the number of strip caps you will require to close the PCR 
tubes.
8.2.4 Pooling of samples (to be done in the safety cabinet)
As the expected prevalence of CT in The Gambia is low, 
samples are processed in pools.
x Label 92 sterile DNA-free 2 ml polypropylene screw cab 
tubes from 1 to 92.
x Arrange tubes containing extracted DNA samples into 
groups of five.
x Identify five samples making up a pool. Add 50 !l of each 
sample to the same 2 ml tube. Mix by vortexing or 
pipetting. Store pooled samples at 2-8°C. Pooled samples 
should be tested within 7 days of DNA extraction. Store 
DNA samples at -20°C if amplification will not be done 
within this period.
x Proceed to fill out document T1 Pool template indicating 
the arrangement of samples into pools of 5. THE TEMPLATE 
SHOULD REPRESENT THE EXACT ARRANGEMENT OF THE SPECIMENS IN THE 
92 MICROTUBES. This will also represent the arrangement in 
further steps of amplification and in the 96 well plate used 
in the Chlamydia trachomatis detection.
8.2.5 Loading the DNA (to be done in the safety cabinet)
x Bring out the pooled DNA samples and organize them in a 
96 position rack. 
x If samples were stored at -20°C, they must be thawed. 
Samples are to be mixed thoroughly by vortexing and 
spun shortly to bring down any droplets on the cap or 
sides of tube. Make sure there is no precipitate present.
x Take one strip of tubes with master mix and transfer to a 
microtube rack.  
x Add 50 !l of each pooled DNA sample to each tube 
containing master mix. Transfer the loaded strip to a new 
rack. Proceed loading one strip at a time. Change gloves 
whenever required.
x Once the samples have been loaded, proceed to load the 
controls in the microtubes containing the master mix. Load 
the Processed CT control first, change gloves and then 
load the Processed NG control. Ensure that both controls 
are in duplicate. 
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x Proceed to cap the strips one by one transferring them to 
the appropriate racks.
8.2.6 Amplification (to be done in Post PCR room)
Place the samples in the PCR system 9700 or CG1-96
thermal cycler for amplification and verify the Program 
conditions. Any change could interfere with the results.
Cycling conditions:
Hold program: hold at 72°C, not to exceed 24 hours.
8.2.7 Detection 
Denaturation (to be done in Post PCR room)
All reagents and MWP are to be pre-warmed at room 
temperature for 10 min.
x Remove reaction tubes (one strip at a time) from 
thermocycler after amplification and remove the caps 
carefully to avoid aerosols.
x Immediately pipette 100 !l of Denaturation Solution DN 
(1) to the first row of reaction tubes using multichannel 
pipette with aerosol barrier tips. Repeat the process for 
each row using new aerosol barrier tips. 
x Note: the Denaturation Solution must be added immediately 
after the amplified products are removed from the thermocycler 
and whilst still hot.
x Incubate at room temperature for 10 min to ensure full 
denaturation.
x Denatured amplicons can be kept at room temperature for 
a maximum of 1 hour, then proceed immediately to the 
hybridization step.
36 cycles
50 
2:00
93 
61 
71 72 72 
94 
5:00 0:20
1:00
0:40 5:00 
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Hybridization (to be done in the laboratory)
x Remove the CT and IC MWP from the foil pouches. If less 
than 12 strips are required, remove the ones necessary for your 
test and place them in a clean frame. Label each strip with a 
permanent marker. Store the strips that are not going to be 
used in the pouch at 2-8ºC. Record the date the pouch was 
opened.
x Add 100 !l of Hybridization Solution CT/NG HYB (2) to 
each well in the CT and IC MWPs to be tested.
x Pipette 25 !l of the denatured amplicon to the appropriate 
wells in the CT and IC MWPs using a pipette with an 
aerosol barrier tip.
x Gently tap the plates 5 times until color changes from blue 
to light yellow to ensure adequate mixing had been done.
x Cover the CT and IC MWPs with clean MWP lids and 
incubate at 35-39°C for 1 hour.
Washing
x While the plates are incubating, prepare the Washing 
Buffer Working Solution by adding 1 volume of 10X 
Washing Buffer to 9 volumes of distilled water and mix 
well. Prepare at least 40 ml of working wash solution for 
each 8 well MWP strip. Working wash solution can be 
stored at 2-25°C in a clean closed plastic container up to 2 
weeks. 
x Empty the CT and IC plate contents and tap dry on 5 layers of 
paper towel. Fill the wells (400-450 !l), wait for 30 seconds, 
empty out contents and tap dry. Repeat process 4 more times. 
After all 5 washes, rinse the back of the plate with water 
to remove any excess wash buffer.
Conjugate
x Add 100 !l of Conjugate Solution AV-HRP (3) to each well 
in the CT and IC plate. Do not touch the walls of the wells.  
x Cover the plates using clean MWP lids and incubate for 15 
min at 35-39°C. If plates are not properly covered the 
content of the wells will evaporate.
Washing
x As described above. Make sure no traces of Conjugate 
Solution are left as it can lead to a false positive result. 
Adding an extra wash is recommended. Be sure to change 
gloves before adding the Substrate Solution. 
Substrate
x Prepare the Substrate by mixing 2 ml of Substrate solution 
A (4A) SUB A with  0.5 ml of Substrate Solution B (4B) 
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SUB B as the working substrate for both CT and IC 8-well 
microwell plate strip (16 tests). For a full plate, prepare 12 
ml (4A) Sub A to 3 ml (4B) Sub B. The reagent should be 
prepared no more than 15 min before use, stored at room 
temperature and in the dark.
x Add 100 !l of the Working substrate into each well.
x Keep the plate at room temperature (20-25°C) and in the 
dark for 10 min to allow color to develop.
Stop
x Stop the reaction by adding 100 !l of STOP Solution (5) to 
each well.
x Measure the absorbance at 450 nm using an ELISA plate 
reader.
8.3 Analysis of Results
A summary of results obtained for each PCR must be 
documented using form T3 Results summary sheet.
Validity of assay
x At least 2 replicates of the Working CT control and 
Working NG control should be included per test. The 
absorbance value of the Working NG control on the CT 
MWP (Negative control for the assay) should be less than 
0.20 A450 units, and ideally around 0.06. IF THE RESULT IS 
0.20 A450 UNITS THEN THE ASSAY IS NOT VALID AND MUST BE REPEATED.
Fill out document T5 Failed run.
x The absorbance value of Working CT control on the CT 
MWP (Positive control for the assay) should be $450
units. IF RESULT IS <2.0 A450 UNITS THEN THE ASSAY IS NOT VALID 
AND MUST BE REPEATED. Fill out document T5 Failed run. 
Interpretation of results
CT 
Absorbance 
at 450 nm
IC 
Absorbance 
at 450 nm
Result Interpretation
< 0.2                               C. trachomatis DNA not detected. 
Sample NEGATIVE for C. trachomatis.
ANY C. trachomatis DNA detected. Sample 
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POSITIVE for C. trachomatis.
 EQUIVOCAL. Sample equivocal for C. 
trachomatis. Sample must be repeated 
neat (undiluted) in duplicate.
< 0.2                              < 0.2                              INHIBITORY. The amplification of DNA 
as not possible due to the presence of 
inhibitors. Sample must be repeated 
neat (undiluted). If sample is still 
inhibited it must be re-tested diluted 
(dilution 1:10).  Dilution should be 
prepared in a fresh mixture v/v CT/NG 
lysis buffer and Specimen Diluent.
8.3.1 Negative samples 
If a pool of samples is negative for C. trachomatis DNA 
according to the Interpretation of results (see above), all five 
samples making up that pool are considered negative. 
8.3.2 Positive Specimens
If a pool of samples is positive for C. trachomatis DNA 
according to the Interpretation of results (see above), all five 
samples making up that pool must be repeated individually 
to identify the positive sample. Fill out document T2 Repeats 
template to indicate the arrangement of samples in the 96 
well plate during the repeated test. 
8.3.3 Equivocal Specimens
If a pool of samples is equivocal for C. trachomatis DNA 
according to the Interpretation of results (see above), all five 
samples making up that pool must be repeated individually 
to identify the equivocal sample. If a sample is equivocal 
when tested individually, it must be re-tested in duplicate. 
The sample should only be considered as positive if at least 
one of these repeats had an OD ,IWKHUHSHDWVDUH
equivocal or negative, the sample is considered negative.
When repeating samples individually, fill out document T2 
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Repeats template to indicate the arrangement of samples in 
the 96 well plate.
8.3.4 Inhibitory Specimens
If a pool of samples is inhibited according to the 
Interpretation of results (see above), all five samples making 
up that pool must be repeated individually to identify the 
inhibited sample. If a sample is inhibited when tested 
individually, it must be re-tested diluted. When repeating 
samples individually, fill out document T2 Repeats template 
to indicate the arrangement of samples in the 96 well plate.
x Prepare a mixture v/v of CT/NG lysis buffer and Specimen 
Diluent.
x Prepare a dilution 1:10 from the neat sample (in a clean 
tube by mixing 10 !l of specimen DNA and 90 !l of 
mixture CT/NG lysis buffer and Specimen Diluent). Mix 
well.
x Re-test the samples following the standard CT/NG 
Amplification and Detection Protocols. If the result is still 
inhibited, re-test by preparing further dilutions (1:20, 1:50 
and 1:100).  
9. RECORDS
Records T1, T2, T3, T4 and T5 must be completed during the 
testing process as outlined above. If technician error renders 
a sample unusable, form T6 Void sample record must but be 
completed. If a sample is found to be ineligible, form T7 
Ineligible sample record must be completed.
Attachments
T1 Pool Template
T2 Repeats Template
T3 Results summary sheet
T4 Reagent batch and expiry log
T5 Failed run record 
T6 Void samples record 
T7 Ineligible sample record 
10. REFERENCES 
AMPLICOR® Chlamydia trachomatis/Neisseria gonorrhoeae
(CT/NG) Test User Manual. Copyright 2007, Roche Molecular 
Systems, Inc. 
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Appendix XIV. STROBE CHECKLIST
STROBE Statement—Checklist of items that should be included in reports of cross-sectional 
studies
<3#O"U/.$(0#")(0"!.$3F+"S0/.*(,/"/1&"\.%-/0 !"#$%&'($)*+$,"-%$*(. T1)+.$3(1"31"
S0+/$,+1$41/pF+"S0/.*(,/4*'2+0+1&+,3."K(,,%13$3+#"()"$*+"536/78#"!0.*32+-/7(:"
9%31+/"53##/% GDMSC4C4AX4@?@VfH
Item 
No Recommendation
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;
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*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at 
www.strobe-statement.org.
